<SEC-DOCUMENT>0001193125-13-129693.txt : 20130327
<SEC-HEADER>0001193125-13-129693.hdr.sgml : 20130327
<ACCEPTANCE-DATETIME>20130327172230
ACCESSION NUMBER:		0001193125-13-129693
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20130327
DATE AS OF CHANGE:		20130327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS INC
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-183675
		FILM NUMBER:		13720821

	BUSINESS ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-489-2100

	MAIL ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d513079d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Filed Pursuant to Rule 424(b)(5) <BR>Registration Statement No. 333-183675 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS SUPPLEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(To Prospectus
dated October&nbsp;9, 2012 as supplemented by Prospectus Supplement dated December&nbsp;5, 2012) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g513079logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>5,565,811 SHARES OF COMMON STOCK </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>This Prospectus
Supplement supplements the prospectus dated October&nbsp;9, 2012, as supplemented by the prospectus supplement dated December&nbsp;5, 2012. This prospectus supplement should be read in conjunction with the prospectus and the previous prospectus
supplement, and is qualified in its entirely by reference to the prospectus and the previous prospectus supplement, except to the extent that the information presented herein supersedes the information contained in the prospectus or the previous
prospectus supplement. This Prospectus Supplement is not complete without, and may not be delivered or utilized, except in connection with the prospectus, including any amendments or supplements thereto. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Unless the context otherwise indicates, references in this prospectus supplement to the &#147;accompanying prospectus&#148; refer to the prospectus
dated October&nbsp;9, 2012, as supplemented by the prospectus supplement dated December&nbsp;5, 2012. </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to
this prospectus supplement and the accompanying prospectus, we are offering 5,565,811 shares of our common stock to Terrapin Opportunity, L.P., or Terrapin, pursuant to a Common Stock Purchase Agreement between us and Terrapin dated as of
December&nbsp;5, 2012, which we refer to as the Purchase Agreement, at a price of approximately $1.62 per share. The total purchase price for the shares is $9.0 million. We will receive net proceeds from the sale of these shares of approximately
$8.9 million, after deducting our estimated offering expenses of approximately $0.1 million, including a placement agent fee of $1,500 to be paid to Financial West Group, member FINRA/SIPC, or FWG, in connection with this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the accompanying prospectus also cover the resale of these shares by Terrapin to the public. Terrapin is
an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act, and any profits on the sales of shares of our common stock by Terrapin and any discounts, commissions or
concessions received by Terrapin may be deemed to be underwriting discounts and commissions under the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
expect to issue these shares to Terrapin on or about March 28, 2013. Our common stock is traded on the NASDAQ Global Market under the trading symbol &#147;DCTH.&#148; On March 26, 2013, the last reported sales price for our common stock was
$1.68&nbsp;per share. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. SEE THE SECTION ENTITLED &#147;<A HREF="#ssupcov513079_1">RISK FACTORS</A>&#148; BEGINNING
ON PAGE&nbsp;S2-4 OF THIS PROSPECTUS SUPPLEMENT. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The date of this Prospectus Supplement is March&nbsp;27, 2013 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospectus Supplement </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_2">PROSPECTUS SUPPLEMENT SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_3">THE OFFERING</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_4">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_5">FORWARD-LOOKING INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_6">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_7">DIVIDEND POLICY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_8">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_9">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_10">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_11">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#ssupptoc513079_12">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospectus Supplement </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_2">PROSPECTUS SUPPLEMENT SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_3">THE OFFERING</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-5</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_4">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-6</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_5">FORWARD-LOOKING INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_6">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_7">DIVIDEND POLICY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_8">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-9</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_9">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-9</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_10">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_11">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_12">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-12</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#supptoc457511_13">INCORPORATION BY REFERENCE</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospectus </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_1">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_3">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_4">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_5">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_6">SELLING STOCKHOLDERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_7">DESCRIPTION OF DEBT SECURITIES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_8">DESCRIPTION OF CAPITAL STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_9">DESCRIPTION OF STOCK PURCHASE CONTRACTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_10">DESCRIPTION OF WARRANTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_11">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_12">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_13">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the accompanying prospectus, dated October&nbsp;9, 2012, as supplemented by the accompanying prospectus
supplement, dated December&nbsp;5, 2012, are part of a registration statement on Form S-3 (File No.&nbsp;333-183675), which we refer to as the registration statement, that we filed with the Securities and Exchange Commission, or the SEC, using the
&#147;shelf&#148; registration process, and that was declared effective on October&nbsp;9, 2012. Under this &#147;shelf&#148; registration process, we may from time to time sell any combination of securities described in the accompanying prospectus
in one or more offerings up to a total of $100&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These documents contain important information you should
consider when making your investment decision. The accompanying prospectus provides you with a general description of the securities we may offer. This prospectus supplement contains information about the shares of common stock issued in this
offering. This prospectus supplement may add, update or change information in the accompanying prospectus. You should rely only on the information provided in this prospectus supplement, the accompanying prospectus or incorporated by reference in
this prospectus supplement or the accompanying prospectus. We have not authorized anyone to provide you with any other information. We may also authorize one or more free writing prospectuses to be provided to you that may contain material
information relating to these offerings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement contains summaries of certain provisions contained in
some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the section entitled
&#147;Where You Can Find Additional Information.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless stated otherwise, references in this prospectus supplement and
the accompanying prospectus to &#147;Delcath,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; refer to Delcath Systems, Inc., a Delaware corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement, the accompanying prospectus, and the information incorporated herein and therein by reference include trademarks, service marks and trade names owned by us or other companies.
All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their respective owners. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not making any representation to you regarding the legality of an investment in the securities by you under applicable law. We are
not making an offer to sell the securities in any jurisdiction where the offer or sale is not permitted. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves
about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement. This
summary does not contain all the information that you should consider before investing in our securities. You should read the entire prospectus supplement and the accompanying prospectus carefully, including &#147;Risk Factors,&#148; the financial
statements and other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus before making an investment decision. This prospectus supplement contains forward-looking statements that involve
risks and uncertainties. Our actual results could differ materially from the results anticipated in these forward-looking statements as a result of factors described under the &#147;Risk Factors&#148; section and elsewhere in this prospectus
supplement and in the risk factors set forth under &#147;Item&nbsp;1A. Risk Factors&#148; in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2012, and elsewhere in the documents incorporated by reference. All references in
this prospectus supplement to &#147;$&#148; are to U.S. dollars. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Business </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a specialty pharmaceutical and medical device company focused on oncology. Our proprietary technology is designed to administer
high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. Our initial focus is on the treatment of primary and metastatic liver cancers. We believe that
the proprietary technology is a platform that may have broader applicability, including the use of other drugs to treat the liver, as well as for the treatment of cancers in other organs and regions of the body. In 2010, we announced that our
randomized Phase 3 clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study&#146;s primary endpoint of extended hepatic progression-free survival. We have also completed a multi-arm Phase 2 trial to treat
other liver cancers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outside of the United States, our proprietary system to deliver and filter melphalan hydrochloride is
marketed as a device under the trade name Delcath Hepatic CHEMOSAT&reg; Delivery System (CHEMOSAT Delivery System for Melphalan). In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for
Melphalan. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT System for Melphalan in Europe. We have initiated commercialization efforts in Europe. In October 2012, we satisfied all of the requirements to affix the CE
Mark to the Hepatic CHEMOSAT Delivery System device for intra-hepatic arterial delivery and extracorporeal filtration of doxorubicin hydrochloride injection (CHEMOSAT System for Doxorubicin), which we believe will provide a regulatory pathway for
approval in Asia. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, our proprietary system for the administration of melphalan hydrochloride to the liver
is considered a combination drug and device product and is regulated as a drug by the United States Food and Drug Administration (FDA). We submitted our New Drug Application (NDA) to the FDA on August&nbsp;15, 2012, with the proposed trade name
Melblez KitTM (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System) (Melblez Kit), and are seeking approval for commercial sale of the Melblez Kit in the treatment of patients with unresectable metastatic ocular
melanoma in the liver. Our NDA was accepted for </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
filing by the FDA on October&nbsp;15, 2012 and has been designated for standard review with a Prescription Drug User Fee Act (PDUFA) goal date of June&nbsp;15, 2013. An Oncologic Drugs Advisory
Committee (ODAC) panel will be convened May&nbsp;2, 2013 as part of the FDA&#146;s review. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have financed our operations primarily through public and private placements of equity securities. We have incurred net losses since we
were founded and we expect to continue to incur significant net losses throughout 2013. We expect that the average amount of capital required for operations to increase in the foreseeable future, as we commercialize the Delcath CHEMOSAT system in
Europe, continue research and development activities, continue the approval process with the FDA and prepare for potential US commercialization. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our principal executive office is located at 810 Seventh Avenue,
35</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, NY 10019. Our telephone number is
(212)&nbsp;489-2100. Our website address is http://www.delcath.com. Information contained in, or accessible through, our website does not constitute a part of this prospectus. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_3"></A>THE OFFERING </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by us</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,565,811 shares.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock to be outstanding immediately after this offering</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">96,749,110 shares.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of Proceeds</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from the sale of the shares for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory
approvals, funding of our clinical trials, capital expenditures and working capital. See &#147;Use of Proceeds&#148; on page S2-5 of this prospectus supplement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Market Symbol</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">DCTH</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk Factors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our common stock involves a high degree of risk. You should read the description of risks set forth in the &#147;Risk Factors&#148; section of this prospectus
supplement or otherwise incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to purchase our securities.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of common stock to be outstanding immediately after this offering as reflected in the table above is
based on 91,183,299 shares of common stock outstanding as of March 26, 2013. Unless we specifically state otherwise, the information throughout this prospectus supplement excludes, as of March 26, 2013: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,616,762 shares issuable upon the exercise of stock options at a weighted average exercise price of $4.36 per share; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,445,646 shares issuable upon the exercise of outstanding warrants or options to purchase warrants at a weighted average exercise price of $1.20 per
share. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_4"></A><A NAME="ssupcov513079_1"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Any investment in our securities involves a high degree of risk. You should carefully consider the risks described below and all of
the information contained in this prospectus supplement and the accompanying prospectus before deciding whether to purchase our securities. In addition, you should carefully consider, among other things, the matters discussed under &#147;Risk
Factors&#148; and &#147;Quantitative and Qualitative Disclosures About Market Risk&#148; in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012, and in other documents that we subsequently file with the Securities and Exchange
Commission, all of which are incorporated by reference. The risks and uncertainties described below and incorporated by reference are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that
we currently deem immaterial may also impair our business operations. If any of these risks actually occur, our business, financial condition and results of operations would suffer. In that event, the trading price of our common stock offered hereby
could decline, and you may lose all or part of your investment. This prospectus supplement, the accompanying prospectus and the incorporated documents also include forward-looking statements and our actual results may differ substantially from those
discussed in these forward-looking statements. See &#147;Disclosure Regarding Forward-Looking Statements.&#148; </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Additional Risks
Related to this Offering </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our management team will have broad discretion over the use of the net proceeds from this offering.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management will use its discretion to direct the net proceeds from this offering. We intend to use the net
proceeds from the sale of the shares for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. Our
management&#146;s judgments may not result in positive returns on your investment and you will not have an opportunity to evaluate the economic, financial or other information upon which our management bases its decisions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The sale of our common stock in this offering will may result in immediate and substantial dilution. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we elect to draw down amounts under the Purchase Agreement, which will result in the sale of additional shares of our common stock to
Terrapin, any such draw downs will have a dilutive impact on our existing stockholders. Terrapin may resell some or all of the shares we issue to it pursuant to draw downs under the Purchase Agreement and such sales could cause the market price of
our common stock to decline. To the extent of any such decline, any subsequent draw downs would require us to issue a greater number of shares of common stock to Terrapin in exchange for each dollar of proceeds received from the draw down. Under
these circumstances, our existing stockholders would experience greater dilution and the total amount of the financing that we will be able to raise pursuant to the Purchase Agreement could be significantly lower than $35 million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future sales or issuances of our common stock in the public markets, or the perception of such sales,
could depress the trading price of our common stock. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The sale of a substantial number of shares of our common stock
or other equity-related securities in the public markets, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We
may sell large quantities of our common stock at any time pursuant to this prospectus supplement or one or more separate offerings. We cannot predict the effect that future sales of common stock or other equity-related securities would have on the
market price of our common stock. Additionally, although Terrapin is precluded from short sales of shares acquired pursuant to draw downs under the Purchase Agreement, the sale of our common stock under the Purchase Agreement, or the perception that
such sales could occur, may encourage short sales by third parties, which could contribute to further decline of our stock price. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_5"></A>FORWARD-LOOKING INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
prospectus supplement, the accompanying prospectus and the documents incorporated by reference into this prospectus supplement contain certain &#147;forward-looking statements&#148; within the meaning of the &#147;safe harbor&#148; provisions of the
Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity and results of operations. Words such as &#147;anticipates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;predicts,&#148; &#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; &#147;could,&#148; &#147;would,&#148; &#147;will,&#148; &#147;may,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;potential,&#148; &#147;should,&#148; and the
negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this prospectus supplement, the accompanying prospectus and the other documents incorporated by reference that are not historical facts
are hereby identified as &#147;forward-looking statements&#148; for the purpose of the safe harbor provided by Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of the Securities Act. These forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in this prospectus, in our Annual
Report on Form 10-K for the fiscal year ended December&nbsp;31, 2012 in Item&nbsp;1A under &#147;Risk Factors&#148; &#148; as well as in Item&nbsp;7A &#147;Quantitative and Qualitative Disclosures About Market Risk&#148; and the risks detailed from
time to time in our future SEC reports. These forward-looking statements include, but are not limited to, statements about: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for additional financing;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the progress and results of our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the commencement of future clinical trials and the results and timing of those clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission and timing of applications for regulatory approval and approval thereof; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully source certain components of the system and enter into supplier contracts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully manufacture the Delcath CHEMOSAT/Melblez kitsystem; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully commercialize the Delcath CHEMOSAT/Melblez kit system and successfully obtain reimbursement; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully negotiate and enter into agreements with strategic and corporate partners. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to
put undue reliance on any forward-looking statements, which speak only as of the date of this prospectus supplement, the date of the accompanying prospectus or, in the case of documents incorporated by reference, as of the date of such documents.
Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus supplement or to reflect the
occurrence of unanticipated events. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_6"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from the sale of the shares, if any, for general corporate purposes, including, but not limited to,
commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_7"></A>DIVIDEND POLICY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never declared or
paid any dividends to the holders of our common stock and we do not expect to pay cash dividends in the foreseeable future. We currently intend to retain all earnings for use in connection with the expansion of our business and for general corporate
purposes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the public offering
price per share of our common stock and the adjusted net tangible book value per share of our common stock after this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net tangible book value of our common stock as of December&nbsp;31, 2012, was approximately $20.0 million, or approximately $0.26 per
share. Net tangible book value per share represents the amount of our total tangible assets, excluding goodwill and intangible assets, less total liabilities divided by the total number of shares of our common stock outstanding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After giving effect to the sale of shares of our common stock in the aggregate amount of $9.0 million at an offering price of $1.62 per
share, and estimated offering expenses, our pro forma net tangible book value as of December&nbsp;31, 2012 would have been approximately $28.9 million or approximately $0.35 per share. This represents an immediate increase in net tangible book value
of approximately $0.09 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately $1.27 per share to purchasers of our common stock in this offering, as illustrated by the following table:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed offering price per unit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Tangible book value per share as of December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase per share attributable to the offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjusted net tangible book value per share as of December&nbsp;31, 2012 after giving effect to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing table is based on 76,820,933 shares of common stock outstanding as of December&nbsp;31,
2012 and assumes no exercise of warrants or options or issuances of shares of common stock since that date. In addition, the table does not take into effect further dilution to new investors that could occur upon the exercise of the outstanding
options and warrants having an exercise price less than the per share offering price to the public on this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above excludes
the following potentially dilutive securities as of December&nbsp;31, 2012: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,788,887 shares issuable upon the exercise of stock options at a weighted average exercise price of $4.85 per share; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,642,580 shares issuable upon the exercise of outstanding warrants or options to purchase warrants at a weighted average exercise price of $1.20 per
share. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_9"></A>PLAN OF DISTRIBUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please see the information set forth under the caption &#147;Plan of Distribution&#148; in the accompanying prospectus, and the
disclosure set forth in our Current Report on Form&nbsp;8-K relating to our equity line of credit arrangement with Terrapin, filed with the SEC on December&nbsp;5, 2012, pursuant to the Exchange Act, which is incorporated herein by reference. For
more information, please see the section entitled &#147;Incorporation by Reference&#148; in this prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_10"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the securities being offered hereby will be passed upon for us by Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP, New
York, New York. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_11"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form 10-K for the year ended December 31, 2012 and the effectiveness of our internal control over financial reporting as of December 31, 2012, as set forth in their reports, which are incorporated by reference in the this prospectus
and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#146;s reports given on their authority as experts in accounting and auditing. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="ssupptoc513079_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement is part of a registration statement on Form S-3 that we filed with the SEC. The registration statement that
contains this prospectus supplement, including the exhibits to the registration statement, contains additional information about us and the common stock offered by this prospectus supplement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we
file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our public filings, including reports, proxy and information
statements, are also available on the SEC&#146;s website at http://www.sec.gov. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INCORPORATION BY REFERENCE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; information that we file with it, which means that we can disclose important
information to you by referring you to another document that we have filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this prospectus supplement. We incorporate by reference
the following information or documents that we have filed with the SEC (Commission File No.&nbsp;001-34828): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Current Report on Form 8-K filed with the SEC on March&nbsp;13, 2013; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Annual Report on Form 10-K for the fiscal year ended 2012 filed with the SEC on March&nbsp;13, 2013 (the &#147;2012 Form&nbsp;10-K&#148;);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information specifically incorporated by reference into the 2012 Form 10-K; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The description of our common stock set forth in our registration statement on Form 8-A filed with the SEC on July&nbsp;23, 2010, including any
amendments thereto or reports filed for the purpose of updating this transaction. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also incorporate by reference into this prospectus supplement all documents (other than
Current Reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act
after the date of this prospectus supplement and until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus supplement. These documents include periodic reports, such as Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any
statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document
or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">810 Seventh Avenue, 35</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10019 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">or by calling us at 212-489-2100 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S2-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS SUPPLEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(To Prospectus dated October&nbsp;9, 2012) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g513079img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>$35,000,000 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COMMON STOCK </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to $35,000,000 of shares of our common stock to Terrapin Opportunity, L.P., or Terrapin, pursuant to a Common
Stock Purchase Agreement between us and Terrapin dated as of December&nbsp;5, 2012, which we refer to as the Purchase Agreement. The offering price of such shares, net of commissions payable by us, will be at a discount of ranging between 3.6% to
5.8% from the volume weighted average price of our common stock at the time of sale, as reported on The NASDAQ Global Market. Upon each sale of our common stock to Terrapin under the Purchase Agreement, we have also agreed to pay Financial West
Group, member FINRA/SIPC, or FWG, a placement agent fee of $1,500. The specific terms of any offering, other than the shares of common stock we agreed to issue to Terrapin in consideration of the execution and delivery of the Purchase Agreement,
will be provided by way of a further prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the accompanying prospectus also
cover the resale of all of these shares by Terrapin to the public. Terrapin is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act, and any profits on the sales of
shares of our common stock by Terrapin and any discounts, commissions or concessions received by Terrapin may be deemed to be underwriting discounts and commissions under the Securities Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is traded on the NASDAQ Global Market under the trading symbol &#147;DCTH.&#148; On December&nbsp;4, 2012, the last
reported sales price for our common stock was $1.45&nbsp;per share. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INVESTING IN OUR SECURITIES INVOLVES A HIGH
DEGREE OF RISK. SEE THE SECTION ENTITLED &#147;<U>RISK FACTORS</U>&#148; BEGINNING ON PAGE&nbsp;S-6 OF THIS PROSPECTUS SUPPLEMENT. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The date
of this Prospectus Supplement is December&nbsp;5, 2012 </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement is a supplement to the accompanying prospectus, dated October&nbsp;9, 2012, which is also a part of this
document. This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 (File No.&nbsp;333-183675), which we refer to as the Registration Statement, that we filed with the Securities and Exchange
Commission, or the SEC, using the &#147;shelf&#148; registration process, and that was declared effective on October&nbsp;9, 2012. Under this &#147;shelf&#148; registration process, we may from time to time sell any combination of securities
described in the accompanying prospectus in one or more offerings up to a total of $100&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This document is in two
parts. The first part is this prospectus supplement, which describes the specific terms of the offering and also supplements, adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into
the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information, some of which may not apply to the securities. Generally, when we refer to this prospectus, we are referring to both parts of this
document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or any document incorporated by reference therein, on
the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by
reference in the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the
summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this
prospectus supplement is a part, and you may obtain copies of those documents as described below under the section entitled &#147;Where You Can Find Additional Information.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless stated otherwise, references in this prospectus supplement and the accompanying prospectus to &#147;Delcath,&#148; &#147;we,&#148;
&#147;us,&#148; or &#147;our&#148; refer to Delcath Systems, Inc., a Delaware corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement, the
accompanying prospectus, and the information incorporated herein and therein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by
reference into this prospectus supplement or the accompanying prospectus are the property of their respective owners. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
not making any representation to you regarding the legality of an investment in the securities by you under applicable law. We are not making an offer to sell the securities in any jurisdiction where the offer or sale is not permitted. Persons
outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this
prospectus supplement and the accompanying prospectus outside the United States. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_2"></A>PROSPECTUS
SUPPLEMENT SUMMARY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights selected information contained elsewhere or incorporated by reference in
this prospectus supplement. This summary does not contain all the information that you should consider before investing in our securities. You should read the entire prospectus supplement and the accompanying prospectus carefully, including
&#147;Risk Factors,&#148; the financial statements and other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus before making an investment decision. This prospectus supplement contains
forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from the results anticipated in these forward-looking statements as a result of factors described under the &#147;Risk Factors&#148; section
and elsewhere in this prospectus supplement and in the risk factors set </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
forth under &#147;Item&nbsp;1A. Risk Factors&#148; in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011 and our Quarterly Report on Form&nbsp;10-Q for the quarter
ended September&nbsp;30, 2012, and elsewhere in the documents incorporated by reference. All references in this prospectus supplement to &#147;$&#148; are to U.S. dollars. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Business </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a specialty pharmaceutical and medical device company
focused on oncology. Our proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. Our
initial focus is on the treatment of primary and metastatic liver cancers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2010, we announced that
our randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study&#146;s primary endpoint of extended hepatic progression-free survival. We also completed a multi-arm Phase II trial to
treat other liver cancers. We obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
delivery system for the delivery and filtration of melphalan hydrochloride in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. In October 2012, we satisfied all of the requirements to affix the CE Mark to
our Hepatic CHEMOSAT Delivery System device for the delivery and filtration of doxorubicin hydrochloride injection, providing a regulatory pathway for CHEMOSAT with doxorubicin hydrochloride injection for countries in Asia that accept CE Marking as
part of their national regulatory requirements. The right to affix the CE mark allows us to market and sell the CHEMOSAT system in Europe. We submitted our New Drug Application (NDA) to the U.S. Food&nbsp;&amp; Drug Administration (FDA) on
August&nbsp;15, 2012, seeking approval for commercial sale of our chemosaturation system with melphalan in the treatment of patients with unresectable metastatic melanoma in the liver. Our NDA was accepted for filing by the FDA, and has been
designated for standard review with a Prescription Drug User Fee Act (PDUFA) goal date of June&nbsp;15, 2013. We will continue to work with the FDA to complete its review with the goal of obtaining approval for commercial sale of our proprietary
chemosaturation system with melphalan. We have not yet received FDA approval for commercial sale of our system in the United States. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Challenge of Treating Liver Dominant Disease </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are two types of liver cancer: primary and metastatic. Primary liver cancer (hepatocellular carcinoma or HCC) originates in the liver and is particularly prevalent in populations where the primary
risk factors for the disease (hepatitis-B, hepatitis-C, high levels of alcohol consumption, aflatoxin, cigarette smoking and exposure to industrial pollutants) are present. Metastatic, or secondary, liver cancer is characterized by microscopic
cancer cell clusters that detach from the primary site of disease and travel via the blood stream and lymphatic system into the liver, where they grow into new tumors. These metastases often continue to grow even after the primary cancer in another
part of the body has been removed.&nbsp;Given the vital biological function of the liver, including processing nutrients from food and filtering toxins from the blood, it is common for metastases to settle in the liver. In many cases patients die
not as a result of their primary cancer, but from the tumors that metastasize in their liver.&nbsp;In the United States, metastatic liver cancer is more prevalent than primary liver cancer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Delcath system for hepatic chemosaturation allows the administration of concentrated regional chemotherapy to the liver. This
&#147;whole organ&#148; therapy is administered by first isolating the circulatory system of the liver, saturating the entire organ with chemotherapeutic agent, and filtering the blood prior to returning it to the patient. The Delcath system
involves three catheters placed percutaneously through standard interventional radiology techniques. The catheters temporarily isolate the liver from the body&#146;s circulatory system, deliver a 30 minute infusion of chemotherapeutic agent
(currently melphalan hydrochloride) directly to the liver, and collect drug-laden blood exiting the liver for filtration by proprietary filters. The filters reduce the concentration of chemotherapeutic agent in the blood, thereby minimizing systemic
exposure to the drug and related side-effects before the filtered blood is returned to the patient&#146;s circulatory system. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The procedure is minimally invasive and repeatable, allowing for multiple courses of treatment with chemotherapeutic drugs and the
potential for concomitant use in conjunction with other cancer therapies. We believe that the Delcath chemosaturation system may play an important role in the management of cancers in the liver, potentially providing time and additional options for
treatment of a patient&#146;s primary disease. We also believe that the Delcath system is a platform technology that in the future may include the use of other drugs to treat cancers in the liver, as well as for the treatment of cancers in other
organs and regions of the body. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>European Market Commercialization </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2011, we obtained the right to affix the CE Mark to our first generation commercial product: the Delcath Hepatic CHEMOSAT&reg;
Delivery System for the delivery and filitration of melphalan hydrochloride (CHEMOSAT System). We believe the CHEMOSAT System may ultimately fulfill an annual unmet clinical need for as many as 59,000 patients with cancers in the liver in this
region. In the EEA, the CHEMOSAT System is regulated as a medical device indicated for the intra-arterial administration of chemotherapeutic agent (melphalan hydrochloride) to the liver with additional extracorporeal filtration of the venous blood
return. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the EEA, we are focusing our initial commercialization efforts on seven target markets: Germany, United Kingdom,
France, the Netherlands, Italy, Spain and Ireland. We believe these countries represent a majority of the total potential liver cancer market in the EEA. Our commercialization strategy for these markets involves the establishment of initial training
and launch centers at prestigious cancer hospitals. Medical teams at these centers are trained in the performance of the CHEMOSAT procedure and proctored for their initial cases by experienced physicians, and are provided additional logistical
support by Delcath. We believe that as the CHEMOSAT teams at these centers gain experience, they will form a European base of key opinion leadership that will help educate other physicians about the potential of chemosaturation therapy with CHEMOSAT
and foster initial market acceptance. To further drive adoption, we are using a combination of direct and indirect sales channels to market and distribute the CHEMOSAT System in Europe. We have recently entered into exclusive distribution agreements
for Italy and Spain. In addition, we have retained Quintiles to provide a third party medical science liaison force to educate medical oncologists in the target markets about the CHEMOSAT system. To support commercialization efforts, we established
our EU headquarters in Galway, Ireland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2011, we announced that it had entered into our first initial training
and launch agreement with the European Institute of Oncology (IEO) in Milan, Italy.&nbsp;As of the end of the third quarter, we had signed a total of 13 such agreements with leading European cancer centers, and has established a presence in all
seven of our target markets. Patients treated thus far include those with inoperable liver-dominant metastases from ocular melanoma, cutaneous melanoma, breast cancer, gastric cancer and cholangiocarcinoma. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, we announced that we received CE Mark approval for the Generation&nbsp;Two hemofiltration cartridge of the CHEMOSAT
System. The Generation&nbsp;Two system has demonstrated filter efficiency greater than 98% during drug infusion of melphalan in an in vivo study; the same study also showed that the Generation&nbsp;Two filter removes fewer blood platelets. Upon
approval of the Generation&nbsp;Two filter, we began supplying our early launch and training centers exclusively with the Generation&nbsp;Two CHEMOSAT system. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Applications for interim reimbursement have been submitted in Germany, Italy and the UK and we expect a response by first quarter of 2013.&nbsp;We are also supporting efforts of treatment centers to
pursue patient specific insurance funding in these countries as well as in Spain. In the other target countries, reimbursement pathways have been identified and are being actively pursued. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Regulatory </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>International Regulations </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recently changed our Notified Body in Europe and as part of this change the CHEMOSAT System was reclassified from a Class III medical
device to a Class IIb medical device.&nbsp;The primary difference between Class III and Class IIb is that for Class IIb medical devices the Notified Body is not required to carry out an examination of the product&#146;s design dossier as part of its
conformity assessment. We must continue to comply with the essential requirements of the EU Medical Devices Directive (Directive 93/42 EC) and are subject to a conformity assessment procedure requiring the intervention of a Notified Body.&nbsp;The
conformity assessment procedure for Class IIb medical devices requires the manufacturer to lodge an application for the assessment of its quality system for the design, manufacture and inspection of its medical devices by a Notified Body.&nbsp;The
Notified Body will audit the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
system to determine whether it conforms to the provisions of the Medical Devices Directive.&nbsp;If the Notified Body&#146;s assessment is favorable it will issue a Full Quality Assurance
Certificate, which enables the manufacturer to draw a Declaration of Conformity and affix the CE mark to the medical devices covered by the assessment. Thereafter, the Notified Body will carry out periodic audits to ensure that the approved quality
system is applied by the manufacturer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;22, 2012, we announced that we had satisfied all of the requirements
to affix the CE Mark to our Hepatic CHEMOSAT Delivery System for the delivery and filtration of doxorubicin hydrochloride (&#147;CHEMOSAT System to deliver and filtrate doxorubicin&#148;).&nbsp;CE Marking confirms that a medical device complies with
the Essential Requirements of the Medical Device Directive, and that the device has been subjected to conformity assessment procedures. Application of the CE Mark for the CHEMOSAT System to deliver and filtrate doxorubicin provides us with a
regulatory pathway for certain countries in Asia that accept CE Marking as part of their national regulatory requirements. Doxorubicin is an established chemotherapeutic agent commonly used globally to treat hepatocellular carcinoma (HCC) via
trans-arterial chemoembolization (TACE) and is widely used to treat HCC in Asia, which is where we see the market opportunity for our CHEMOSAT system to deliver and filtrate doxorubicin injection. In China, these requirements include conducting a
local clinical trial and approval by the China State Food and Drug Administration (SFDA).&nbsp;We intend to seek approvals for the CHEMOSAT System with doxorubicin in key Asian markets such as China and South Korea. We do not intend to market the
CHEMOSAT System to deliver and filtrate doxorubicin in the European Economic Area at this time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Having previously obtained
the CE Mark for the CHEMOSAT System with melphalan, we believe the right to affix the CE Mark can result in an accelerated regulatory approval in a number of countries outside the EEA and the United States. We recently received regulatory approval
for the second generation CHEMOSAT System in Australia and has completed the product notification process in New Zealand. We have submitted applications for regulatory approval as a device for the CHEMOSAT System in Hong Kong, South Korea,
Singapore, Canada and Israel and we intend to submit regulatory applications in Mexico, Argentina, Brazil, Russia, India, Japan, China, and Taiwan.&nbsp;We are in the process of determining the regulatory pathway in some of these countries subject
to negotiations with the applicable health authority.&nbsp;It is our intention to leverage the CE Mark in some or all of these countries to commercialize the Delcath CHEMOSAT System, where appropriate.&nbsp;Delcath Systems Limited&#146;s facility in
Galway, Ireland has obtained certificates of free sale from the Irish Medicines Board as many markets require country of origin manufacturing, such as Mexico, Argentina, Brazil, Japan, China, and Taiwan, as a prerequisite to obtain regulatory
approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>United States </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the United States, the Delcath chemosaturation system for the administration of melphalan hydrochloride is considered a combination drug and device product and is regulated as a drug by the U.S. Food
and Drug Administration (FDA).&nbsp;In August 2012, we submitted our Section&nbsp;505(b)(2) New Drug Application (NDA), to the FDA, seeking an indication for the percutaneous intra-arterial administration of melphalan for use in the treatment of
patients with metastatic melanoma in the liver.&nbsp;The NDA was accepted for filing by the FDA, and has been designated for standard review with a PDUFA goal date of June&nbsp;15, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the NDA submission, we submitted to the FDA an amendment to our Investigational New Drug application to include the
Generation&nbsp;Two system in the FDA&#146;s Expanded Access Program (EAP), as well as all future clinical trials and compassionate use cases.&nbsp;We announced acceptance of these amendments on June&nbsp;18, 2012, and expect the first centers to
begin treating patients under the EAP by the end of 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have financed our operations primarily through public and private placements of equity securities. We have incurred net losses since we
were founded and we expect to continue to incur significant net losses throughout 2012. We expect that the average amount of capital required for operations to increase in the foreseeable future, as we commercialize the Delcath chemosaturation
system in Europe, continue research and development activities, continue the submission process with the FDA and prepare for potential US commercialization. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our principal executive office is located at 810 Seventh Avenue, 35</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, NY 10019. Our telephone number is
(212)&nbsp;489-2100. Our website address is http://www.delcath.com. Information contained in, or accessible through, our website does not constitute a part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_3"></A>THE OFFERING </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares of common stock with aggregate gross sale proceeds of up to $35,000,000.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds of offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The proceeds from this offering will vary depending on the number of shares that we offer and the offering price per share. We expect that our net maximum proceeds, after
discounts and placement agent commissions and offering expenses, will be up to approximately $33,410,517. We may sell fewer than all of the shares offered by this prospectus supplement, in which case our net offering proceeds will be less, and we
may raise less than the maximum $35,000,000 in gross offering proceeds permitted by this prospectus supplement.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of Proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from the sale of the shares for general corporate purposes, including, but not limited to, commercialization of our products, obtaining
regulatory approvals, funding of our clinical trials, capital expenditures and working capital. See&nbsp;&#147;Use of Proceeds&#148; on page S-7 of this prospectus supplement.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividend Policy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never declared or paid any dividends to the holders of our common stock and we do not expect to pay cash dividends in the foreseeable future. We currently intend to
retain all earnings for use in connection with the expansion of our business and for general corporate purposes.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Market Symbol</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DCTH</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk Factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our common stock involves a high degree of risk. You should read the description of risks set forth in the &#147;Risk Factors&#148; section of this prospectus
supplement or otherwise incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to purchase our securities.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Purchase Agreement governing this offering became effective on December 5, 2012.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_4"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Any investment in our securities involves a high degree of risk. You should carefully consider the risks described below and all of
the information contained in this prospectus supplement and the accompanying prospectus before deciding whether to purchase our securities. In addition, you should carefully consider, among other things, the matters discussed under &#147;Risk
Factors&#148; and &#147;Quantitative and Qualitative Disclosures About Market Risk&#148; in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011, in our Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2012,
and in other documents that we subsequently file with the Securities and Exchange Commission, all of which are incorporated by reference. The risks and uncertainties described below and incorporated by reference are not the only risks and
uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. If any of these risks actually occur, our business, financial condition and results of
operations would suffer. In that event, the trading price of our common stock offered hereby could decline, and you may lose all or part of your investment. This prospectus supplement, the accompanying prospectus and the incorporated documents also
include forward-looking statements and our actual results may differ substantially from those discussed in these forward-looking statements. See &#147;Disclosure Regarding Forward-Looking Statements.&#148; </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Additional Risks Related to this Offering </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our management team will have broad discretion over the use of the net proceeds from this offering. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management will use its discretion to direct the net proceeds from this offering. We intend to use the net proceeds from the sale of
the shares for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. Our management&#146;s judgments
may not result in positive returns on your investment and you will not have an opportunity to evaluate the economic, financial or other information upon which our management bases its decisions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The sale of our common stock in this offering will may result in immediate and substantial dilution. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we elect to draw down amounts under the Purchase Agreement, which will result in the sale of additional shares of our common stock to
Terrapin, any such draw downs will have a dilutive impact on our existing stockholders. Terrapin may resell some or all of the shares we issue to it pursuant to draw downs under the Purchase Agreement and such sales could cause the market price of
our common stock to decline. To the extent of any such decline, any subsequent draw downs would require us to issue a greater number of shares of common stock to Terrapin in exchange for each dollar of proceeds received from the draw down. Under
these circumstances, our existing stockholders would experience greater dilution and the total amount of the financing that we will be able to raise pursuant to the Purchase Agreement could be significantly lower than $35 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future sales or issuances of our common stock in the public markets, or the perception of such sales, could depress the trading price of our common
stock. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The sale of a substantial number of shares of our common stock or other equity-related securities in the public
markets, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We may sell large quantities of our common stock at
any time pursuant to this prospectus supplement or one or more separate offerings. We cannot predict the effect that future sales of common stock or other equity-related securities would have on the market price of our common stock. Additionally,
although Terrapin is precluded from short sales of shares acquired pursuant to draw downs under the Purchase Agreement, the sale of our common stock under the Purchase Agreement, or the perception that such sales could occur, may encourage short
sales by third parties, which could contribute to further decline of our stock price. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_5"></A>FORWARD-LOOKING INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference into this prospectus supplement
contain certain &#147;forward-looking statements&#148; within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity and results of
operations. Words such as &#147;anticipates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;predicts,&#148; &#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; &#147;could,&#148; &#147;would,&#148;
&#147;will,&#148; &#147;may,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;potential,&#148; &#147;should,&#148; and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this
prospectus supplement, the accompanying prospectus and the other documents incorporated by reference that are not historical facts are hereby identified as &#147;forward-looking statements&#148; for the purpose of the safe harbor provided by
Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of the Securities Act. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ
materially from the results contemplated by the forward-looking statements, including the risks discussed in this prospectus supplement, the accompanying prospectus, in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2011
in Item&nbsp;1A under &#147;Risk Factors&#148; as well as in Item&nbsp;7A &#147;Quantitative and Qualitative Disclosures About Market Risk,&#148; our Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2012 in Part I, Item&nbsp;3
&#147;Quantitative and Qualitative Disclosures About Market Risk&#148; and the risks detailed from time to time in our future SEC reports. These forward-looking statements include, but are not limited to, statements about: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the progress and results of our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for additional financing;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the commencement of future clinical trials and the results and timing of those clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission and timing of applications for regulatory approval and approval thereof; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully source certain components of the system and enter into supplier contracts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully manufacture the Delcath chemosaturation system; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully commercialize the Delcath chemosaturation system; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate partners; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to
put undue reliance on any forward-looking statements, which speak only as of the date of this prospectus supplement, the date of the accompanying prospectus or, in the case of documents incorporated by reference, as of the date of such documents.
Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus supplement or to reflect the
occurrence of unanticipated events. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_6"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from the sale of the shares, if any, for general corporate purposes, including, but not limited to,
commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_7"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never declared or paid any dividends to the holders of our common stock and we do not expect to pay cash dividends in the
foreseeable future. We currently intend to retain all earnings for use in connection with the expansion of our business and for general corporate purposes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the public offering
price per share of our common stock and the adjusted net tangible book value per share of our common stock after this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net tangible book value of our common stock as of September&nbsp;30, 2012, was approximately $24.9 million, or approximately $0.34
per share. Net tangible book value per share represents the amount of our total tangible assets, excluding goodwill and intangible assets, less total liabilities divided by the total number of shares of our common stock outstanding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After giving effect to the sale of shares of our common stock in the aggregate amount of $35,000,000 at an assumed offering price of
$1.45 per share, the last reported sale price of our common stock on December&nbsp;4, 2012 on The NASDAQ Capital Market, and after deducting an estimated discount of $5% (the discount that would apply under the Purchase Agreement based on the last
reported sale price of our common stock on December&nbsp;4, 2012) and estimated offering expenses, our pro forma net tangible book value as of December&nbsp;4, 2012 would have been approximately $58.4 million or approximately $0.60 per share. This
represents an immediate increase in net tangible book value of approximately $0.26 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately $0.85 per share to purchasers of our common
stock in this offering, as illustrated by the following table: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed offering price per unit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$1.45</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Tangible book value per share as of September 30, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.34</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase per share attributable to the offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjusted net tangible book value per share as of December&nbsp;4, 2012 after giving effect to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.85</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing table is based on
73,393,908</FONT><FONT STYLE="font-family:Times New Roman" SIZE="3"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> shares of common stock outstanding as of September&nbsp;30, 2012 and assumes no exercise of warrants or options or
issuances of shares of common stock since that date. In addition, the table does not take into effect further dilution to new investors that could occur upon the exercise of the outstanding options and warrants having an exercise price less than the
per share offering price to the public on this offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above excludes the following potentially dilutive securities as of
September&nbsp;30, 2012: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,834,053</FONT><FONT STYLE="font-family:Times New Roman" SIZE="3"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> shares issuable upon the
exercise of stock options at a weighted average exercise price of $4.78</FONT><FONT STYLE="font-family:Times New Roman" SIZE="3"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> per share; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,643,480</FONT><FONT STYLE="font-family:Times New Roman" SIZE="3"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> shares issuable upon the
exercise of outstanding warrants or options to purchase warrants at a weighted average exercise price of $1.59</FONT><FONT STYLE="font-family:Times New Roman" SIZE="3"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> per share.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_9"></A>PLAN OF DISTRIBUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;5, 2012, we entered into the Purchase Agreement with Terrapin, which provides that, upon the terms and subject to the
conditions set forth therein, Terrapin is committed to purchase from us up to $35,000,000 of our common stock over the approximately 24-month term of the Purchase Agreement, provided that, except as set forth in the immediately following sentence,
we may not sell under the Purchase Agreement more than 15,015,343 shares of our common stock, or the Trading Market Limit, which is equal to one share less than twenty percent of our issued and outstanding shares of common stock on the effective
date of the Purchase Agreement. The Trading Market Limit will not be applicable to the extent (and only for so long as) the average purchase price of all common stock issued by us to Terrapin, taking into account all discounts, equals or exceeds
$1.46 per share (subject to adjustment), which represents the consolidated closing bid price per share of our common stock as reported on the Nasdaq Global Market on the effective date of the Purchase Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time over the term of the Purchase Agreement, and at our sole discretion, we
may present Terrapin with draw down notices to purchase an aggregate dollar amount of our common stock, or a draw down amount, over ten consecutive trading days or such other period mutually agreed upon by us and Terrapin, or the draw down period,
with each draw down subject to limitations based on the price of our common stock and a limit of 4.9% of our market capitalization at the time of such draw down. We are able to present Terrapin with up to 24 draw down notices during the term of the
Purchase Agreement, with only one such draw down notice allowed per draw down period and a minimum of five trading days required between each draw down period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Once presented with a draw down notice, Terrapin is required to purchase a pro rata portion of the draw down amount on each trading day during the draw down period on which the daily volume weighted
average price for our common stock equals or exceeds a threshold price determined by us for such draw down. The per share purchase price for these shares equals the daily volume weighted average price of our common stock on each date during the draw
down period on which shares are purchased, less a discount ranging from 3.6% to 5.8%. If the daily volume weighted average price of our common stock falls below the threshold price on any trading day during a draw down period, the Purchase Agreement
provides that Terrapin will not be required to purchase the pro rata portion of the draw down amount allocated to that day. However, at its election, Terrapin may buy the pro rata portion of the draw down amount allocated to that day at the
threshold price less the discount described above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Purchase Agreement also provides that from time to time and at our
sole discretion we may grant Terrapin the right to exercise options to purchase additional shares of our common stock during each draw down period for an amount of shares specified by us based on the trading price of our common stock. Upon
Terrapin&#146;s exercise of an option, we would sell to Terrapin the shares of our common stock subject to the option at a price per share equal to the greater of the daily volume weighted average price of our common stock on the day Terrapin
notifies us of its election to exercise its option or the threshold price for the option determined by us, less a discount calculated in the same manner as it is calculated in the draw down notices. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our issuance of an aggregate of $35,000,000 of our shares of common stock to Terrapin pursuant to the Purchase Agreement,
the Registration Statement also covers the sale of those shares from time to time by Terrapin to the public. Terrapin is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terrapin has informed us that it will use an unaffiliated broker-dealer to effectuate all sales, if any, of common stock that it may
purchase from us pursuant to the Purchase Agreement. Such sales will be made on the Nasdaq Global Market, or any other exchange that our common stock may be traded on at such time, at prices and at terms then prevailing or at prices related to the
then current market price. Each such unaffiliated broker-dealer will be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act. Terrapin has informed us that each such broker-dealer will receive fees and commissions from
Terrapin that will not exceed customary brokerage fees and commissions. Terrapin also will pay other expenses associated with the sale of the common stock it acquires pursuant to the Purchase Agreement. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares of common stock may be sold in one or more of the following manners: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ordinary brokerage transactions and transactions in which the broker solicits purchasers; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a block trade in which the broker or dealer so engaged will attempt to sell the shares as agent, but may position and resell a portion of the block as
principal to facilitate the transaction. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terrapin has agreed that during the term of and for a period of
90&nbsp;days after the termination of the Purchase Agreement, neither Terrapin nor any of its affiliates will, directly or indirectly, sell for value any of our securities except the shares that it owns or has the right to purchase pursuant to the
provisions of a draw down notice. Terrapin has agreed that prior to and during the periods listed above neither it nor any of its affiliates will enter into a short position with respect to shares of our common stock except that Terrapin may sell
shares that it is obligated to purchase under a pending draw down notice but has not yet taken possession of so long as Terrapin covers any such sales with the shares purchased pursuant to such draw down notice. Terrapin has further agreed that
during the periods listed above it will not grant any option to purchase or acquire any right to dispose or otherwise dispose for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
value of any shares of our common stock or any securities convertible into, or exchangeable for, or warrants to purchase, any shares of our common stock, or enter into any swap, hedge or other
agreement that transfers, in whole or in part, the economic risk of ownership of our common stock, except for the sales permitted by the prior two sentences. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, Terrapin and any unaffiliated broker-dealer will be subject to liability under the federal securities laws and must comply with the requirements of the Securities Act and the Exchange Act,
including, without limitation, Rule&nbsp;10b-5 and Regulation&nbsp;M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares of common stock by Terrapin or any unaffiliated broker-dealer. Under these
rules and regulations, Terrapin and any unaffiliated broker-dealer: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not engage in any stabilization activity in connection with our securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">must furnish each broker that offers shares of our common stock covered by the prospectus supplement and the accompanying prospectus that is a part of
our Registration Statement with the number of copies of such prospectus and any prospectus supplement that are required by each broker; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the
Exchange Act. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These restrictions may affect the marketability of the shares of common stock purchased and
sold by Terrapin and any unaffiliated broker-dealer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify and hold harmless Terrapin, its directors,
officers, employees, partners and affiliates, and each person who controls Terrapin, against certain liabilities, including certain liabilities under the Securities Act. We have agreed to pay up to $35,000 of Terrapin&#146;s reasonable
attorneys&#146; fees and expenses (exclusive of disbursements and out-of-pocket expenses) incurred by Terrapin in connection with the preparation, negotiation, execution and delivery of the Purchase Agreement and related transaction documentation.
Further, we have agreed that if we issue a draw down notice and fail to deliver the shares to Terrapin on the applicable settlement date, and such failure continues for ten trading days, we will pay Terrapin as partial damages, cash or restricted
shares of our common stock, at the option of Terrapin. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terrapin has agreed to indemnify and hold harmless us and each of our
directors, officers, employees and affiliates and persons who control us, against certain liabilities, including certain liabilities under the Securities Act that may be based upon written information furnished by Terrapin to us for inclusion in a
prospectus or prospectus supplement related to this transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and Terrapin have agreed that no shares of common stock
may be issued to Terrapin pursuant to the Purchase Agreement to the extent that the issuance of such shares of common stock would result in the beneficial ownership by Terrapin of more than 9.9% of our then issued and outstanding shares of common
stock (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule&nbsp;13d-3 promulgated thereunder). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
entered into a placement agency agreement with FWG, pursuant to which FWG agreed to act as the placement agent in connection with the sale of shares of our common stock to Terrapin. Subject to our and FWG&#146;s receipt of written confirmation from
the Financial Industry Regulatory Authority, Inc., or FINRA, to the effect that FINRA&#146;s Corporate Finance Department has determined not to raise any objection with respect to the fairness or reasonableness of the terms of the Purchase Agreement
or the transactions contemplated thereby, we will pay FWG a placement fee of $1,500 upon each completed sale of our common stock to Terrapin under the Purchase Agreement, as compensation for its services in acting as placement agent in the sale of
our common stock to Terrapin. We have also agreed to indemnify and hold harmless FWG against certain liabilities, including liabilities under the Securities Act, and to pay up to $15,000 in the aggregate for FWG&#146;s reasonable attorneys&#146;
fees and expenses incurred in connection with the preparation of certain filings required to be made by FWG in connection with the transaction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please also see the information set forth under the caption &#147;Plan of Distribution&#148;
in the accompanying prospectus, and the disclosure set forth in our Current Report on Form&nbsp;8-K relating to the Purchase Agreement with Terrapin, filed with the SEC on December&nbsp;5, 2012, pursuant to the Exchange Act, which is incorporated
herein by reference. For more information, please see the section entitled &#147;Incorporation by Reference&#148; in this prospectus supplement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_10"></A>LEGAL MATTERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the
securities being offered hereby will be passed upon for us by Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP, New York, New York . </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_11"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ernst&nbsp;&amp; Young LLP,
independent registered public accounting firm, has audited our consolidated financial statements as of and for the years ended December&nbsp;31, 2011 and 2010 included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011 and
the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2011, as set forth in their reports, which are incorporated by reference in this prospectus supplement and the accompanying prospectus and elsewhere in the
registration statement. Our financial statements as of and for the years ended December&nbsp;31, 2011 and December&nbsp;31, 2010 are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports given on their authority as
experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements of Delcath Systems, Inc. for the year ended
December&nbsp;31, 2009 incorporated by reference in this prospectus and elsewhere in this prospectus supplement and the accompanying prospectus and elsewhere in the registration statement from our Annual Report on Form 10-K for the year ended
December&nbsp;31, 2011 have been so incorporated by reference in reliance upon the report of Grant Thornton LLP, independent registered public accountants and successor to the practice of CCR LLP, upon the authority of said firm as experts in
auditing and accounting in giving said report. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_12"></A>WHERE YOU CAN FIND MORE INFORMATION
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement is part of a registration statement on Form S-3 that we filed with the SEC. The registration
statement that contains this prospectus supplement, including the exhibits to the registration statement, contains additional information about us and the common stock offered by this prospectus supplement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we
file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at<BR> 1-800-SEC-0330 for further information on the Public Reference Room. Our public filings, including reports, proxy and information
statements, are also available on the SEC&#146;s website at http://www.sec.gov. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="supptoc457511_13"></A>INCORPORATION BY REFERENCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; information that we file with it, which means that we can disclose important information to you by referring you to another document that we have
filed separately with the SEC. You should read the information incorporated by reference because it is an important part of this prospectus supplement. We incorporate by reference the following information or documents that we have filed with the
SEC (Commission File No.&nbsp;001-34828): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Current Reports on Form 8-K filed with the SEC on January&nbsp;13, 2012,&nbsp;January&nbsp;31, 2012,&nbsp;February&nbsp;2,
2012,&nbsp;March&nbsp;26, 2012,&nbsp;April&nbsp;18, 2012,&nbsp;April&nbsp;24, 2012,&nbsp;May&nbsp;30, 2012,&nbsp;May&nbsp;31, 2012,&nbsp;July&nbsp;9, 2012,&nbsp;July&nbsp;19, 2012,&nbsp;August&nbsp;16, 2012,&nbsp;October&nbsp;15,
2012,&nbsp;November&nbsp;1, 2012 and December&nbsp;5, 2012; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Annual Report on Form 10-K for the fiscal year ended 2011 filed with the SEC on March&nbsp;6, 2012 (the &#147;2011<BR> Form&nbsp;10-K&#148;);
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Quarterly Reports on Form 10-Q for the quarters ended September&nbsp;30, 2012,&nbsp;June&nbsp;30, 2012 and March&nbsp;31, 2012 filed with the SEC
on November&nbsp;7, 2012,&nbsp;August&nbsp;8, 2012 and May&nbsp;9, 2012, respectively; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information specifically incorporated by reference into the 2011 Form 10-K from our definitive proxy statement on Schedule 14A filed with the SEC
on April&nbsp;27, 2012; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The description of our common stock set forth in our registration statement on Form 8-A filed with the SEC on July&nbsp;23, 2010, including any
amendments thereto or reports filed for the purpose of updating this transaction. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also incorporate by
reference into this prospectus supplement all documents (other than Current Reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC
pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement and until we file a post-effective amendment that indicates the termination of the offering of the securities made by this
prospectus supplement. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed
to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the
statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or
telephone number: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">810 Seventh Avenue, 35</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10019 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">or by calling us at 212-489-2100 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>$100,000,000 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g513079img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Warrants </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Debt Securities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>Stock Purchase Contracts </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems,
Inc. (the &#147;Company&#148;) may offer to sell from time to time common stock, preferred stock, warrants, debt securities and stock purchase contracts. The preferred stock of the Company may be convertible into common stock or preferred stock of
another series. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, selling stockholders to be named in a prospectus supplement may offer, from time to time, shares
of our common stock. To the extent that any selling stockholder resells any securities, the selling stockholder may be required to provide you with this prospectus and a prospectus supplement identifying and containing specific information about the
selling stockholder and the terms of the securities being offered. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company may offer securities and selling stockholders
may offer shares of our common stock at an aggregate offering price of up to $100,000,000. The common stock, preferred stock, warrants, debt securities and stock purchase contracts of the Company may be offered separately or together, in multiple
series, in amounts, at prices and on terms that will be set forth in one or more prospectus supplements to this prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus describes some of the general terms that may apply to these securities and the general manner in which they may be
offered. Each time the Company sells securities, a prospectus supplement will be provided that will contain specific information about the terms of any securities offered and the specific manner in which the securities will be offered. The
prospectus supplement will also contain information, where appropriate, about material United States federal income tax consequences relating to, and any listing on a securities exchange of, the securities covered by the prospectus supplement. The
prospectus supplement may add to, update or change the information in this prospectus. You should read this prospectus and any prospectus supplement carefully before you invest in our securities. This prospectus may not be used to sell securities
unless accompanied by a prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company may offer the securities directly to investors, through agents
designated from time to time by the Company, or to or through underwriters or dealers. If any agents, underwriters, or dealers are involved in the sale of any of the securities, their names, and any applicable purchase price, fee, commission or
discount arrangement with, between or among them will be set forth, or will be calculable from the information set forth, in an accompanying prospectus supplement. For more detailed information, see &#147;Plan of Distribution.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is traded on the NASDAQ Capital Market under the symbol &#147;DCTH.&#148; On September 26, 2012, the last reported sale
price of our common stock on the NASDAQ Capital Market was $1.66. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in
our common stock involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading &#147;<A HREF="#tx457511_2">Risk Factors</A>&#148; on page&nbsp;3 of this prospectus. </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The date of
this prospectus is October 9, 2012. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_1">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_3">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_4">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_5">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_6">SELLING STOCKHOLDERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_7">DESCRIPTION OF DEBT SECURITIES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_8">DESCRIPTION OF CAPITAL STOCK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_9">DESCRIPTION OF STOCK PURCHASE CONTRACTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_10">DESCRIPTION OF WARRANTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_11">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_12">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#tx457511_13">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ABOUT THIS PROSPECTUS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission using a &#147;shelf&#148; registration process. Under this shelf process, we may sell any
combination of the securities described in this prospectus in one or more offerings and selling stockholders to be named in a prospectus supplement may, from time to time, sell our common stock up to a total aggregate dollar amount of $100,000,000.
This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus
supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with additional information described under the heading &#147;Where You Can Find
Additional Information.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should rely only on the information contained in this prospectus and the accompanying
prospectus supplement or incorporated by reference in these documents. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus or the
accompanying prospectus supplement. If anyone provides you with different, inconsistent or unauthorized information or representations, you must not rely on them. This prospectus and the accompanying prospectus supplement are an offer to sell only
the securities offered by these documents, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or any prospectus supplement is current only as of the date on the front of those
documents. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">iii
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained elsewhere or incorporated by reference into this prospectus. Because it is a summary, it
does not contain all of the information that you should consider before investing in our securities. You should read this entire prospectus carefully, including the section entitled &#147;Risk Factors,&#148; any applicable prospectus supplement and
the documents that we incorporate by reference into this prospectus and the prospectus supplement, before making an investment decision. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a specialty pharmaceutical and medical
device company focused on oncology. Our proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those
agents. Our initial focus is on the treatment of primary and metastatic liver cancers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Delcath system for hepatic
chemosaturation allows the administration of concentrated regional chemotherapy to the liver. This &#147;whole organ&#148; therapy is administered by first isolating the circulatory system of the liver, saturating the entire organ with
chemotherapeutic agent, and filtering the blood prior to returning it to the patient. The Delcath system involves three catheters placed percutaneously through standard interventional radiology techniques. The catheters temporarily isolate the liver
from the body&#146;s circulatory system, deliver a 30 minute infusion of chemotherapeutic agent (currently melphalan hydrochloride) directly to the liver, and collect drug-laden blood exiting the liver for filtration by proprietary filters. The
filters reduce the concentration of chemotherapeutic agent in the blood, thereby minimizing systemic exposure to the drug and related side-effects before the filtered blood is returned to the patient&#146;s circulatory system. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The procedure is minimally invasive and repeatable, allowing for multiple courses of treatment with chemotherapeutic drugs and the
potential for concomitant use in conjunction with other cancer therapies. We believe that the Delcath chemosaturation system may play an important role in the management of cancers in the liver, potentially providing time and additional options for
treatment of a patient&#146;s primary disease. We also believe that the Delcath system is a platform technology that in the future may include the use of other drugs to treat cancers in the liver, as well as for the treatment of cancers in other
organs and regions of the body. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We obtained authorization to affix a CE Mark for our Hepatic CHEMOSAT Delivery System
(CHEMOSAT System) in April 2011 and for the second generation hemofiltration cartridge for our CHEMOSAT System in April 2012. The right to affix the CE mark allows us to market and sell the CHEMOSAT System in Europe. On August&nbsp;15, 2012, we
submitted our new drug application (NDA) to the United States Food and Drug Administration (FDA) seeking approval for our proprietary chemosaturation system for use with melphalan hydrochloride in the treatment of patients with unresectable
metastatic melanoma in the liver. We included our Generation 2 filter in our NDA submission as a technical change to the Chemistry, Manufacturing, and Control (CMC) module. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have financed our operations primarily through public and private placements of equity securities. We have incurred net losses since we were founded and we expect to continue to incur significant net
losses throughout 2012. We expect that the average amount of capital required for operations to increase in the foreseeable future, as we commercialize the Delcath chemosaturation system in Europe, continue research and development activities,
continue the submission process with the FDA and prepare for potential US commercialization. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our principal executive office is located at 810 Seventh Avenue,
35</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, NY 10019. Our telephone number is
(212)&nbsp;489-2100. Our website address is http://www.delcath.com. Information contained in, or accessible through, our website does not constitute a part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our securities involves a high degree of risk. You should consider carefully the risk factors set forth in the documents and
reports filed by us with the Securities and Exchange Commission, which we refer to as the SEC, that are incorporated by reference into this prospectus, as well as any risks described in any applicable prospectus supplement, before deciding whether
to buy our securities. Additional risks not known to us or that we believe are immaterial may also significantly impair our business operations and could result in a complete loss of your investment. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_3"></A>DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus, any prospectus supplement and the documents incorporated by reference into this prospectus contain certain
&#147;forward-looking statements&#148; within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity and results of operations. Words
such as &#147;anticipates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;predicts,&#148; &#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; &#147;could,&#148; &#147;would,&#148; &#147;will,&#148;
&#147;may,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;potential,&#148; &#147;should,&#148; and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this prospectus and the other
documents incorporated by reference that are not historical facts are hereby identified as &#147;forward-looking statements&#148; for the purpose of the safe harbor provided by Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, and
Section&nbsp;27A of the Securities Act of 1933, as amended. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results
contemplated by the forward-looking statements, including the risks discussed in this prospectus, in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2011 in Item&nbsp;1A under &#147;Risk Factors&#148; as well as in
Item&nbsp;7A &#147;Quantitative and Qualitative Disclosures About Market Risk,&#148; our Quarterly Report on Form 10-Q for the period ended June&nbsp;30, 2012 and our Quarterly Report on Form 10-Q for the period ended March&nbsp;31, 2012 in Part I,
Item&nbsp;3 &#147;Quantitative and Qualitative Disclosures About Market Risk,&#148; and the risks detailed from time to time in our future SEC reports. These forward-looking statements include, but are not limited to, statements about: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the progress and results of our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for additional financing;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the commencement of future clinical trials and the results and timing of those clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission and timing of applications for regulatory approval and approval thereof; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully source certain components of the system and enter into supplier contracts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully manufacture the Delcath chemosaturation system; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully commercialize the Delcath chemosaturation system; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully negotiate and enter into agreements with strategic and corporate partners. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to
put undue reliance on any forward-looking statements, which speak only as of the date of this prospectus or, in the case of documents incorporated by reference, as of the date of such documents. Except as otherwise required by law, we do not assume
any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_4"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>This prospectus is part of a registration statement we filed with the SEC. You should rely only on the information contained in this
prospectus, any applicable prospectus supplement or documents incorporated by reference into this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state
where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of
securities. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We file reports, proxy statements and other information with the SEC. You may read and copy any reports,
proxy statements or other information filed by us at the SEC&#146;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800)&nbsp;SEC-0330.
The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Delcath Systems, Inc. The address of the SEC website is http://www.sec.gov. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Important Information Incorporated By Reference </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The documents incorporated by reference into this prospectus contain important information that you should read about us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following documents are incorporated by reference into this document: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:108pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC Filing (File No. 001-16133)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date of Filing</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quarterly Report on Form&nbsp;10-Q for quarter ended March&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 9, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Quarterly Report on Form&nbsp;10-Q for quarter ended June&nbsp;30, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 8, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proxy Statement on Schedule&nbsp;14A for our 2011 Meeting of Stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 27, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Report on Form&nbsp;10-K for year ended December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 3, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Reports on Form&nbsp;8-K and 8-K/A</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 13, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 13, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 31, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">February 2, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 26, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 18, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 24, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 30, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 31, 2012</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(excluding that</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">information that is</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">expressly not filed)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 9, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 19, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;15, 2012</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also incorporate by reference into this prospectus all documents (other than current reports furnished
under Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of
the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
initial registration statement and prior to effectiveness of the registration statement, or (ii)&nbsp;from the date of this prospectus but prior to the termination of the offering. These
documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge
upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus, other than exhibits which are specifically incorporated by reference into such documents. Requests should be directed to
Controller at Delcath Systems, Inc., 810 Seventh Avenue,
35</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, New York 10019 or by calling us at
212-489-2100. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_5"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless we provide otherwise in a supplement to this prospectus, we intend to use the net proceeds from the sale of our securities covered
by this prospectus for general corporate purposes, including, but not limited to, obtaining regulatory approvals, commercialization of our products, funding of our clinical trials, capital expenditures and working capital. We will not receive any
proceeds from the sale of shares of our common stock by any selling stockholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_6"></A>SELLING
STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus relates in part to the possible sale by certain of our stockholders, or the selling
stockholders, who own shares of common stock granted under, or resulting from exercise of options issued under our 2009 Stock Incentive Plan, as amended. As of August 31, 2012, 833,700 shares of common stock had been issued to such officers and
directors pursuant to the 2009 Stock Incentive Plan. The selling stockholders may from time to time offer and sell these shares of common stock pursuant to this prospectus and any applicable prospectus supplement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The applicable prospectus supplement will set forth the name of each of the selling stockholders, the amount of common stock owned by
each selling stockholder prior to the offering, the number of shares of our common stock to be offered by each selling stockholder and the amount of the common stock to be owned by each selling stockholder after completion of the offering. The
applicable prospectus supplement will also disclose whether any of the selling stockholders has held any position or office with, has been employed by or otherwise has had a material relationship with us during the three years prior to the date of
the prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_7"></A>DESCRIPTION OF DEBT SECURITIES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description, together with the additional information we may include in any applicable prospectus supplement and in any
related free writing prospectuses, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. While the terms summarized below will apply generally to any debt securities that we may offer, we will
describe the particular terms of any debt securities in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue debt securities from time to time in one or more distinct series. The debt securities may be senior debt securities or
subordinated debt securities. Senior debt securities may be issued under a senior indenture and subordinated debt securities may be issued under a subordinated indenture. If we issue debt securities pursuant to an indenture, in the applicable
prospectus supplement we will specify the trustee under such indenture. We will include in a supplement to this prospectus the specific terms of debt securities being offered, including the terms, if any, on which debt securities may be convertible
into or exchangeable for common stock, preferred stock or other debt securities. The statements and descriptions in this prospectus or in any prospectus supplement regarding provisions of debt securities and any indentures are summaries of these
provisions, do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of the debt securities and the indentures (including any amendments or supplements we may enter into from time
to time which are permitted under the debt securities or any indenture). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise specified in a prospectus
supplement, the debt securities will be direct unsecured obligations of the Company. Any debt securities designated as senior will rank equally with any of our other senior and unsubordinated debt. Any debt securities designated as subordinated will
be subordinate and junior in right of payment to any senior indebtedness. There may be subordinated debt securities that are senior or junior to other series of subordinated debt securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The applicable prospectus supplement will set forth the terms of the debt securities or any series thereof, including, if applicable:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the title of the debt securities and whether the debt securities will be senior debt securities or subordinated debt securities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any limit upon the aggregate principal amount of the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the debt securities will be issued as registered securities, bearer securities or both, and any restrictions on the exchange of one form of
debt securities for another and on the offer, sale and delivery of the debt securities in either form; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date or dates on which the principal amount of the debt securities will mature; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the debt securities bear interest, the rate or rates at which the debt securities bear interest, or the method for determining the interest rate,
and the date or dates from which interest will accrue; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the debt securities bear interest, the dates on which interest will be payable, or the method for determining such dates, and the regular record
dates for interest payments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the place or places where the payment of principal, any premium and interest will be made, where the debt securities may be surrendered for transfer or
exchange and where notices or demands to or upon us may be served; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any optional redemption provisions, which would allow us to redeem the debt securities in whole or in part; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any sinking fund or other provisions that would obligate us to redeem, repay or purchase the debt securities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the currency in which the debt securities will be issuable is United States dollars, the denominations in which any registered securities will be
issuable, if other than denominations of $1,000 and any integral multiple thereof, and the denominations in which any bearer securities will be issuable, if other than the denomination of $5,000; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if other than the entire principal amount, the portion of the principal amount of debt securities which will be payable upon a declaration of
acceleration of the maturity of the debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the events of default and covenants relevant to the debt securities, including, the inapplicability of any event of default or covenant set forth in
the indenture relating to the debt securities, or the applicability of any other events of defaults or covenants in addition to the events of default or covenants set forth in the indenture relating to the debt securities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the name and location of the corporate trust office of the applicable trustee under the indenture for such series of notes;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if other than United States dollars, the currency in which the debt securities will be paid or denominated; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the debt securities are to be payable, at our election or the election of a holder of the debt securities, in a currency other than that in which
the debt securities are denominated or stated to be payable, the terms and conditions upon which that election may be made, and the time and manner of determining the exchange rate between the currency in which the debt securities are denominated or
stated to be payable and the currency in which the debt securities are to be so payable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation of the original currency determination agent, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the debt securities are issuable as indexed securities, the manner in which the amount of payments of principal, any premium and interest will be
determined; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the debt securities do not bear interest, the dates on which we will furnish to the applicable trustee the names and addresses of the holders of the
debt securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if other than as set forth in an indenture, provisions for the satisfaction and discharge or defeasance or covenant defeasance of that indenture with
respect to the debt securities issued under that indenture; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date as of which any bearer securities and any global security will be dated if other than the date of original issuance of the first debt security
of a particular series to be issued; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether and under what circumstances we will pay additional amounts to non-United States holders in respect of any tax assessment or government charge;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the debt securities will be issued in whole or in part in the form of a global security or securities and, in that case, any depositary and
global exchange agent for the global security or securities, whether the global form shall be permanent or temporary and, if applicable, the exchange date; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if debt securities are to be issuable initially in the form of a temporary global security, the circumstances under which the temporary global security
can be exchanged for definitive debt securities and whether the definitive debt securities will be registered securities, bearer securities or will be in global form and provisions relating to the payment of interest in respect of any portion of a
global security payable in respect of an interest payment date prior to the exchange date; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent and manner to which payment on or in respect of debt securities will be subordinated to the prior payment of our other liabilities and
obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether payment of any amount due under the debt securities will be guaranteed by one or more guarantors, including one or more of our subsidiaries;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the debt securities will be convertible and the terms of any conversion provisions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the forms of the debt securities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other terms of the debt securities, which terms shall not be inconsistent with the requirements of the Trust Indenture Act of 1939, as amended.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus is part of a registration statement that does not limit the aggregate principal amount of
debt securities that we may issue and provides that we may issue debt securities from time to time in one or more series under one or more indentures, in each case with the same or various maturities, at par or at a discount. Unless indicated in a
prospectus supplement, we may issue additional debt securities of a particular series without the consent of the holders of the debt securities of such series outstanding at the time of the issuance. Any such additional debt securities, together
with all other outstanding debt securities of that series, will constitute a single series of debt securities under the applicable indenture. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to disclose any restrictive covenants for any issuance or series of debt securities in the applicable prospectus supplement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_8"></A>DESCRIPTION OF CAPITAL STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description of our common stock and preferred stock, together with the additional information we include in any applicable
prospectus supplement and in any related free writing prospectuses, summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus. The following description of our capital stock does not
purport to be complete and is subject to, and qualified in its entirety by, our Amended and Restated Certificate of Incorporation, as amended, and our Amended and Restated By-Laws, which are exhibits to the registration statement of which this
prospectus forms a part, and by applicable law. We refer in this section to our Amended and Restated Certificate of Incorporation, as amended, as our certificate of incorporation, and we refer to our Amended and Restated By-Laws as our by-laws. The
terms of our common stock and preferred stock may also be affected by Delaware law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Authorized Capital Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our authorized capital stock consists of 170,000,000&nbsp;shares of our common stock, $0.01&nbsp;par value per share, and
10,000,000&nbsp;shares of undesignated preferred stock, $0.01&nbsp;par value per share. As of August&nbsp;31, 2012, we had 67,510,123 shares of common stock outstanding and no shares of preferred stock outstanding. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Voting </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Holders of our common stock are entitled to one vote per share on matters to be voted on by stockholders and also are entitled to receive such dividends, if any, as may be declared from time to time by
our board of directors in its discretion out of funds legally available therefor. Holders of our common stock have exclusive voting rights for the election of our directors and all other matters requiring stockholder action, except with respect to
amendments to our certificate of incorporation that alter or change the powers, preferences, rights or other terms of any outstanding preferred stock if the holders of such affected series of preferred stock are entitled to vote on such an amendment
or filling vacancies on the board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividends </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of common stock are entitled to share ratably in any dividends declared by our board of directors, subject to any preferential
dividend rights of any outstanding preferred stock. Dividends consisting of shares of common stock may be paid to holders of shares of common stock. We do not intend to pay cash dividends in the foreseeable future. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Liquidation and Dissolution </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon our liquidation or dissolution, the holders of our common stock will be entitled to receive pro rata all assets remaining available for distribution to stockholders after payment of all liabilities
and provision for the liquidation of any shares of preferred stock at the time outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Rights and
Restrictions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock has no preemptive or other subscription rights, and there are no conversion rights or
redemption or sinking fund provisions with respect to such stock. Our common stock is not subject to redemption by us. Our certificate of incorporation and bylaws do not restrict the ability of a holder of common stock to transfer the
stockholder&#146;s shares of common stock. If we issue shares of common stock under this prospectus, the shares will be fully paid and non-assessable and will not have, or be subject to, any preemptive or similar rights. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Listing </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;DCTH.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transfer Agent and Registrar </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has the authority to issue up to
10,000,000 shares of preferred stock in one or more series and to determine the rights and preferences of the shares of any such series without stockholder approval, none of which are outstanding. Our board of directors may issue preferred stock in
one or more series and has the authority to fix the designation and powers, rights and preferences and the qualifications, limitations, or restrictions with respect to each class or series of such class without further vote or action by the
stockholders. The ability of our board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of us or the removal of existing management. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we decide to issue any preferred stock pursuant to this prospectus, we will describe in a prospectus supplement the terms of the
preferred stock, including, if applicable, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the title of the series and stated value; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares of the series of preferred stock offered, the liquidation preference per share, if applicable, and the offering price;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable dividend rate(s) or amount(s), period(s) and payment date(s) or method(s) of calculation thereof; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date from which dividends on the preferred stock will accumulate, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any procedures for auction and remarketing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any provisions for a sinking fund; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any applicable provision for redemption and the price or prices, terms and conditions on which preferred stock may be redeemed;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any securities exchange listing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any voting rights and powers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether interests in the preferred stock will be represented by depository shares; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and conditions, if applicable, of conversion into shares of our common stock, including the conversion price or rate or manner of calculation
thereof; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a discussion of any material U.S. federal income tax considerations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the relative ranking and preference as to dividend rights and rights upon our liquidation, dissolution or the winding up of our affairs;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any limitations on issuance of any series of preferred stock ranking senior to or on a parity with such series of preferred stock as to dividend rights
and rights upon our liquidation, dissolution or the winding up of our affairs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other specific terms, preferences, rights, limitations or restrictions of such series of preferred stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Certain Anti-Takeover Provisions of Delaware Law and our Certificate of Incorporation and Bylaws </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits Delaware corporations from engaging in a
wide range of specified transactions with any interested stockholder, defined to include, among others, any person other than such corporation and any of its majority owned subsidiaries who own 15% or more of any class or series of stock entitled to
vote generally in the election of directors, unless, among other exceptions, the transaction is approved by (i)&nbsp;our board of directors prior to the date the interested stockholder obtained such status or (ii)&nbsp;the holders of two thirds of
the outstanding shares of each class or series of stock entitled to vote generally in the election of directors, not including those shares owned by the interested stockholder. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Staggered Board of Directors </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our certificate of incorporation and by-laws provide that our board of directors be classified into three classes of directors of approximately equal size. As a result, in most circumstances, a person can
gain control of our board only by successfully engaging in a proxy contest at two or more annual meetings. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Authorized
But Unissued Shares </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our authorized but unissued shares of common stock and preferred stock are available for future
issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, corporate acquisitions, employee benefit plans and stockholder rights plans. The existence of
authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_9"></A>DESCRIPTION OF STOCK PURCHASE CONTRACTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description, together with the additional information that we include in any applicable prospectus supplement and in any
related free writing prospectuses, summarizes the material terms and provisions of the stock purchase contracts that we may offer under this prospectus. While the terms we have summarized below will apply generally to any stock purchase contracts
that we may offer under this prospectus, we will describe the particular terms of any series of stock purchase contracts in more detail in the applicable prospectus supplement. The terms of any stock purchase contracts offered under a prospectus
supplement may differ from the terms described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will file as exhibits to the registration statement of which this
prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of stock purchase contract that describes the terms of the particular stock purchase contract we are offering before the issuance of the related
stock purchase contract. The following summaries of material provisions of the stock purchase contracts are subject to, and qualified in their entirety by reference to, all the provisions of the stock purchase contracts applicable to the stock
purchase contracts that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the stock purchase contracts that we may offer under this prospectus, as well as any related free writing prospectuses,
and the complete stock purchase contracts that contain the terms of the stock purchase contracts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may issue stock purchase
contracts, including contracts obligating holders to purchase from us and us to sell to the holders, a specified number of shares of common stock or preferred stock at a future date or dates. Alternatively, the stock purchase contracts may obligate
us to purchase from holders, and obligate holders to sell to us, a specified or varying number of shares of common stock or preferred stock. The consideration per share of common stock or preferred stock may be fixed at the time the stock purchase
contracts are issued or may be determined by a specific reference to a formula set forth in the stock purchase contracts. The stock purchase contracts may provide for settlement by delivery by us or on our behalf of shares of the underlying
security, or they may provide for settlement by reference or linkage to the value, performance or trading price of the underlying security. The stock purchase contracts may require us to make periodic payments to the holders of the certain of our
securities or vice versa, and such payments may be unsecured or prefunded on some basis and may be paid on a current or on a deferred basis. The stock purchase contracts may require holders to secure their obligations thereunder in a specified
manner and may provide for the prepayment of all or part of the consideration payable by holders in connection with the purchase of the underlying security or other property pursuant to the stock purchase contracts. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The securities related to the stock purchase contracts may be pledged to a collateral agent for our benefit pursuant to a pledge
agreement to secure the obligations of holders of stock purchase contracts to purchase the underlying security or property under the related stock purchase contracts. The rights of holders of stock purchase contracts to the related pledged
securities will be subject to our security interest therein created by the pledge agreement. No holder of stock purchase contracts will be permitted to withdraw the pledged securities related to such stock purchase contracts from the pledge
arrangement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_10"></A>DESCRIPTION OF WARRANTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description, together with the additional information we may include in any applicable prospectus supplement, summarizes
the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will
describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports
that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular warrants we are offering before the issuance of the related warrants. The following summaries of material
provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the warrants that we may offer under this
prospectus. We urge you to read the applicable prospectus supplements related to the warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates
that contain the terms of the warrants. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may issue warrants for the purchase of common stock or preferred stock in one or more series. We may issue warrants independently or together with common stock and preferred stock, and the warrants may
be attached to or separate from these securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may evidence each series of warrants by warrant certificates that we
will issue under a separate agreement. We may enter into a warrant agreement with a warrant agent. We will indicate the name and address and other information regarding the warrant agent in the applicable prospectus supplement relating to a
particular warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we decide to issue warrants pursuant to this prospectus, we will specify in a prospectus supplement
the terms of the warrants, including, if applicable, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the offering price and aggregate number of warrants offered; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each
principal amount of such security; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on and after which the warrants and the related securities will be separately transferable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares of stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms of any rights to redeem or call the warrants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the dates on which the right to exercise the warrants will commence and expire; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the manner in which the warrant agreement and warrants may be modified; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a discussion of any material U.S. federal income tax considerations of holding or exercising the warrants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms of the securities issuable upon exercise of the warrants; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before exercising their warrants, holders of warrants may have no rights of holders of the securities purchasable upon such exercise,
including, in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exercise of Warrants </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each warrant will entitle the holder to purchase shares of our stock at the exercise price that we describe in the applicable prospectus
supplement. Holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of the warrants may exercise the warrants by delivering the warrant certificate
representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. If we so indicate in the
applicable prospectus supplement, the warrants may also provide that they may be exercised on a &#147;cashless&#148; or net basis. We will set forth on the reverse side of the warrant certificate, if applicable, and in the applicable prospectus
supplement the information that the holder of the warrant will be required to deliver to us or a warrant agent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon receipt
of the required payment and the warrant certificate properly completed and duly executed at our offices, the corporate trust office of a warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver
the common stock or preferred stock purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so
indicate in the applicable prospectus supplement, holders of the warrants may surrender shares of common stock or preferred stock as all or part of the exercise price for warrants. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Enforceability of Rights by Holders of Warrants </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any warrant agent will act
solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of
warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand
upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its
warrants. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_11"></A>PLAN OF DISTRIBUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may sell the securities offered by this prospectus from time to time in one or more transactions, including without limitation:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">directly to one or more purchasers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">through agents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to or through underwriters, brokers or dealers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">through a combination of any of these methods. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants, subscriptions, exchangeable
securities, forward delivery contracts and the writing of options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the manner in which we may sell some or all
of the securities covered by this prospectus includes, without limitation, through: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a block trade in which a broker-dealer will attempt to sell as agent, but may position or resell a portion of the block, as principal, in order to
facilitate the transaction; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">purchases by a broker-dealer, as principal, and resale by the broker-dealer for its account; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ordinary brokerage transactions and transactions in which a broker solicits purchasers; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">privately negotiated transactions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may also enter into hedging transactions. For example, we may: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into transactions with a broker-dealer or affiliate thereof in connection with which such broker-dealer or affiliate will engage in short sales
of the common stock pursuant to this prospectus, in which case such broker-dealer or affiliate may use shares of common stock received from us to close out its short positions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sell securities short and redeliver such shares to close out our short positions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into option or other types of transactions that require us to deliver common stock to a broker-dealer or an affiliate thereof, who will then
resell or transfer the common stock under this prospectus; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loan or pledge the common stock to a broker-dealer or an affiliate thereof, who may sell the loaned shares or, in an event of default in the case of a
pledge, sell the pledged shares pursuant to this prospectus. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we may enter into derivative or
hedging transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. In connection with such a transaction, the third parties may sell securities covered by and pursuant to
this prospectus and an applicable prospectus supplement or pricing supplement, as the case may be. If so, the third party may use securities borrowed from us or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
others to settle such sales and may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus and an applicable
prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement or pricing supplement, as
the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A prospectus supplement with respect to each offering of securities will state the terms of the offering of
the securities, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the name or names of any underwriters or agents and the amounts of securities underwritten or purchased by each of them, if any;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the public offering price or purchase price of the securities and the net proceeds to be received by us from the sale; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any delayed delivery arrangements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any underwriting discounts or agency fees and other items constituting underwriters&#146; or agents&#146; compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any discounts or concessions allowed or reallowed or paid to dealers; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any securities exchange or markets on which the securities may be listed. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offer and sale of the securities described in this prospectus by us, the underwriters or the third parties described above may be
effected from time to time in one or more transactions, including privately negotiated transactions, either: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at a fixed price or prices, which may be changed; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at market prices prevailing at the time of sale; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at prices related to the prevailing market prices; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at negotiated prices. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any public
offering price and any discounts, commissions, concessions or other items constituting compensation allowed or reallowed or paid to underwriters, dealers, agents or remarketing firms may be changed from time to time. Underwriters, dealers, agents
and remarketing firms that participate in the distribution of the offered securities may be &#147;underwriters&#148; as defined in the Securities Act. Any discounts or commissions they receive from us and any profits they receive on the resale of
the offered securities may be treated as underwriting discounts and commissions under the Securities Act. We will identify any underwriters, agents or dealers and describe their commissions, fees or discounts in the applicable prospectus supplement
or pricing supplement, as the case may be. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Underwriters and Agents </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If underwriters are used in a sale, they will acquire the offered securities for their own account. The underwriters may resell the
offered securities in one or more transactions, including negotiated transactions. These sales may be made at a fixed public offering price or prices, which may be changed, at market prices prevailing at the time of the sale, at prices related to
such prevailing market price or at negotiated prices. We may offer the securities to the public through an underwriting syndicate or through a single underwriter. The underwriters in any particular offering will be mentioned in the applicable
prospectus supplement or pricing supplement, as the case may be. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise specified in connection with any particular offering of securities, the
obligations of the underwriters to purchase the offered securities will be subject to certain conditions contained in an underwriting agreement that we will enter into with the underwriters at the time of the sale to them. The underwriters will be
obligated to purchase all of the securities of the series offered if any of the securities are purchased, unless otherwise specified in connection with any particular offering of securities. Any initial offering price and any discounts or
concessions allowed, reallowed or paid to dealers may be changed from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may designate agents to sell the
offered securities. Unless otherwise specified in connection with any particular offering of securities, the agents will agree to use their best efforts to solicit purchases for the period of their appointment. We may also sell the offered
securities to one or more remarketing firms, acting as principals for their own accounts or as agents for us. These firms will remarket the offered securities upon purchasing them in accordance with a redemption or repayment pursuant to the terms of
the offered securities. A prospectus supplement or pricing supplement, as the case may be, will identify any remarketing firm and will describe the terms of its agreement, if any, with us and its compensation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with offerings made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant
to which we receive our outstanding securities in consideration for the securities being offered to the public for cash. In connection with these arrangements, the underwriters or agents may also sell securities covered by this prospectus to hedge
their positions in these outstanding securities, including in short sale transactions. If so, the underwriters or agents may use the securities received from us under these arrangements to close out any related open borrowings of securities.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dealers </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
may sell the offered securities to dealers as principals. We may negotiate and pay dealers&#146; commissions, discounts or concessions for their services. The dealer may then resell such securities to the public either at varying prices to be
determined by the dealer or at a fixed offering price agreed to with us at the time of resale. Dealers engaged by us may allow other dealers to participate in resales. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Direct Sales </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may choose to sell the offered securities directly. In
this case, no underwriters or agents would be involved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Institutional Purchasers </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may authorize agents, dealers or underwriters to solicit certain institutional investors to purchase offered securities on a delayed
delivery basis pursuant to delayed delivery contracts providing for payment and delivery on a specified future date. The applicable prospectus supplement or pricing supplement, as the case may be, will provide the details of any such arrangement,
including the offering price and commissions payable on the solicitations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will enter into such delayed contracts only
with institutional purchasers that we approve. These institutions may include commercial and savings banks, insurance companies, pension funds, investment companies and educational and charitable institutions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification; Other Relationships </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may have agreements with agents, underwriters, dealers and remarketing firms to indemnify them against certain civil liabilities,
including liabilities under the Securities Act. Agents, underwriters, dealers and remarketing firms, and their affiliates, may engage in transactions with, or perform services for, us in the ordinary course of business. This includes commercial
banking and investment banking transactions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Market-Making, Stabilization and Other Transactions </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is currently no market for any of the offered securities, other than the common stock which is listed on the NASDAQ Capital Market.
If the offered securities are traded after their initial issuance, they may trade at a discount from their initial offering price, depending upon prevailing interest rates, the market for similar securities and other factors. While it is possible
that an underwriter could inform us that it intends to make a market in the offered securities, such underwriter would not be obligated to do so, and any such market-making could be discontinued at any time without notice. Therefore, no assurance
can be given as to whether an active trading market will develop for the offered securities. We have no current plans for listing of the debt securities, preferred stock or warrants on any securities exchange or on the National Association of
Securities Dealers, Inc. automated quotation system; any such listing with respect to any particular debt securities, preferred stock or warrants will be described in the applicable prospectus supplement or pricing supplement, as the case may be.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with any offering of common stock, the underwriters may purchase and sell shares of common stock in the open
market. These transactions may include short sales, syndicate covering transactions and stabilizing transactions. Short sales involve syndicate sales of common stock in excess of the number of shares to be purchased by the underwriters in the
offering, which creates a syndicate short position. &#147;Covered&#148; short sales are sales of shares made in an amount up to the number of shares represented by the underwriters&#146; over-allotment option. In determining the source of shares to
close out the covered syndicate short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment
option. Transactions to close out the covered syndicate short involve either purchases of the common stock in the open market after the distribution has been completed or the exercise of the over-allotment option. The underwriters may also make
&#147;naked&#148; short sales of shares in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing shares of common stock in the open market. A naked short position is more likely to be created if
the underwriters are concerned that there may be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of bids for or
purchases of shares in the open market while the offering is in progress for the purpose of pegging, fixing or maintaining the price of the securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with any offering, the underwriters may also engage in penalty bids. Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities
originally sold by the syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty bids may cause the price of the securities to be
higher than it would be in the absence of the transactions. The underwriters may, if they commence these transactions, discontinue them at any time. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Fees and Commissions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In compliance with the guidelines of the Financial
Industry Regulatory Authority (the &#147;FINRA&#148;), the aggregate maximum discount, commission or agency fees or other items constituting underwriting compensation to be received by any FINRA member or independent broker-dealer will not exceed 8%
of any offering pursuant to this prospectus and any applicable prospectus supplement or pricing supplement, as the case may be; however, it is anticipated that the maximum commission or discount to be received in any particular offering of
securities will be significantly less than this amount. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_12"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated in the applicable prospectus supplement, Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP, New York, New York
will provide opinions regarding the authorization and validity of the securities. Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP may also provide opinions regarding certain other matters. Any underwriters will also be advised about legal matters
by their own counsel, which will be named in the prospectus supplement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="tx457511_13"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements as of and
for the years ended December 31, 2011 and 2010 included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011 and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2011, as set forth in
their reports, which are incorporated by reference in the registration statement. Our financial statements as of and for the years ended December&nbsp;31, 2011 and December&nbsp;31, 2010 are incorporated by reference in reliance on Ernst&nbsp;&amp;
Young LLP&#146;s reports given on their authority as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial
statements of Delcath Systems, Inc. for the year ended December&nbsp;31, 2009 incorporated by reference in this prospectus and elsewhere in the registration statement from our Annual Report on Form 10-K for the year ended December 31, 2011 have been
so incorporated by reference in reliance upon the report of Grant Thornton LLP, independent registered public accountants and successor to the practice of CCR LLP, upon the authority of said firm as experts in auditing and accounting in giving said
report. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g513079img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g513079img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`6`$<`P$1``(1`0,1`?_$`,4```("`P`#`0$`````
M```````)!P@&"@L#!`4"`0$``00#`0$```````````````0%!@<"`P@!"1``
M``8"`0($`@@%`@('"0$``0(#!`4&!P@1`!(A$Q0)%0HQ02)3U)475]$R(Y,6
M46%")(%B0R:7UUAQL3,T9"5&&!H9$0`"`0($`P0&"0$$"`4%```!`@,1!``A
M$@4Q0091(A,'87&!D3(4\*&QP=%"4U05(U)B@I+Q<K+2,Y,D%N&B8],7PD-S
MH[/_V@`,`P$``A$#$0`_`-W/;@JYM4MG"M5#(N3:]9H*W6*H9$R2XXWLH(J%
M6(('2,13@0,'B7CD.G78J?S=GJ^'YJ+_`/HN&_=P3M5T!Q^7D_V&QQV6MWNO
MIFW_`'RMG_P$?_R29^[+_P#6]=Z_+6_Z:?Y1^&.1)[F<3.`[4U'GZ<21%5S8
MR>C6LQ!0&<IN'?)"NREH>)R%)QCQ$#&(*S208MUVCE(#D$!,0Y@`0$/JZ223
M;1$YCE>V60<02@(]8.-R1;I(@DC64H>!SQ\6J9FS-CBT,K/2\J9,I%SKKHQF
M$W7[K9X&PPKPG*:@(NVDBV?,E@\2G+R41#D!#ZNMLVW[=>0F&XAADMW&89%9
M2/410XUQWM_:RB6*21)0<B&(.7801]1QM->T!\Q]FZG93I>O6_\`=%LJXBO,
MNQJ]?SU.-DOU(QE8)=R5G"*7:1CT$$KK17DBX30=NW*7Q2-*IZ@RZZ*9T@I7
MKSREV^:RDW7IB/P;Z-2S0CX)%&9T`_`X&8`[K<*`FN+5Z0\QKM;E-OWUO$MW
M-!(?B4]K'\R]M:D9FN6D[\?7,N+TP=&#!T8,'1@QJ1?-S6%_"ZP:D(14L]BG
M[W86R+=\=(N8]XJS9XQG2.`Y:+(J*MB+O4>_GDI3B3ZQ#J\?(R)9-ZO2ZAE%
MJO$5%2X_`XJSS6E:/:(-)HQE/W?CC4?]L2:NEE]QO1:#-;+NNF^VLPAYZ;"P
M2BCD6K2^PSYX<"+NSI"@DU:G.L)BF`$2G'@>..KTZRCMX>D]RDT1@BRFXJ*5
M,;`<O=Z<5%TM)/-U#9H6<CYF+@?_`%%QUO>N&L=88.C!@Z,&#HP8.C!@Z,&#
MHP8CC,>0TL18BRIE=Q%+SR&,,<7C(:T&U<$:.9E*E5F4LBD4W=*)+D;+R)(T
M42*"0X$,<!$H\<=*["T-_?P6(8*9IDCU',#6P6M/16N$UY<"TM);LC4(HV>G
M;I4FGMIC0JSE\VQN;=$%T<"8'PCA".506,E)VE>Q9@M27?P=!5%=92D5A%1)
M(.!*I&.2F,//T!V]=,;;Y';!;][<[FXN'[%TQ+[N^WN88H^^\U=UDE\&R@BB
M&H@DU<\:5!-![T.-Y#3Z]W;*6IVLV3<E/&\CD+(V`\17R[/F<8WA6CJTW"A0
M-AG%VL2U_P"6CFYY&14$B*?V$R\`'AUSEOUM;66^7EG9@BUBNI40$U.E795J
M>>0XXNC:)Y[K:K:YNB#<R01LU!3O,H)RY9G&BK\UK<;#'^XEC*(B;!-Q;=GJ
MQ272C:-DY&/1%5_D/)P"J<K5RDDJH<K0`YXY```/].NDO).WB?I6:21%)-ZX
MJ0#P2/\`'%'>:EQ(F_QQHQ`%LA][28^-\JTG9[A[D]NEI5_.S\=2]8<C2HJR
M,W).VT0^E[CCB`:.P;.79TE5W+=\X0+R4>TJAA\/IZV>=7@6_24:(%5Y+R,9
M``D!9&(^H'&/E89YNH'9R6C6W<YG@:H!_M$>W'1/ZY3QT)@Z,&#HP8.C!@Z,
M&#HP8.C!@Z,&#HP8.C!@Z,&#HP8.C!BKN\$XVK6E^VT^\$P-8C6C.;]<2"4I
M@3;XRLYS"4QOL@(<<^/3STY&9NH;&)?B:\A'_P"Q<->]N(]FNY#P%M*?_(V.
M.@W`2MT"C])44P_VY`A0Z[WQR#,=4S'D6/VXZOGLA5A*K>T_HW'%31`7F%6%
MD.)"<=Y[?.SEJ$R@BFF)EA"9`#B(#R8/`1#@1XC\Q)C-UMN+YY7&G_*JK]V.
MK>CHO"Z9LURSCU9?WF+??A<_S*OM^X2RAH[D#;6"IU4I^<]=G$!:E;K$Q3:(
MDKO2)JS1-9L]0LRT:U)\=5$TXB^8+.@.JV<M>PBA$UE0-+/*/JC<;+J.+8Y)
M'DVVZ#+H))".JEE9:GN_"5(&1!J14#$<\Q>G[*\V9]R1%2]A(.H"A8,0M&H,
MZ%@17/(@$`G'.?.`B4P`(E$2B`&*82F*/'@8I@X$I@'Q`0\0ZZPQSFC:7##B
M#CJF8HWZINN'LS:_[O;`.Y&0;0>J.')B08(&XL=_O4E4H*`KU<C#.?,`TY=;
M&9$GGJ<I(@L=RKPDF<0XKONF9]V\P+KIW:P`6O90#^5$#%F8^A%KEQ-`!F1C
MJ>TWR+;NC[?>+\DZ;6,GM9M(``/:QY\`*DY#&@;N?[R'N!;W7.5&U9DNU`Q]
M,S!DZG@7"TU-U&G1;1RY70AX5RG7%6=AR#->4\!$SF35<J.EC#Y2211(D7IW
MI_H#I?IJV'A01RW2KWII0&<GF1JJ$&7!:`#C7CBA]XZSW_?;C2)62$MW8T)"
M\P`1^;(\6J>=1P&+9UTR]U'4/&=;V`SG2-C\08\DI>#8PUV?Y.D"N8F<FVRK
MZ";RS&`N[ZQTZ0=`W,5/X@W9G*X`$N05$I1W;;OW1.^WC[7MLEK/=A22@3B!
MD:%E"L,_RDY9\,\:[[:^K=HMUO[R.:*`D4;NY&E16A++P_,!V<<L-O\`9?\`
M?SVBQSL+A_6G;3*+W,VOF4K3!XV9W/)*ZLGD/$TW8!0@*;)M;P/_`-RG*D:=
M.T;2#>7%X=!NL9PBNEY1R*P;S!\L=FNMKGWC8X1;[I"AD*1Y)(!WF&C@&I4J
M5I4BA!K42OHSKW<HK^+;-TD,ME(0NIJED)R!U9DBOQ:JC34BE,[_`/SA"Q0Q
MEHFW!<X'/D7."PM@,'8H1*JT(GGG+SW"=$RP%*/''"AO]NHOY##_`*W<33+P
MH<_\4F)!YMD?)6@KGJD^V/&MA[(T,O.^[%HRT;L_7':YD&:.CYHH@FA`4VUS
M3AX)^#>$>BQ,N!?^T%,">'=U;OF-((^B-Q8F@,%/\S*M/;6F*UZ$4MU3:J!7
M^I]G>^JE<;R_OK>[N^]LO$--JF(HZ#G]G<YISY:`2P(DD:_CNIP`,VL[DFP0
MY'"*LJX1?R:+6&9*<-GCPJQUA,BU515YO\M^A1UA?R37I9=GMJ:].3.QJ0@/
M(4!+D9@4`H6!%X];=6#IJT5+<!MPFKIKF%`_,?23\-<LF.>G2>=GF;=+;C82
MV.KQFG93,]^LCM3N!S)Y`L#*.9`8"IE;PM=A7L97(%KP`%*@Q:-T_P#J\]=6
M;?T[L.U0"WV^T@BA'8@J?6QJS'TDDXYYN]_WG<9C+=3R/(>TU`]0X`9<!0>C
M'HFM6X6+V[6ZA9]H\<HK-3*QMO/.9?J#=1JL5!0%F<^HZCT%&JOFI#W%5%,W
M<7GZ0Z]^7Z?O";?19RD'-:1MGZ5S^S&8FWVU*S%ID4\QE45ID10Y^C'4SUCV
M%<2'M8X4V;GI][891II!4,JV2R2[F0D9*:L,!AAI.6&3D'J_KI22?OYN.7.H
MJ;SEW"AA-P8YN!XQWC:U7K2XV>%0L9W%HU44`"M+10.``"D=@`QTWMU\XZ8A
MW"8DRK9*[$UKJ6.K5XFM0:\\:$]6Q5\PQ[CK-I8DUMVKO5)`%U&4M=;[+X0Q
MPHC+>G,Y"*;STSCJM23`Z:Q`$6;9=,$P\."@(!TQ+?>5G2A,1&WQSBE0B"60
M4[=(=@?61BCA:=?[\VI3=/$"14L50CM`=E0U_N_9BL&ZFA/N8>WU!4VT[1DO
M5-JU]F7=<K5B@<\%NT2YGVC):24AG:E9MS]>-?*QK95=(JZ9"JII'[3")1#I
MYZ=ZEZ/ZIED@V?PY)XE#,IB*'232O>45%<LL-6][+U-T_&DVX:EB<T!JA%>S
MNEN6>>+>>RY[NFV>O.W6`L,W7,][R9KAE_)55Q7;L?9"EY6^)UL;W)LZO!VB
MBOIIX[FJU(PDX\9G51;+BS<,BJIF;F/Y9TV+S"Z$V/=-BN=PMK>*'=8(6D5T
M`35H!8JX`HP8`YD5!H0>(+IT9UANEGNL-E<RO)8RR*A5N]340H*U^'3Q[M*Y
M@@URNG\T!?MEV>\S2,QI.;%P6)('5^F,+S_A#_)\5B9<\O8\@/99>?6KZJ%.
M7.ZB)))L_%T(@*!$TU>2\!U'O)RVV9NG-5XMJU^UXY36$,F2H!2O>R()%.=2
M,/GF7+NR[L?E#,+(6ZAJ$Z3FY.5>Q@#EGPY9:E'``''``4`XX\```^CC_0`X
MZO3%/9DUYXV(/8MF-SR>Y?IE"W:4VR1PPWD[8T/%6ASF<N*DH!MAJ\A7&BS&
M8.6G)0"*R;4&11*#8@E2\H.0)U4_F1'T\>D=PDMELCN)"FJB/Q-7BIJ-1WJ\
M:\^-<6;T.=]'4%FMRT_R`)R).FGAMI%*\.&)$^:VDF3WW+Z<S;'1.XA]5\:L
MY$$P$%$G+B\91DD4EQ$`Y,#)XD<O'(=J@?7STG\DD9>D)&-:->R$>K1&/M!P
M>:K`]1HHXBV2O^:0_81A*VIN[V>=(SYBF]<K"A0L@9BQVWQ<^R6V1%>U4VHC
M98NT3(4L7!CQD9.S+N$:H_$%4%EV:!3BV%-4X*EL'?>G-LZC$$>[*9+6"7Q!
M'^5FTE1KYD`,3IJ`32M1EB&[/OU]L?BMMYTSRIHU<P"03I["2H%>(%:$$UQ"
MTWGK-]LEWT_8LW9<L4Y)K&=R4Q+Y/NLG)/EUC"8R[IXZG55UC'$1\3&'_;IP
MBVO;(4$4-O`L8&0"*`/4`,)9=RW-F+S2R%SS;,GUDYD^O/#4/:B]VS;C3?9#
M$M:2RG=LD8%OV1JC3<BX<O5C?VF#7B+=/1]?<SE-6L;MXO3;5#F?E=(+,EFZ
M#DR7E.B*)G'B%=;]"[%ONT3S>#'#N443,DJ*%-5!(#:::E-*$&M.*T.)5TEU
M=N^V[E%`9&DLW<!D8Y4)S(["!4@BE32IIECJ5=<98Z;P=&#&/VBUUNE0CVQV
MR:80,)'IBHZD9%<J"!/`1*DF'BHX<*]H@FDF4ZJAO`I1'PZW6]O/=2B"V4O*
MW`#Z</2<L822)$I>0@*.9Q06Z>XE3HYRY:42D3%G(GR1&8F7J5=CUS``?U$F
M0-I"3.ASSQYA$#CQ]`=3&UZ*N74->2K&?[*C4??4#[<-,N\Q@TB4MZ3E^)QB
MM<]QT!6!.WXO,FW,H`"ZK5@*NJBD(_:'T,HR;%7.4/\`1P0!_P!NE$_1&5;:
MX[W8RT^L$_9C6F]9_P!2/+T'\<7MQ;FO'&8XY1]1I])ZX;$`\C"/""PGXL!$
MI0%]%K#YQ41,<`!9/S$#"/!3B/AU$=PVJ^VQ]%VA"G@PS4^H_=D?1AU@NH;E
M:Q&IYCF/9B5^F["C!T8,'1@P=&#!T8,45]SZ?85CVYMY)F3X!FCJMG%J?E,%
M2^=*X]GHEH!TQ$H&3%V])W?Z%Y'Q^CJ2='1--U9ML:?%\["?<ZD_4,,?4SA.
MGKUCP^5D'O4@?6<<AHOV$@Y_X4PYY_ZI?'_W==VXY'/>D-.9^_'7%]IF`=UC
MVS=%(=\8QW"6L.(WG<<P'-Y$M4H^7:`80$0`2M7Q`X_X>./JZX7ZWD67J_<G
M7A\Y*/<Q!^L8ZUZ65EZ<L@W$VR'WJ#]^%V_,S;/53"7MJ7;$+F1B%,@;1V&M
M8UJ=<='\R36KL)8(BYWRT-&93`8&D!&0B#8RYOL).I)N7^8Y>I5Y0;-/N/5T
M=\`WRMFK2,PX:F4HBU[2233F%.&#S&W2*PZ=>W)'CW#!5!S-%(8FG9D%KR+#
M'--.(E(8P`(B!3"```B(B`"(````B(C_`+!UU]CFA!J8+VG&W9[ZS>WX6]H;
MV:=<)-:4C@/1H"P72%>(*-SA8*3A6IMV4?(>6\=-A<0+N_O4O*$R@]P`<.WM
MXZHGRV-ON'7>_P"[)I/]5E0C^R\KDD95ST*<7#UQXMITCM5@]0?"#$?W@B"A
MIED'88UA]:'^:H;/V)K%KE69"XYTJ=SBKABZO15.;9!D'ENJ9SV"-<-:4\8R
M;2Q*19HX7?IU&ZQ/Z'>)1`O5Q[PNW2;7/%NSB/;7C*R,7T`*W=-7!!6M:5J.
M.*MVE[V/<(I-O4O>*X9`%UFJG4*+1JTIV'#T-C=H?F*=LL,7;7_.^!,YW+%>
M0FC!G:(%/2F'@W3E.+EX^=CEF,U#8[9RT4]9RL6@JFNW535*).`'@1YK7:=F
M\J=DW"/=-MNK:.]B)*M\V3Q!4U!D((()R(Q/MQW3K_=+-[&\@N'MWI4?+]A!
M'"$'B!P.%=4?VW/<("[TD?\`]+-GV@A<:J(.U\/7F.0:"$_'\.EY%:+;(QR+
M<?MG<'43(@4HG,8H%$0FEUU=TL;:0?R%F?Z;9>*AY'E7/U<\1:TZ:W];E";2
MY&?Z<@^O2*>_&QI\X%8E5+_HI4#(JD28TW.EE!?U`&255DIC&<4H@HWY$PK-
MBQ91(IX`(*F#Q^JI_(>("VW*;F9(5X=@D/UU^K%A^;KL7LD_*%?WL5^S3]>%
M._+>Q#&6]W[6U1\=`/@U:SG,LDET551<2"&&;HR;IM_+24(BY1)('7`Z@D(!
M43`!N\2%--_-N1TZ$NPM>\T(/J\5#]U/;B*>6T:/U5`S4JH<C_E28DGYG^WS
M%C]U^ZP<BY!:/Q_A+"M7KZ!5G"A6D=)0DC=G9#)K&%)NLM,6QR<P)`!#$$AA
M^V)ND?DU`D714<B#O2W$K-PXAM'V*./V85>:$K2=2%&X)&JCU:0WVLW#MQ+?
MRLNLN&L\;IY:O>6JI%WE]@/$D7:L<UZQQ+"9K3*W6FU)P8W!VRD!507FJW&L
MU"1H';JD26>'<`9-9!`PH?.C>-PVWI^"UL7,:W,Y5V4D,552=((Y,::LQD*9
M@G"ORMVNSO=TEN;I`[0QU4$`BM5&K/F*Y94J0>*C'1(EHB)GHUY#3D7'3,1(
M(F;/XJ69-I&-?-S<"9!XQ>)+-7*)A`.2G*8H\?1URJDCQ.)(F*R`Y$&A'J(S
MQT$Z)(I1P&0\014'V8HKNSNGJM[76M"&1,J,&5:H\>HA1\68>QU7HAM*7.P"
MS<O&%(HE6;_"X"-:-F#15PX66,UCF#5(QCG`QDDU)'T[T]O766[_`"ED2]R>
M_)*[&BK6A=VS8DG(`58GT5(9=YW?;.F]N^8N0%@7NHB@9G^RHR`':30#UD`Z
M:.Q/S8F[-]>2+'77$^'M?JV+QT,7*S[1_EV_ECQ\XC7UKR84A*2B[*D8BARE
MAEB%5*(=YR>`]`;5Y(=/6RAMVGGN9:"H!$:5YY"KT_Q\,4[N/FMNLS%=NBCA
MCJ:&FIO1FW=]--&$7;7;G;N;O$BLD[2Y6R3E.KPLNLPJZ\G&IP.+*_.R#511
M=G58"NQ4+16,ZZCFQO-,W0%\HW3_`*AS$#JR=CZ?Z<Z<+6FRPPPS,M6H=4C`
M<V9B7(KVF@)RQ!MXWG?=Z43[I)))"&(%<E![*`!0?8":9UIC[_M;QB4S[DFB
M4<X9N7Z"^U>%%%VK1'U"JB+2[Q3U4QTNXO+1$C<5'!N?L(%.;ZNM76CF/I+<
MF!`/R4V9]*$>_L].,NE$$G45FI!(^9BX?_D7ZNWT8Z+_`+]EA+7/:,W6=?$C
M1:LECVNUUNJ0PE.Z4LF1Z7"*18"'')95L^4;G`?`Q%!#Z^.N3_+2(S=<;>M-
M0$K-ZM,;FOLI7'1?6THAZ8NF+::JHKZY%%/:,L<JM;CRE.0Y#L-R'T<AQXAS
M]7(==K''*T?_`!%]>.T5AY!-KB3%K5)LW9I-L<TA!)HT$PM6J:-9C$R-FPG(
MF<6Z!2@4@B4H]H!R`?1U\^K\EKZ9B2297S//O''95F*6D0`H/#7_`&1CF[_,
MU3:\K[MV66*R2)"5K%6#(1J=(YCG6;KT1K8Q.X*;[*2Q74^J4`+X"F4H_2/7
M6OD]&$Z'A85J\TQ/^<K]BC'.OF<[-U/(II140#_(I^_ZL>Q\N)HUBW='>2=D
M,WUN+NV,=>L;*9.=4><;MG\!;KG)6"-K=-C;)$NBJ(3%?8^H?/UFRI#(++-$
M2*@)#"0^/FUU)>]/].*FW.T=Y=3>&'6H94"EF*D<&-`H/$`DC//'OEQL=KO&
M\-)>HKVT,9;2:$%JJ`"#Q&9)]5#D3C8&^:4UFU_@-`:+ENM8GQ_3<C4?/=$J
ME<L]2J<+6I/_`!BWPEK3GZNY6A&C`'L.Z-$-G)45@4*BLT*9,""8_=5WDSO&
MZ2]3R6,T\LEI);.S*S%AJ5EHV9-#F14<0<\3_P`SMKV]=A2[2*-+B.8`%5"F
MA5JC*E14`T]&6-$C!-:5N><L*4]%!PZ5M>7\8UI-LS[O5KFG;Q!18)->P!-Z
ME3U7!.`Y[N.NE=TF%OMEQ.:`)!(V?#)2<_=BB]JB$VXPPG\\@'OR'O..SJ0H
M$*4@<\$*!0Y'D>"@`!R/UCP'7S]QV/CXMEL<-4*_,6BPO4HZ$@F#B2DGBH_9
M1;-DQ.?M+_,HJH(`5,A>3*',!2@(B`=;8();F9;>$:I7(`'I.,)'6-#(YHH%
M3A$67LN9!V=R&T91S&3<1RD@=E1*)']RP-4E#=A'CI(@@BXF7210.Y<G'L1+
MR4HD3+XV[MNVV6PV19RH?3620\_0/[HY#GZ\12XN)KZ8``TKW5^G/M.+>XT]
MO)D9FVD,KVMZ+Q=#O6KE2,@@DQ4.')4UYYVBY,[51Y#O!)`B?=R`','`C&[_
M`*T;44VZ,:0?B?G_`(12GM.'*#9Q35<-GV#\?_#&<6OV\L9OF!PIUIM==E2@
MH9-6569V".6-Y7"2*[;TL<Y23\T.1.17N`!'P'P#I);]:7Z/_P!3'&\?HJI]
M]2/JQLDV>`C^DS!O3GA>-MI.6]7\@QCEPLM`SK-07E>LT.JHO#3C5%0@K$15
M.1(KQHIX%=,G!`'M'@Y!`0,,TMKO;=_LF4`/"<F5OB4_<>QA[#AGDBN+&8$Y
M,.!'`_3F,.8UWS?&9TH:-@22386*+53BK9#D,':REBH)J^I9@)SJFBI$AO,;
MG-X^!B#]HANJPWO:9-IO#"<X&%4;M'8?2.?OYXDMG=+=0Z^#C(CT_@>6)ZZ9
M\*\'1@P=&#!T8,*F]\.[-*%[3^[\P[\OB4PV\I38J@F`IWN0IV$H[,`$I3_U
M"KV`#%Y\!,4`$0^GJ:^75LUUUMMT:\I]?L12Y_V<1GK*9(.F;MW^$QA?\[!?
MOQRC!`!`2_4(<?\`0(<==N8Y/!H:\\/6Q+\Q=[EF#\08ZPCCBQX6B*5BRD5O
M'U0,]Q&UF)IM7ZK$MH6*%](R,\LE(2/I&A!5641X44Y-VASQU6E]Y3]);E?R
M[C=K<-<32,[4D(&IC4T``H*G(8GUGYC;_8V<=E!X8BBC5%[HK110<0<*KV9V
MLV"W"R:_S%LKE.PY2O;Q`62$E.*MFT9`0X.%G:4!5*]&H,H"JU]NX<'.1FQ;
MH(]YS',!CF$PS79]DVK8+,6.T0I#;`U('$G^TS&K,WI8D^S$4W/=MRWNY^9O
MY&EF/"O+T`"@`]``''+,X<O['WLQY;W9S;CW/&9Z!-U/37'T^SMLM/V9HK#&
MS5*P"J,C!T>CQTBW!U8*O)2J:7QF433^'E8IKMDUA<J%*6`>8WF#8]/;=+MF
MWRJ^_P`JE0JFOA`Y%W(R5@*Z5KJU4)&D8F?1'1EWN]Y'?WJ%=J0AB2/^)_=7
MM!RU&E`*BNK+&S]\R[H]?]L-'J[D#$4#(VF]ZKW)[DE2FPC-R_E[!CB9@SP5
M^2@8MDFJJ_E8%N@RE`1(05#LV+@J?)Q*0]-^4/4=KL?4;6U\P2VO8Q'J)H%D
M!JE2>`:I7UD5RQ9_F-LD^Z[();0%IK=BVD<2A'>H/00I_P!4&F.=GAC,&0,`
M98QYF[%,X-:R1BNVQ-SILV+5N^)'ST(Y!5`'D<]34:OV2Y>]!RV6*)%D%#IF
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M[G)<)&K,0J@$,S411V*>+'CEPS>^D^MMRZGWLVK1QQ621,Y`%2:4&9)/-EH0
M!P-1GDKGYNFP`\W0UBK))(%RP&LSV55B@,4?AKBR90M"`NS%`>XAY5O74R^(
M<"5J''U\3/R+BT[!>3:::KNE>W3&F7LU?7B+^;4H.YV\.K-8`:>MI,_J&*F_
M+!QAW_NR41V5F[<EA<(YODE%F[4%T(\BT%&0X/'ZPB`LFQU)4K<J@`(F67(G
M_P`?3YYR/IZ)D6H&JXB'K[U:#MX5IV`GEAJ\KUU=2`TK2-CZNZP]V=/73MQ?
MGYKW2&]Q.9\<[YU2$?S&,[;2(/$.69)BU*JC1[I5'TFK2I:;.B'G(1-R@I8S
M)-RH44D7<85(Z@&<($&,>274=J]A+TU.P6[21I8P3\:,!K`]*,*D<2&K3(G#
M]YJ;'<&YCWJ$%H&4(U!\+#@3S[PH!RJI%:D`ZT^EV[.P6@F;&.>M<;.Q@;BE
M"R-8FHR>C?CE1N-5ECMEWU;MD%ZEF:1C3/6+=TD9-9!PW=-TU4E"&+XV_P!0
M].[7U1MQVS=D+0:@P*FC*PX,ISH:$C@002",5ELF^[AT_>"]V]@)*$$$5#`\
MB.8J`>68&8(P]&W_`#5/N1Y';PM/QQCG6S%]DFW+"")8H&C7.ZS2\M+/&C%H
MXB8FV763AD5O/5`"(*M'O>)^/$>WBM8?)7I.S+7%W+=S1+4Z6=%6@S-2J`^T
M$8GS>:6_73+#;QP(YR)5#JKZ-3./>IQ<#YN#'^5PC="LA2X2<[0:_7\G4&S6
M=$GD0J.5IQ&ARZ2CR,;I(LXE_:HFMO56P@0@*$9*IE``2`O3#Y&75CXFYVJ4
M6Y9HW5>?AC6,CQ(4L`?]8=N';S8M[HP64[`M$JLK-RU=TG+D6I7AP4]F-8OV
M^,KZOX0VWQ5D[<?$,AG'7^LN9M>VX_C6,?,+NI%Q!OVU6FU*[+2L)%6=I7+"
MHW=JQSETF@Y*GP8%`#RCW'U58[SN6QS6>P3BVW-P-+DD9:@6&H`E2RU`8`D5
MY<16'3EYM=CNL=SN\)FLE)JHIS!`R)`(!()!(!`H:\"T;WM/>%P?[B50PM@S
M6?!U@Q3AS"UMF+LWF;6RK%9DIZ7D8)>M,HV(H=/<2D/6X2.CG*J@J'?*K.%5
M2E\E$J7<K#/+OH+<NE;BXW+>+E9K^X0+12S``'427>A8D_W0!3B:Y2GK7K&Q
MWZWBV_;(#%:1L34Z0:Y4HJU4#+^T:UX"F=)/9<;*.O=8T3321%<Q,\0[DQ2G
M.F)$VD)/.55NXA3"(()I"<2B'!@#@1`!$0D7F&:=%;D3^V/UD##+T/GU/:#_
M`-5?M!^ZOLQOS?,.PDI.^T'MLC$QRTFK'1^+YYXF@D"QVD1`YDQ_*R\F8O\`
M,5"+CFJBZIP\4TR&-]`"/7,?E9*D775BTAT@F0#UF)P![3EB^>OHGEZ4NEC7
M4W],T]`D0D^P8Y;AB@<IB#SP8!*/'@/`AQX#]0]=GXY;4E6##B#C>#]F7WT-
MX]R=I]7=+;72,)A0H.AVI/*&18^NW52_V.M8XQW)&AYEPY/;7%<@9=Y,LXU%
MRJ5B9!RLN?@$A4(4O./F!Y;].=/[->]00R7'S+2+X:%DT*SR"HIIU$`%B!JJ
M`.=,7CT;UOO.\[E;;1(D/@*A#MI;455#0UU$5J%!.D`D\JX0'[^UB;67W=-R
M7+1PZ<(1=KHE;$77>!D7->Q-0XQ^V0*H4HE:I2"*OE\<E,`]P#P/5H>6$1BZ
M%L`0`2CME_>E<CVT(Q7_`)@/XG5=V172&4"OH15/LJ#AXWR?%>>FL&]]M]"@
M,<E%8$K820N$1=)OEG6490[`C0?^8*W5;I%4,J'V#&*!1\2AU7'GS*OA;;!7
MOZIFI3E2,5KB<^4,3`WLU.YIC%?;)^'U88/\V)8$8WVW\>P*C4ZRMGVJQRDW
M<AP)&9X>CY.EE#'`?M`*Z*)B`(?Z\?7U%?)&$R=6RR@T"63^VKQC$A\TYA'T
MZB$5UW`'J_IR8T2](V#J4W0U$CF*KEN[>;/8&00<LP*+IJ8V4:L(NFX'(H3S
MFI`%0HF*8H"7D0$.NE>HV"=/7[-32+.;CP_X;9>W%$;"I;>K116OS,7#EWUS
M]F.IOGGW+]/=:]@:%K-ES)2\#E2_M(9^U9MJ],RD%66-DF"0-<=76PL6JL;6
MTIF2/]CS3&,W;`+MR"#/^OUQ;MO26^[KM<N\64.JRB)%=0!8J*L$4YM0=G$]
MT5;+'4E]U)M&W;A'MEU)INI`#2A(4$T&HC):GW#,T&>,&]PS)ZK&*J^)XY<4
MQFA_RJS=BG`FC(]<R$*Q5`H^*;F2347,4WUM2#X\].W1=@'DDW%Q\/<7UGXC
M[!0>TXRWB>BK;CGF?N^O[,93JCC"NX+Q/)YPR)Z>/EYF%&;4=NT0,XKE0["J
ML(]L4W*A9*<,8BBA"<**&411X[BB`I^HMPGW;<5VFRJT2/IH.#/S)]"\!R&9
MQGM\"6MN;J;)B*^H=GK/X#%1LN[K95OLHX0ILJ\QU5$UQ+'-(94B5A>)%,8J
M3B5FBE%PFNN`\^0U%-,G/:(J"'<,DVWI;;[.,&Y43W-,RWPCU+]YJ?5AON-S
MN)FI$2D?*G'VG\,1_4]J<^4Z72D"Y!G9\A#D,YAK@NK.1SQ$IRB=$Z3[EVT\
MP"]OF(*)'+S]/2RYZ>V>ZCT>"B=C)W2/=D?;7&F._NXVU:R?0<QAGT)8,?[K
MX3EXIRV+%3;<$D9%@H)%WU.MJ;8ZL9+,%Q(4SF-<&[A24`"^>@*J1@`P'`(%
M+#>=*[JLBG5$>!X!TKF#V'M'(T/9A]5X=SM2IR;[#R/J^["]=9+;+X*V(3JU
MF`\>A+2CC'-M:=Y/(1?J/?3Q#XQS@)3(M)@$Q*H''+=<P@/`\#,]^MH]WV7Y
MB#,JOB(?13,>T?6,,]C(UI>>&^53I/W?7AY?538E.#HP8.C!@Z,&(5V'UXP_
MM9B"VX&SU427O%-Z+$$M-54F)Z!)*D@IR-LD64TI692&FFP-9F(;K?T7*??Y
M?:;D@F*+AM6ZW^R7Z;GMDGAWL==+45J:E*G)@1F"1F,([^PM-SM6LKU==L]*
MBI'PD,,U(.1`/'"OO_YW_9]_](3#_P`7,Z_^9O4R_P#E3KO]\?\`E0_^WB,_
M]@=)_M3_`,R7_?P?_P`[_L^?^D)A_P"+F=?_`#-Z/_E3KO\`?'_E0_\`MX/^
MP.D_VI_YDO\`OXFO$?LN>UOA"<8V6@Z7XB"?C'97T=*7)K.9+<,'9#@=)=H7
M(\U:T$%$#ARF8I`,0?Y1#INOO,#K+<8S%<[A/X9%"$TQU'I\,+A=:](=-V;!
MX;2,L#4:M3T/^,MAG+5JV9-F[-FW0:,VB"35HT:I)H-FS9!,J2#=N@D4B2*"
M*1`*0A0`I2@``''4/)+$LQ)8G,XD8`44&0&//UYCW"I-G?9*]M#;*9G;9DO6
MBM05]L2RCN5R!BQ_+8PL[R16'N6E7P5)XP@)>37.(F57?,71UCF$RG<8>>IM
ML_F)U?L<:PV=X[6R"@20"10.P:@6`[`K"G+$7W+HSIS=6:2XMU69C4LA*$GM
M(7ND]I(->>**I?*N>UHFJHH8-DEBG2(0B*N9T@21.4"<KIBE44E3*J=H\@<Q
MR?:'@H>'$C/G1UG2G_2?\H_[^&;_`.,^F:\)O>G^YAGNEWM::0>W_*SMEU@P
M]_A=RM-;1J5FNLM;[E;[+.5]"11EB1SIQ9IV28M$32+9)4_I&[;S#)$[N>T.
MH?U!UGU%U0BQ;S/XD"/J5`J*H:E*]U03D3Q)XXD>S]-;-L3%]MB*2,M"Q9F)
M!()&9(&8'`#@,>#:_P!J;0G=_(\7EK9[`[7)N086HQ]$C;`M><DUD[>JQ<K,
MS3"*]#3[A7XQ8K>3L#Q0%3HF6'SNT3B4I0#W9.M>ING;0V.SW)AM6D+E=$;=
MX@`FKJQX*.=,L8[ITOL>]7`NMRA\2<(%KK=>Z"2!16`XL??CY>KWM&^WUIEE
M1'->MF`T\:9*0KTS52V)KD3*L\"E?L'I!EHUQ$VB[S<*Z1='8(G`5&YC)J)%
M,02F`!ZSWGKGJCJ"R_C]WN?&M-0;3X<:]Y>!JJ`\^W'FV=*[%L]S\WMT)CGH
M177(V1XY,Q'U88-9ZO6KM7IBI7*O0ELJMA8.(J?K5DBF,Y`S<8[(*;J.EHB3
M0<Q\BQ<)CP=)9,Y#!](=1>&::WE6>W=DF0U5E)#`CF",P?5A]EBCFC,4RJ\3
M"A!`((["#D1A%67_`):?VH\L6%6QQV)KYAU=R+E1[%8<R;/5VN.7+I8JPN4J
M_826R+B?)'N*FBP3:-2$.(`EP!.VR+#S<ZVLHA$T\<X'`RQ@M_F723ZVJ?3B
M%W?EWTQ=2&41/$QXA&R]SAP/4M!Z,>YASY;;VK<.VR(N:6+,B9%FJ_+0T[`A
MDK+5ME(Z+F()XSD8]^G&5M>JLGQROV1%3)NR.$#")B]G8/:&-_YM=:7\#6YF
MBBC8$'PXU!((((JVHC(\J'TUQ[:>7O3-I,)Q$[R+PU.0/<FD&O.M1[,.6S)A
M3$VPV.K#B7-^/JOD_&]K;E;3U0M\8C*Q#XJ9P4;KE35`%6;]FL`*-W*!TG+=
M4`.D<A@`>H!8;A?;7=+?;=*\-VG!E-".WU@\P:@C(C$NN[.UOH#;7B+)`W$,
M*C+@?01R(S'+"*K9\KO[5-FGWDW'U?.%):.W"BY*U4<R2A*\R(HF4@-61+'%
M6.72;)&*)R@9X<_<8>3"7@H63!YR=:PQ"-GMY&`^)HA4^DZ2H^K$*D\MNF'<
MNJ2J":T#`CWLK-]>)JKORZGM$055BZN[U;-:%8U4[A:TV3*F6U;;+N%$4T#G
MEI6'NT,@JB()@8K=%!%JF<1,1(HF,(MTOFMUU+.TRWF@$4TK'%I'J!0GVDDG
MF<*X_+_I5(A$;8M0UJ9)`23_`*K`>P`#T8F;!WLF>V1KAEBD9PPWK*PJ.3\<
MRBLW3;+^HV6YP8:458/(T7A(JPWR5AG:I6CY4"^>W5*0P@8``Q0$$&X^8?6&
M[6,FW7]X9+.5:.OAQ"HJ#2JH",QR(PLL>C>G-NNDO;.WTW,9JIUR&AX<&<@^
MT89[8:]!6V!FJM:(>-L-:LD5(05@@9EDWD8B:AI5JJQDXJ3CW::K5ZP?LUSI
M+)*%,11,PE$!`>H=%++!*L\+%)D8,K`T((-001P(.8.)))''+&T4H#1L""#F
M"#D01V'"!\C_`"QGM49`MLE:HZB99QBC)N".E*EC/*TC$TYFIW*'7)%Q,_&V
M9Q%M7)C^*"#@B")2@5$B1?`;-M/.#K6U@6!I8)BHIJDC!8^LJ5!([2*GG7$'
MN?+GIFXF:8)(A8U(5@17_&K$5[*T[*8N!H[[-.B7M[WM]E37NA6]/)[^O3%2
M5O=XR'9[9+)5B=?1LA(PC:.5=LJP@W5<0[;A4(_U(%2X\T>XXF8NH^O^I>J;
M866Z2Q_)A@VA$51J4$`US;F<M5,^&'79ND=DV&<W5A&PN2I746)R)J1047EQ
MTUISQZ69_9#]L783*MZS9F#6AO<LG9*G5K+=+.XR=F*-5F9A9!NU,Y&/A<@1
MT2R(5LU33(DW022(0@`!0ZRV_P`Q.L-JLH]OL+OP[.)=*+X<1H/64)/M)QC>
M]&].;A<O>7EN7N'-2?$D&?J#@#V#%CM/_;WU#T+;7YIJCB-#%3?)[FNN[PFA
M;+S:?CCBIHS"$`<QKK9;$=EZ!*>=@`-Q1!3S?M@82EX:=^ZIWWJ8Q-O<_C&$
M-H[J+3535\"K6ND<:\,.&T[#M6QAQMD7AB2FKO,U=-:?$QI34>';C)-MM)M9
MMYZ/7<;[28W+D^E52U)7:"@E;1<:N@SLZ$5)PB$J9Q3+!7GKI1&+F7212+*G
M2`%A'M[N!#5L?46\=-W#W>S3>#<.FACI1JK4-3OJP&8!RSRQLW79=MWN%;?<
MX_$B1M0&IEH:$5JI!X$CVX5S`>UI[%^!,GTZY5W$U0K>2,=VV#ME7E8[*V=+
M)_CUJK4FVE(=\Y(A>9N%*=A(MDSF2>%,B/;PH42\AU-Y.K/,W=;*2"261[.6
M,JP,4*ZE8$$"J*V8/+/LQ'(^E>C;*X6:.(+.C!@?$E:A4@C\Y&1'/#!LBZ0:
M,[:Y4I6SMXQC3LK9"I[2#C8&ZL[-81CG32JS9K)7XZQPD!8&=:LY(.:5%9-&
M3:.1X'RE`,CPGU$K??\`J38K.39899(+60DLA45!8:25++J6HRJI':,\\/ES
MLFR[I=IN4\227*``-4TH#4`@'2:'M![.&6*69I2#+VY3JK.3J%8NKS6Z$(&`
MZGE1L2#-I*`4J8<@F<X.E.0^@#\B/TCU,MJ/\;TP+A?C$32>TU(^["*Z_P"H
MW+PSPUA?8./WXG_W"[\:,C:-B6)7(U8N$5+/.M$#%*'H8TP1U<9J%*/<1J"Y
M'"O8/V3&13'_`(>F;HNS\1YMRD%7!TJ?2<V/KX#VG"O>)M*I;KPXGV9#[\9M
MJ[@JAXGQNVS)E5*(;3\I'DFP?6DJ"3"EP3@.8]%!-]_21EI!%0JBJO'G<J%1
M3XX-WI-_W>\W&^.U[=J,*MIHG%V''AR'(<,JGT;;"TBMX?F9Z:R*Y\A^/^C$
MU3L#@+;"G33."D:[87+$HMF]CAVY&]BJ\D<JIF+@?4-FTDBV643,/EJD\ATF
M!@#G^8&N&;>.G;E&E5T4YE6^%QS&1(KZ1F#3"ITM+^,A2K$<QQ'W_CA:VM<S
M8<([-,*9,G61]?8'F-[0Q;K<,W;APLHUB7_88Q4U44)4$5T3C]H$%3<?S"`S
MK?8H=UV$W45#1!*AY@#-A[J@CM&&2R9[6^$3<SI/W?7C*=^*J-6S/%6^-`C4
M;9764H"B']-0D[7'/HE70@0"B544`:&`_/)C%$?I#I/T?<?,;6UL^?AN1_A8
M5I]N-F[1^'<B1<M0K[1]!AN=)GO\AH]2LS@Q4QFJM!S;@QSE`B9I"*:OEA.?
MO.4H$,J/(B80#CZ>JWNX?!NY(%_)(RCV$C$AB?7$LAYJ#]6(QE=H,`0LI\'?
MY3K(/O,%(_HU7<HS24`PE$KB4C&CR,;=I@\146*`=+X^G]YEC\5+>31Z:`^X
MD$^P8T-?V:-I,BU]_P!8RQ,D'/PEFBVLU79>.G(AZ3O:244\;OV2Y0'@WEN&
MRBB0F(;P,7GN*8.!`!#CILFAFMY#%.K)*.(((/N.%*.DBAT(*GF,?6ZU8RQ0
M5QE2DD<+D-E?(A#%65*8A95_VD,50P"4O#CCM*(<!_MU-!M]T5!^6M^'8,,Q
MN$K_`,1_I[<>']5J1^[.1?S5_P#B.O?XZZ_;6_N'X8/F$_4?Z>W!^JU(_=G(
MOYJ__$='\==?MK?W#\,'S"?J/]/;@_5:D?NSD7\U?_B.C^.NOVUO[A^&#YA/
MU'^GMP?JM2/W9R+^:O\`\1T?QUU^VM_</PP?,)^H_P!/;@_5:D?NSD7\U?\`
MXCH_CKK]M;^X?A@^83]1_I[<'ZK4C]V<B_FK_P#$='\==?MK?W#\,'S"?J/]
M/;@_5:D?NSD7\U?_`(CH_CKK]M;^X?A@^83]1_I[<'ZK4C]V<B_FK_\`$='\
M==?MK?W#\,'S"?J/]/;@_5:D?NSD7\U?_B.C^.NOVUO[A^&#YA/U'^GMP?JM
M2/W9R+^:O_Q'1_'77[:W]P_#!\PGZC_3VX/U6I'[LY%_-7_XCH_CKK]M;^X?
MA@^83]1_I[<'ZK4C]V<B_FK_`/$='\==?MK?W#\,'S"?J/\`3VX/U6I'[LY%
M_-7_`.(Z/XZZ_;6_N'X8/F$_4?Z>W!^JU(_=G(OYJ_\`Q'1_'77[:W]P_#!\
MPGZC_3VX/U6I'[LY%_-7_P"(Z/XZZ_;6_N'X8/F$_4?Z>W!^JU(_=G(OYJ__
M`!'1_'77[:W]P_#!\PGZC_3VX/U6I'[LY%_-7_XCH_CKK]M;^X?A@^83]1_I
M[<'ZK4C]V<B_FK_\1T?QUU^VM_</PP?,)^H_T]N#]5J1^[.1?S5_^(Z/XZZ_
M;6_N'X8/F$_4?Z>W!^JU(_=G(OYJ_P#Q'1_'77[:W]P_#!\PGZC_`$]N#]5J
M1^[.1?S5_P#B.C^.NOVUO[A^&#YA/U'^GMP?JM2/W9R+^:O_`,1T?QUU^VM_
M</PP?,)^H_T]N/7=Y.QZ[:N6K[*F0%V3E!5N[0<2CX4%FZQ!3626`SD`%)1,
MP@8!\!`>LEL+Q6#);0!P<J`5K[L>&>,BAD>GT].(W!GK$4``LDJ`!]``W0``
M_P"@%.EVO?\`^R/><:*6?;]0QDU;LF$ZF9U_B5WLM?.]!,7I8)RJR]4"7()F
M<)M7!04%/N$`,8.0YXYZT3P;K<@?,PQN!PU"M/548V(\$9_ILPKV?^&/D-E]
M=6UD_P`K:6"01MH/UY+X\@5,LY\37\WU+WUA%?5>L5\T_>?GN'N'GZ^MC#>F
M@^7:-3;4`TYZ:<A3A3&`-H'\0$^)6M>=<?JT.M>+A($D[E8Y*Q2B;0C)-]8`
M(]>E9)J*J)-BK.U15].158XE+]`"8?\`4>BW7>;9/#M8T2.M:+D*]N7/'LAM
M9&U2DLU.>/MS]JPS8X5*OV>]6>9KR1VAD8>9<J.8DAV(<,?+:N5Q;@+4I?Z?
M`?9X\/HZU0V^YP2F:"&)9L^\HH<^.8[<9/)`Z:)'8IV'A]N(<U:4BHK;J4C,
M9N'+NB/8>R(+G5[NWX2A'LWI#&#NX,FTLA4T43CW#V'X#^81Z<.H1))TXLE\
M`+L.OOJ1]:YG&G;Z+N!$-?"(/N_TXQ'9OLC]QE'$2((.BV+&#WS&Q1<*%DQ;
M0(BJ*(=W<XY(0?+#^;P^CGI1L/?Z8"R9KHE'9E5OI7&J^RW*J\:K[\L33[D7
M'J\2"(CSY%S`/LAQQWUSD>_Z>0'CPZ:^A_AN?6G_`-6%6]<8_P#%]V/+1KY0
M1Q;5*]9;]<6R0U*+CYF!3?.4H=,OHTTUV(-BK)H@R$O!>S@"F*/`AP/65U9W
M?S\D\$,)/B$JU.]QXU[<>131>`J.[TTBHY>K'I@WUA```))4`#P``0;@`!_H
M``IP`=9UW[L7WG'E++M/U8RNMV_#-42=-JE>K3`(.U2+O&\&[59I+K$*8B:R
MZ35<"F4`HB`&$.1#I//:[I<D-<PQ.1PU"OVXV1R6\=1&SBO9_IQF/ZJTGX=Y
MWZJY#[/B'D^;\5?>;W^E\SRN?/Y\OM^U_P"WI-_'77B:?EK?X:\!3CC;\Q'I
MKKDXXMCE;*&,<'8[MV6\O6ZN8]QM1(A>=MURLSI&/A8.+0,1,7#IP<IC'467
M5(BBBF4ZSA=0B21#J'*48K96=YN-TEC8H\MW(U%5<R3],R>`%2<L.%S<P6D#
M7-RRI`@J2>`Y>\G(#B3D,\5UP3OAK7L?=&]"Q>YRJK/2%=>6R'<7?6_8+%E:
MGJ^Q]`9:1@;EDW%]2J4P!V\HW6220>G6705!1,AB`80==SZ:W?:;?YF]\`1A
M])"7$$C*QKDR1R,PX$&HH"*'#=8[YMVXS>!:F4OIU#5%*BD99AG15/$<#GBY
M?D(_<I?VR?PZ8*GM.'C!Y"/W*7]LG\.BI[3@P>0C]RE_;)_#HJ>TX,'D(_<I
M?VR?PZ*GM.#!Y"/W*7]LG\.BI[3@Q\V,DX&;([5AI"(ETX^1>Q#]2,=LGY&4
MM&JBWD8MV=JHJ5M(L%P[%D#]JJ1_`Q0'K-TEC($@920"*U%0>!%>1Y'GC%71
MZE"#0T-#6A'$>L=F/I>0C]RE_;)_#K"I[3C+!Y"/W*7]LG\.BI[3@P>0C]RE
M_;)_#HJ>TX,'D(_<I?VR?PZ*GM.#!Y"/W*7]LG\.BI[3@P>0C]RE_;)_#HJ>
MTX,'D(_<I?VR?PZ*GM.#!Y"/W*7]LG\.BI[3@P>0C]RE_;)_#HJ>TX,'D(_<
MI?VR?PZ*GM.#&%9*OU(Q#CR\Y5R')(5ZAXWJ5@O-SGCL'D@6&J]6BG4U.RAF
M,6T>R3PK&,9*JBDW156/V\$(8P@`J+.VN;^[CLK4%[J:141:@59B`HJ2`*D\
MR!C1<W$-G;O=7!TP1H68T)HJBI-!4F@'(8\N/+O3LJT&DY/H;]*<I&1:E7;S
M3YKX>\COB]7M<0TG8&3^'RK1E)L?71;Y)7RG"*2Z?=VG(4P"`%W;W%E=26=R
M"MS$[(XJ#1E)#"H)!H0<P2.S'MO/#=VZ74!U02(&4T(JK"H-#0BH/,5QF'D(
M_<I?VR?PZ3U/:<;L'D(_<I?VR?PZ*GM.#!Y"/W*7]LG\.BI[3@QZC^)BY1D[
MC9*.9/X]^W6:/63MLBX:NVJY#)K-W""I#)JI*IF$#%$!`0'K)))(W$D;$.#4
M$',$<QCQE5AI8`J<49M/MT8%L4T>6CY3)-/06<'<+P=7MB"<*8#G*84$$)J(
MFG3%N``(`5%8@%`WAQP'$MM^MMX@B\-U@E-*:F3O?^4J"?6,-,FRV;MJ!D4=
M@.7U@XLQB7!6-,)PZ\10X(6@O12-*2\F[<3$[+'1[_)-(2KXZJZA$O,-V)D[
M$2<CVD#GIAW'=[_=91)>/6G``44>H#[>/IPNMK2"U73"*5XDYD^LX4_?!1Q3
MNRM+/_\`E8UME"&LBQD$R)E+#6D6KEV)2J`1/RBMY14JGU#VFX'JQ;.NX]*B
M-,Y#;LO^)*@?6!A@EI;[IJ.2^(#[#_IQ,?N*4%1.5HN16C,18/(]U3YARD`^
M6B[;K*RD*"O'V4S.T'+L"B'\WE>/U=-?1-X#'-9,>^&#J/0<F]U![\*=YB.I
M)A\)%#]H^_$\8-LF.MI,&-,>7M)F_L%?8L8FQQ(+)L)8BT4F",-:X@R!BKIE
M7;D*(+$`0(N"B9P[1X,T;M!>]/[L;VTJ(7)*GB,_B1OP[*$856KPW]KX,N;J
M*$<\N!&)`JN+<(:E5JS75)=RS*9EV2-@L<@@]F7:"1A6:P,7V(,D14>.2E`B
M"*8&65`HFY[0$$=QN&Z]1SQVI`.>2J"%':QX\!S)R&-T=O:[>C2\,N)X^H86
MCA\TSG[;&'M3UN<H/+BI?95(P&<)1<)7#%>1L>JH42@":16K1D0W(!WF`0Y^
M@9WN?A;/TXUNIX1>&.56;(GZRV&2WU7FX!SS;4?0!]`,2+[A=I)+Y1K-3:'%
M4U4J@K.4R*";LD[([]01$4O`J:P,&+<_(>)BJAS]72'HNW,6WR7+9>))EZE%
M/M)]V-V\2:KA8Q^5?K/T&&@4RCPZ>)ZI1Y^$C7D>G1X*"F8AVR259N.R&:MW
MZ#ANH!RF\Q8#";GD>[QYY\>H#=7<IW&2[A=@_BLRD',=XD9X?8HE^76)P"N@
M`CV9XJC.>W%@"8F1E&DGDZNM5'*SA>!@[H;X0<%N1!LE\6C962:-D3#]@J3@
MG`>'/``'4ABZWWF.+PV6!VI34R9^O(@$^L8;WV6T9M0,BCL#9?6"?KQ:W%^'
ML?8=KI*S0X%*-9"?SGCMTLM)3$JY\0]3*R[XZSY\J4!$"`<_8F4>"%*'AU'M
MPW.]W.?Q[QRS\@,E`[`!D/OYX<+>VAMDT0B@^L^LXDCR4?NDO[9/X=(=1[3C
M?08ISO\`ZEH[NZI9-UW3MJE#G[,6MV.C7+T82K&MY#Q]:(>]423FX0YBHSU=
M2M%?;%D&1^0<,S*%+P?L,#]TQOAZ=WN'=='B1)J5UK0LCJ4<`\FTL=)Y&G+#
M1ONU#>=LDL-6AFH5;C1E8,M1G45&?HX9TQ"VEV[]VO\`D"7TWW`QZ3".\N,*
M1'VJ?A6*Z+O$V?Z0FY^#JYIUVLHG24GZJY>D3-*1*J*<A773D&JP*>6=0KAU
M!T[;VMLN_P"PR_,=.32%5)RDA?CX4Z\F`^%@2'`U"E15)L^\3SRG:]VC\'>(
MUJ0""DB_J1GB5/,$"AJ,]+4L?NW5<R7/4K8*"UYOD]C3.9L8V65Q/<JT#4TO
M'7RNLQL-<9(D>MW;51M/R,62.<E.F8!;.U.`YX'IIZ=FL(-\M9-TC67;O&42
M*W`HQTL<J9J#J'I`PX;O'=2;9.MDS)=B,E"IH=2]X"N=-5-)]!PM_,&\UZV,
MTDT4B]7;F]H>Q_N5O,<U&H6>*19GLN'J[$Q"5NVKR:RCWK==BJ\PW6Z_*LB@
MHF*7Q5TU*`?:#J6V/3=MM74.YOO,8DVG:!(S*:Z96)TVT9/'^JS*?]4'$>N=
M\FO=IL%V]M.X[@R*"*'0%&J=N(J$"E30\2*<L.RA8X\1#1,2K(R$PI%QC".4
MEY=9-Q*RAV35)L>1DUTDD$EI!\9+S5CE(0IE#&$"@`\=5Y(XDD9P`H8DT'`5
M/`>@<L3%%*($))(`%3Q-.9])P@W3JTY-R'N=ES&.WFV^U6*MOL>YLO=\H.M!
M)JD4O6S,>JT=95C8TE\35LE$>H90J@4PB"-E<-I8)]C*`L+D4@#N-9F_0V=K
MT_!=['8V4^QRVZ(]Q1WN(K@K_4$C:QX;:O@!705I2N(1M3W%QN\L.Y75W%N4
M<Q*Q5587BXKH&BCJ0#7O:QG7@</TEV"DK$RD8C)2$.K(QSU@E+Q)VR<K%*/&
MRK<DE&*/&SUHG(,3*`JB95%5,%"@)B&+R4:SC8(ZN0&`(-#P-.1I0T/.A&)N
MZZT*@D$@BHXCTCCF.6$+^R/KG*0V/<@YV>;,[*V]U)[8[LQMEQ=:+G4W^*K%
M96&>KO2G&0+'$M<>QLW*WV9:UY*1=O&THC'*R+A14C8@?TRV7YB;LDEU%MJV
M=G&JV-H5D5&$BJ84?0I+D!!4J`5+:12IXX@_1NVM%!)>FYN7+74]49E*%O$9
M=1`4$L?B-&I7D.&+Z^Y]M+?=0=.[WE7$\(,]EN:LN-\1XK:C#'L:;*_9COL!
MCJOSIZTFJ@K9U*\XL`OD(LIR?$W*";43$*L)RQGH[9K7?=^BLKYM%BJ22R&N
MFJ1(7(U?EU4H6_*"6SI3#]U'N4^U[4]S:*7NBRH@I7O.P6M,ZD`D@4S(`.1P
MJ0F0MM\5V?7RWX.FO=PSC>4\R8V@MC:IL]KEZ+!^1\1VV?80N6[/"0[&K11,
M,3%)C71YF#"'<*II)M19KI._-,L6;&TV.]@NH-Q78K>V\!S`UO<5FCE4$QJ2
M6/BACW7U`$UU`K2F(I'<;G;S02VK;M+-XBB430GPG0_$0`H\,C\M"0/S`YG&
MR_U4.+'QK-:V4K>7;O6/:/8F^>X9L%B-_CG->Y5=UOK>*6F.H^)@(S#V5\BQ
M\9)YG"3JLU*90:HRD.,4VA3J1;=E!QR(`*JZYE@M[=KGIS9-WL]JMMJM9UEM
M[5IVD+DDRQH2(J,!'D=1:C$NQX`4Q7MG;[SN-C<;A-N$\?AO+X2H%`&@D_U*
M@L^?=TU4`+4<<L/L]NWI'VL*G[LMNW9S)6=B!QWBS/,7@RHQN/6&J[NGV:UU
M%M"XRG,7'J`35@=72I2J1GTHK-D=IR;\_IA20323!1!!TV>LWZ(@VZW;:O%D
MA,S%S<AU5BT@DU:0$8&BZ*:5%:FIPFN9=YCZ;_[H>^E^="+(L:A1`RE@%!CT
MU)92"3JKJ)'#&T8R5769M%G*14'*K9!5P@0_F$1742(=5(JGAWE34$0`?K`.
M>J:8`,0N8KBRE)*@GC3""<BS>6[1[EF4L#[.;=;2:HUK(:E!6]NH,(2U+I."
M\LQ$53V;K)5.G;%8<?VP+9GI&X"\5<04HY0,O$"0\<F8"D,2S;2.Q@Z2AW+:
M+&RO9HM?SWC!WFC)8Z&"JZZ8=-*.H-&^+GB$W'S4^_RV=]=7=K&P4V_AE5C<
M4HP)*-5]5,FYG+BF'_!R`!R/(\>(_1R/^O`>'CU6.)OC^]&#!T8,+S]VFP(5
MCVQM])9R98B8:J9IC2';F[%2.)VD2T$T.4WAP!'4D01^L0`>.I3T/&9>L-L4
M?O8C[%<,?J&&+J@G_MV]`^)K9U'K92H^LXLKJU"*UG6372N+-E&2T!@G$<*L
MS5(9)5JM%T"OL56RJ9_MIJ(G0$I@'Q`0\?'IIWJ03;Q=R@U#7,IKVU=CA?M:
M>%MEO'S6",>Y`,*PSJKM5G+W:9;5+'&U&1,"Z[,=%J#F'*"&.&U1_P`X1L*^
M;;_68Q''$W:*[9&U1GK>#1N64DS-71R1<7Z9$B9W(JA--M&R[;T.N]W=E#<[
MJ=R>*/Q-6C3X*,?$"LI95J=*U'>:IK2F(O?'=+[JH[5;74D%@+))'T:=5?$8
M#26#!2U!4T^$$<\9UJ^XSUK[[D62],+/LGDS9K!D[J!7=FZ;)9T7K4[EC%=M
M1RP?%,A45+O6X.M&L]9L[%`\B3US0%VZR0%(80%0ZJ;>5VS=.DH>H8;2&SW%
M;]K=Q#J6.1?"\0-H8MI93W<C0USY`*-M:]L.H7V62>2XLS:"8-(074^)HTU`
M%014\.0RK4M<'W"MEYO3S2W879"KP3*S6O&5&%Y4(23.J2*>V^PS,34*I\7%
M`07-#MK#8&RSLJ8@H=NF<I!`P@/3!TML\>_=06NTS,4AFDHQ'$*H+-3TE5('
MIP[[]N1VC:)]Q45>-,N8J2%!(J*@$@D5%>%<0?@O2'/\27%&4LV>X1MQ=LQ,
MW]<NN5JO`SN-ZSKW:I4SDDU/X_BL2EQ@N:OX\%58T>D#=\E*"S3`PN2J#]AR
MW+J+;'\>RV_:[&.P(9(V*R-.HI0.9?$[S_FS!6O(\T5GLM\K1W=W?W;750SJ
M&01'.I0)HR7E4$-3F.3.^H=B28.C!A57N(8U53D:EE1BV#T;QL-/L:J8&[BO
M$A7?0+A;CD.U=N9RCW>'`ID#ZPZL+HJ^!23;W/>!UKZN##WT/M.&#>8*,MP.
M!R/W??B;<(62J[5Z].\;7-P"MC@HUG7[#V%1"3;+,B_]V;A'>802`JL1L41.
M`<>H25(8`(8`,U;K!<=/;T+ZU%('8LO8:_$A]_N(.%5J\=_9^!)\8%#V^@X7
M!DC!^7\!V8[M1I.HM8]<ZD)?ZJ$BFQ60,)TTU@D8\07AW9R>"B"QB&#GC[11
M`PSBQW;;=X@T@H68=Z-Z5]Q^(=A&&6>UN+22N=!P85^[AZL8JBEF?.<VQCC*
MWK)$LDH5LT]>XE)5O&><!0$ZSEV88^(1$A0%150R8=H<F'@.E!.U[3$9/Z,$
M9S-``3[!FWJSQ@/F;M@O?=O::?<,->PMBBK:CXMLE\OK]FK95XXC^TRC<!.F
MT03[?AU2A#&^VY,=\H!.X`*+IT<!X`I2<5WNFXW'4FX1V=F#X`:B`\^UV[,O
M</;A_MK=-O@:64C73,_</IGA>N((F9V2V9:3D\B8Z+^QJWJS$(90S=C"PJR+
MAG%%5^T8B`F2:L4_$.2CSU--RDBV/83%"<U3PT]+-D3]K'#/;*U[?:GX$ZCZ
MAR^P8>[U46)7@Z,&#HP8.C!B"]A8/8F>H;9'6"_XRQYDUC9H:4&0R[1)K(%&
MG:VT!V$S5I.+KEHJ,[&*2XJI"20:NQ6;"D(`F<#CPY;5)M45R3O,4TMF4(I$
MX1U8THP+*RFF?=(H:\<L(K]-P>"FVO%'<A@:R*64C.H(!4BN68/*G/%(\;Z<
M[27C<G%6X^XN6\&RLOKYCC)5`PQC+7''-PJM>3=Y?0B6%YM%\M>1K;:[+.+%
MBX1!%@P;%:MFYS&5$PF[@4D5WO\`LUML$^P;!!<K'=2QO+)/(C-_2J45%C55
M&9-2:D\.RC-;;3N<VZQ;MO$D!E@1UC6%64=\48L79B<N7JI3/4T=R[9M`(+M
MTV;%5%0B8N5TD05,F@JY5*3S3%`XIMD#J&`.>"$,8?`!'J&!6;X03B2DJ.)`
MQKP>S_K=6YW9/<+;:KVTUTUPI>>MB<)Z)1YD4U*[5JG=LF!D;92W8\=MW2T:
MYJ-KR\J>%BG38@$7CX,YBF$BWC:G7>[31;18;'-&(]VDMH)KP_F9DC\.!9*Y
MZEC[[`\"XYC$!Z3V^-]QN]TB<OMR32QVXRT@%RTK)3+26.E3S"GMQL1.2KG;
MKD;*D1<F15*W643\U-)<Q#`DJ=+N)YA$U!`1+R'(!QSU58I45X8GQK3+CA/U
MDTJW3V$S[J%E#:7*6I[>!U#RPYS#"3&`\3Y-K^5;U,EK<O6D:D^G[OD&?85&
MASJ$OY\TQ9^J!\JV1`>"$*!9Y%U#T]M>V7UGLT-\9;Z#PB)I(VC0:@VH*B*6
M=:40FE*G$3?:-ZOKZUN-SEM!':R:P8D<.QI322S$*I_,!6M!AP_4"Q+<+-T-
MU7VEU"<W3%-HR9@[(.M3O)>=LFTE>.IM[B<[-7V7LFR.1(V&LTRZM#FCO&,"
MM8)!-PNFR.Z=F,CP9,"&[Y?U-O6R[Z([V&&YBW<0PQO5T,)$480E0%#@G2M!
M6@SXXC>Q[9N>TL]K))`^VF21UHKB6KMJHQ+:>)-<N?+%B=TM5Z]N9KM=<$3M
MHG*$^F759M-&R-62(K6'&^3,?V2+NN.[Y$-G)B-GKBM6V#:N#ME#$*Y0*HEW
MI]X'*U=/[S+L&ZQ[E&BRJH971OA>-U*.A[-2DBO(T-#PPY[KMR;I8M9LQ1B0
M58<592"IXBHJ,Q45%14<<0UAZJ>Z7#3^,HK->8=*;C0Z\[10R?9:=B',$!D_
M(L0UCW38KF*9N\CJ42EV"1>BBX<G3:NV93`<J*!""4@.%_/T9)%,^WP;C'=.
M/Z:O+$8T->=$UNH%0*D'M).$-I%U,DL:W<MFULI[Q5)!(P_S:`QYT%.P`988
M=U%</^%M8*TGR%B+V_<K:GO,B5>2RGDYCMJZ6R)&1,LRJD=:=D;QE&W1<BE$
MF<!-`SK"=\;)K%!8555&IS$,`&*`2[<NHK6^ZI@WQ8G%E";;^F2"Q6!(U(KP
MJV@TRYYXCECLMQ:;!+M3R*;J43]\`Z09F=@:<>[J'NQC6:-`;IDKVM\>^W_#
MY!JT?9Z=BS5G'$M<IF'EGE,LS7`D]BR3M;)["M5TY;X%>HR@N694A.)TB/"]
M_/:/.[;^J+>TZSEZHDB<PR3W,@0$!U\99`I!X50N#7T8U7FP2W'2\>P)(HD2
M*%"Q!TMX10FHXT;21[<-((4"E*4`*4"E`H%*'!2@``'!0^HH?5U"\2C"=]M]
M,-X]SHF1PCD[+NIU=U_/G&J9(KEXIV(LECLM3*G0;^RNE39U*:E\A.*37<F%
M8QJ<8YL;-!'_`)5PY!-L4JQB#/=BZ@Z<Z?<;C9P7S[I\LT;(\L?R[LZ%&+`)
MK:.IU",DY@5.6(ANVS[YO"FRN9K5;#Q@X94?QE56U+I);2'IW2P'"N6>+BO+
MIM3,;NQ6/JY28&NZ?TG"IK1D3)-GAW+NPY)RY:Y>4CJM1,6R#.P-T(MG1HJ*
M"1GW#U@X*MZQ!NB)#"<X,"V^RQ]/-=32,^^R7&E(U("QQ*`6>0$9ER=*`$<"
M3V8>C-N3;N((T5=K2*K.:U9S4!5Y99$G/F*9@XN+TPX=<'1@Q4W>W7>>VUT[
MV,UHJ]EB:=8,VXLLF/HJT3K%U)1$&ZGFX-RR$@Q8G3>.6Z).>2I&`_(\@/(=
M/73FZ1[)OMKNTR,\=O,'*@T)IR!.6$&Z6;7^WRV:$!I%I4\.(]?V8G+$U-=X
MZQ7C/'S^1"8?43'],IKV7`7!@E'=8KD;".9$#.CJ.A!\LQ%7E0QE/M?:$1Y'
MIOOKA;N]FNE&E997<#L#,33+LKC?:0FVM8K=CJ:.-5KVZ0!7VTQ6:C:N6JI;
M]9]V[<6^`?4[,>OV$\/Q]++%O_\`)H&:Q/9+]-.I@\RHN$=\%F&]V[?3)I"H
M*R(',8```%WN=YAGZ9MMB",)X+J64O4:2)%04IQJ-/'LPAAVYXMYFW/4NB6%
M$IS&@D\>S,^NO*F?E@=7K-#^X-D3<=2V0B]0N^J6/-?&])!A(?Y''S](R?<K
MVK8_B9EOA?P:086H&XH%3\_SD0.)@+X"2[S#)TM%L`1A/'>O/KJ-)5XU333C
M4%:UX4.,$VR1-^DW?4OA/:K%IH=55<M6O"F?#MQ*6UFN%'V\UURYK7DAQ+,:
M=EVHNZO)RD"LBWG(1QY[:2A;!#JN$EVQ92O3K!L];@H0Z9E6Y0.42B(=(MEW
M:YV+=8-WM`IN('U`'@>14\Z,I(-,\\*MSV^#=;"7;[BO@RK0TXCF".61`.?9
MBMV`,?>YE0W^-J9F?-VI.4,7TU08FV7R'Q-E2M9PR'68J/<-()RY9GR([QQ7
M;?(+)MCR;E%NX:FX5\E`AC`;IWW2ZZ0NDEN-OM[Z&]DS5#)&T*,35A70)&49
MZ02#PJ<-UA!U)`\<-Y-:2VJ9,P1Q*P`R_-H#'F:$=F+29(@<^2F3<&2F+[]1
MJMBB`GK:YV!JMDJ3J=M.0*\[K8M:7&T2?1>MV]1>P]H'U3U95);U+8/**!1Y
M$66TDVQ+.Y2\BD>]95\%E8!4(;OEQ^8%<AV'#K.EXUQ$UNZ+;`MX@(J6X:=)
MY4SKPX@URH9OZ;L*\83D6AP>3:58*/82&&,GV)VIUD@*+ABY*8JS*1:"<!`K
MI@[3(J3ZA$O`^`B'2NQO);"Z2[A_XB&OH(Y@^@C+&J:))XC$_P`)&$4OFF4]
M4,MB"*QHVPPBB@LGPHJG@;?7EE0`%!1,9,'L/)$3`%4^XJS=4..2*D`0MM&V
M_J+;<QJA?B/S(WW,.1X$=H.(JPGV^XRR<>XC\#]7KPR?'6]^(;5&HH7[U=!G
M`3(F]1>,GDQ7W2@)E\Q5C(QS9TJ1!17NX3<I)G*'`<F_FZ@M[TCN5NY-G2:+
ME0A6'K!(^HG#W#NMM(M)NXWO'O'WXS.R[EZ[51BY7C+4G97O891.*J<2]<+.
MU@)RF0SQ5JSBTNX>"B=1<.WZ_HXZ30=,;W<.%DC\-.UR!3V5)^K&Q]RLXQ56
MU'L`^@PL#.FP]ZV(GF$4DP<QM:2D")UBCQ9E7SAY(+CY#9U)&1(4TO-*`<2I
ME*0$D`,()EY$QS3W:-DM-EA,A(:<KWI#D`.8'8O;S//LPQ75Y+>.%I1*Y*/O
M[3AHFI^`0PK23/)Y!+]0+65%W8U"F(M\*:)]QH^NMUB"8AR,BG$ZYBCPHX.;
M@1*0@]0'J+>?Y2ZT0G_HH\E])YM[>7H]-</NWVGRT57_`.,W'T>CZ<\6MZCN
M'#!T8,'1@P=&#%$MI/<ST5TNM<)0]D]BJ?CJ\V!DWE(^EE8V:W6PD,Z7.W0F
MY.NT>"LLM"PJITCB1T\201.5,XE,8"FXDNS=(=2=00M<[1:22VZD@O556HX@
M,[*"?0"3GADW/J/9=GD$.XSK'*U.[1F.?"H4&E:&E:5H>S%Q:Y=JC;F$+)5N
MQ1,LUL59B[E"^F>)>I?U6;;H.HJ?38JBF^)&/D'*8D5.F4O)@`>#>'3!+;SP
M,R3(RLCE#EP89%:\*C#M'/#*JM&P(90PSXJ>!IQH<1AFC#.O.SE?)BO-]+Q]
MEN#8O6-O0I]H*QEE(Y\T([8,K$U:$7+(1ZA47SAL#E,2`=)=5(3"0YRBMV_<
M-UV>7YW;9)8)""NM:BH-"5)X'@#3M`/+":]L]OW./Y6]2.9`0VEJ&G*O:.)%
M?21C***CAO&^/Z]7,;ACBD8OK)4*M5XBH*5N!I,)Y:HIH0,.UB3MH5DKZA0>
M&Z0%.90PCP)A'G1<G<+NZ>6[\:2\?O,6U,Y_O&N9]>-L`L[:W6.W\-+9>ZH6
M@4>@4R]F,[>S<+&JMT9&7BV"SMVW8-4GL@T:JN7SO_Y5DW3753,L[<_]FF4!
M.?Z@'I,L<C@E%8@"IH"<AQ/J&-[.BFC$`DTS//LQ@E1S7B"_V/(50H^3J);K
M1B::9UO)T%7;1#R\G0;"_06<M(*VM6+M92"F%D&YS>F<>6L4"#R4..E,^WWU
MM%%/<0R)#.I:,LI`=1Q*U&8SXC+&B*\M9Y'BAD1I(C1P""5)KD>PY'+T'&8)
M6NKKN8]DC9(!9Y+LCR42T2F(Y1S)QR91.H_CT".!5>LDR%$153`Q``.1'K08
M)@"Q1M*FA-#D>P]A]&-HEB)"AEU$5&8S':.T8JR]W^U"0=XP:1.:Z]=D\PY;
MEL%T.4QG'V')]>D,IP*T8WFZK*V7'\/9*_5UHI:7;E7<2CEFT3$X\J_8/VO*
M],;Z5F9[=X_`@$SB0K&PC-:,%<JS5H:!03Z.&&UM\VH&,+,K^+)X:E*N"^61
M*@@?$,R0*&O"N+9-YJ&=OU8MK+1CF3;M4GR\<W?M5GZ+)=0Z2+Q5FFJ9PFU6
M53,4J@E`AC`(`/(=,ACD5=;*0A-*T-*]E>W#H'0MI!!:E:5SQ^(J?@IWU?P2
M:B9CT#@S1]\*D6<AZ)V03%.U=^D66],X(8@@)#]I@$!\/#H>*6.GB*RU%14$
M5':*X\22.2NA@U.-"#3%4\G>X#I;AR'OD]D39/%L'%XMR%6\3Y'7:SY;$K1L
ME6])\M7*1:6581F7T+8Y1*-<"5LND10GE&`X%$.GJSZ8Z@OWBCM;29GFB,D=
M5TZT6@+J6H"HJ,QVBF&Z?>MJME=YIXPL3:7H=6DT8T(6I!HK5[*&O#%HO\MJ
MHPZMA"S5\8!!8S=><^,QWP=%<C@&AT%9/U/HDUB.C`D)1.!@4'MXY\.F?P)_
M$\+0_BGE0U[>''#AXL6CQ-2^'VU%/?C`LY9ZQ!K5BVQYLSI?(;'&*ZB$0-CN
MLV#U6)B@GIF.KT.*X1K1^[.$A-2S9NGV)'^VL7G@.1!3MVV7^[WB;?ML32WK
MUTH*5.D%CQ(&0!/LQIO+VUV^V:[O'"6RTJQJ?B(4<`3F2`/7B*M=MZM1=L82
M]6/7K/5&R3"XQ?P\9D%]'N7\.2H/;"DY6@TYU*S,(1PQ)+$9K`W4,3RU3HG(
M4PF(8`6[KTWONR2QP[I;2123`E`:'4%I6FDFM*BOK!YX2V&];5ND;36$Z21I
M34<Q2M0*Z@.)!`/:".6+4^M9]AU/5MNQ,B2AS^>EV$37`!0.<W?P4BP#]@1\
M#?5TS:6[#ASU+VC'IR,["1")W,M,Q46W27;M55Y&0:,D4W+LP$:-SJN5DB$7
M='$`3((]QQ\``>O4CDD-$5F-.0)X<?=C%I$05=@!Z33'G4DXU%XWCEI!BE(/
M#J)M&*CMN1XZ.BW,[5(W;&4!9<Z34AE3`4HB5,!,/@'/7@1RI<`Z1Q-,AR^W
M'I900I(U'EC\+R\2VD640YE(YO+22;A6.C%WK9*1?I-">8Z49,E%2N72;9/[
M2@IE,!`\1X#KT1NR&0*2@XFF0KVGE@+H&"$C6>`KF?4,5?P=O#K!LCEG-.$,
M*Y-)>,DZ]S+NO9<A6E5NL:PJTW'S#NOR$86RS5=C:Q-O&,NR415)'O'0EX`_
M\ABF%XW+IW>-ILK?<=PA\.TNE#1$LA+`@,#I#%@""#W@/?AMLMYVW<;F:TLY
M-<\!(<:6`!!*D5(`-"",B<0#:/>)]M*GY:G\(S>VF/@R%5`L06AE$L;=8J_7
MG%3BGLU8F$O=Z]6Y2DLY*)CHYP99L:0\XJB)TNWS0[.G2'H+J^XL5W&*QE^5
M?3I)**S:B`I",P<@DBATTS!X9X03=7=.071LI;I!.H).3$#36O>"E<J&N?$$
M<<L73PYGG#NP6/Z_E/#60ZW?Z#:81"R0=AA79BHNX)TJZ1;2BC-\FSDV#1PH
MR5[#.$4N\$Q$.0#GJ/7VVW^V7+6=_$\5RC:2I'/+*HJ"<QP)P]6UY:WD0FMG
M5HR./M(S!H1F#Q&)`3LU;5BB3R5@@U(-5%=PG,IRS`\4HW:B<KE<DB5P+,Z+
M<R9@4,!^T@E'D0X'I*89@_A%&\3LH:^[CC=XL93Q`RZ.VHI[\>=M.PCP7A6D
MS%.C1S=J[D`;2#1<6#5\W,\9.7@)+&%JW=M"BJD<_:51,!,41+X]>&.1::E8
M5)`R.9&1IVT/'`)$-:,#09Y\*\*XC^[YTPQC6*ITY?\`*V/J=#Y#M<)1:%)V
M&W0<6QN=RLCD6<#6*LY=/4TIZ;E7)1*BW:BJH;M,/'!3""JWVW<+MY([6"62
M2)"[A5)*(N;,V7=`YDXT37UG;*CSRQHDC!5)8`,QX!<\R>P8QS$6S^O^>92^
MPF(LJU2\3.,,AV3$][BHQTLA(U_(=01;N++6%F4DW9.'CR';NTSJJ-BK-^PX
M""@AR/6Z^V;=-L2*2^@>..:)9$)X,C_"U16@/*M#Z,:[7<K&^+K:RJ[)(R,.
M!#+\0SI6G:*CTXF-O.PCM>3;-9F*<N85=)M,-V\@T67B7*Y0.@WDTDUC*,%U
MB#R0BH$,8/$`Z;S%(H!96`85&1S]7;[,*Q(A)`8$KQSX>OLQZP6JL&6C&Y;'
M`BO-J.$H9`)B/%:759J'2=IQB8..]^HU53,50$@.)#%$#<"`]9>!-1CH:B\<
MCE7A7L]N//%BJ!J6K<,QGZNW$<Y&I&(,UL'].MRL!-O(,/5*@PEV*=FJIU>"
M^K37;+'?Q)5N``P*%\E7@`.4W`<+K&\W':G%S;:E5LLP=+>BAR/LS'+&F:.U
MN@8I"I9>PBH^\873<_;XN+1ZK^GUWK=B9&0,Z;L)\ZT--`B8P^6'<S0D&#E,
M>2E!;E$IC#_*'4VM>L[5E'SD3H]:$KWE^L@^S/#/)M$@/]%U8>G(_?C'X'V^
MLR2#D"3LU2Z\T!4I5%R/W\RX,ER03J-VS9@W3.8"B;@IU4^3%\1X'D-TW6>V
M(M84E=NR@4>^I^S&";/<D]\J![\,`PAJMCG"AOBK0BUHMYR=@VB<0;^>S*(<
M'3A6*8';Q)%.1[CE$ZY@'M%02^'4.W7J&^W4>&U([;^PO/\`UCQ/V>C#O:V$
M-KWAWI.T_=V8LUTPX78.C!@Z,&#HP8.C!C7>OFC6^FOGN?;([X:LXXUBV;K>
MT5#I%7<PN?;W/T"]89DJO$04,X0K$^TJ=I26I[X(`BJ[=L!57*1D4A*F+8%%
M;4MNH^FMTZ.M.F]YEO+.:SD=JPHKI*&+'O#4O>&K(G(&IJ=5!`9]FWNPZBN-
MYVV.WN8[A0*2,5:,@**`T/=[N=,R*"@TYKU4]DGW)TMN;#F=O9L(*VP-A\H9
MP0VX<9:R8ODFX8[M-+?1]9UKDL:.V#B#946*G#)HI%.86[9N<..])(J(RD>8
M?2)V--O9+GP/E8X?EO"C\-75JM.)`02Y&?:2.TUPQGH_J(;D]TK0>,97?QR[
MZBI`I'H-0!5:'A0,172-)P*N_+M[?TFEX@/BN=I6+\ON]'MA<2["7]IF^\+.
MK#G6[ST__@K6/>,8@7*N/7%*4:Q2WD)MTVB*@B=NJH0YS[Y?-38[FXG%ZLDU
M@-PADA3P4[L2!=9-3\8?4PJ22>!`.0G0=]!&C6A5+HPNKL7(U,3)0&E:!D\-
M30$<:U(S\N2?8IW)M^+]<8*KZW:YXRK%`CLF5_,>N..]D9A*N9!NEDJ%4JT-
MLP2W9#Q=D*"89*DD6S@BB81CAU"$CT58]R1=<12RL_,C8(+V[EGN[J::4QM%
M.\`U(BNS&WTI)&3&,OS`.6(<$#--=]%;O-:0116\*(@(>-9CWFT!/%U.K@,1
MZRH1=-">[ZN0/EWMO+NAL58I=[5K1DPS32N,U2N%RV'M]DF:>PQ6SKT5FU:V
M39JC#)2DTUKT*G&0SU6.%19J@42$:F,/7MMYJ;';FTBC#I9UNC<HL"J'\0L8
MM(U-0$DLX#<3F3C*;H#<9Q<2RE6NRL7@L9"2I50K5-!6@"A3I%!6@Y8\=]^7
M_P!SWEBVSHM+Q]@)IC;.VX]`RK"Y6)F^XQ&1&^OE?MMCEI#'1($*T^:`].RF
M2.UW3I87JDD02E442'S`+;S.V!8K*YGEN3>6U@T9B\%3'XQ51KU:@:=T@`"F
MD\L#]#;IXES;I'"+::Y+!_$;7X9UT6E*?F6I.8*U%<2/?O8AVUM6]=,O;*@:
MZ0FJ>*=AJ2UQW"TZ[/JI+ET[AF?^-K4*P.5*[,90GK7'T]@T;JH+SY(U10[O
MTY">H\PB6U\RMC@Z;DMFENFWN>U<N60,/FCWM:]X1A2Y)!":@--?ASV7'1&Z
M3;TLPC@&VQS*%`>A,(:FDY&2HC`![]"=5,FRC7!7L6^XGB.K:VUIA0];H']#
M]D\XY<M4O$9GM"LAE&.L]&BH'%CB?CCU;X3Y=1=-E6:"8"1P=F;O<%`Y2@*K
M<O,?I2^GNIFENV^8M88U!B4"/2S&0*=5>]4$\J\,86/1N_6L$40CMU:.1V)\
M0DN3HTDU%`!I;AGG0BF(CM_L1;JZN80@LJT[),%A*TTG1+.4!M%E3'V3<GW"
MRWG(LU=KA-1508UFM5=Y8GM('&'PN%7=1B`JMS`9RFT.J@)E%UOYD[!O6X-8
MW$37$,FXQ&WC>.-51`B`OJ9@-?B:W`8Y\-0!R33]%[GMEL;RWD$3);N965F)
M>K2'3I`-`8_#0Z01Q-"5SN#\M#C629[-[Y9.KN(T\5XA_P`$P'C.LDJQLH/\
M9SUJKT2N2V2];L>6HFM6VR6&;DHI66FE%XY$S9[*&(4J2)D2G8_-V[1MHVVS
MEG\:_P#$FD;5X8D56-5#+$655`;2M&-0O,@X</+J!OY"]N(X_#LO#C52-94L
M`%-"]&)[FH@C+5E0$8A_(_R_>XTO8-NZ+3<=Z^L,<Y[WII6:(#*!,R6MC=X[
M7&'N5WL"^.FU<6K;]HA)Q2%A:N@6<'%V>0(<I5SI%*<RZT\S]ACBL;F>6Z-W
M;;<T31^$I0SE4&O5J!H=)%!E0C('">;H;=7>YMTCA%M-=%PXD;5X9\0A:4Y:
MEK7/NY$X\^2_E]MSXQG<:MBA''DOK^RWOSGENJ:SN\YS,15;!@&T5ZOP>'7G
MI;=1+U1(?(%0;M)!-R61C)$XF<IJ@JH<G(%GYH=/N\<][XJ[F=MAC:X$(++.
MI8RCNNCE&)%-+`9'(5QC==";PL;0VI1K$7<K+"7H/#)'A?$KKJ500203G3,#
M-LNRWMK[&7/V/*[[=V)E(20S*,'B^,F"Y4R[)6^.BFT-E>,R=9(DF4U:3#O;
M"A7A:`QC5#0S4AFB*:0$*4I3=0?:.KMJMO,5^JKW4+#5(1X<84FL1C4^'K:A
M:NIN\<R37$JW'IZ_N>CQL4)`NSI)U-J`(D\0@-1<@:**``+P&0Q3G:GY?>=K
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MC/BBM5U`DH,P"0*(.%`14"@&,DOOR_&^5@QWA2X7.8Q]G/+MGLV<;EMY07>:
M7E6CINR71E#U/$\E3;=<<;7^L/GV.J=&J"D[<0I',>[<*&9"5007+JM?-'IJ
M*ZN((%EMK%$A6V<0AB`A+2!U61&H[',!J,`-666/;OH/>I+>)W9;BY+R&4&3
M36O=2A9'7(=[A534*375AF7MM>SA=M>=W;]M%L;'I6YO4,18&J.L$Q.9JL&4
M+S4+7!8I:43+LC8Y#X%4&LLN"*!XJ,>+-Q*O$''N;I'$.V(=6]?6^Z=.Q;-M
M),?B3S-<`1"-'4REX@HU,1QU,`?BYG$CZ>Z2ELMY?=-R`9E1!"=>HJ?#57J0
M%!I0JN0`4Y#LK+O9[+F\FQ>]6;,S4^8Q=-UO+N3,`6K$>Q]ES/E&LY=T\HV.
MO2(9#H^-Z)"MSQ+P+@0#GY0<%3$B)3%,@LLJ(._3?F!TYM73=OM]PLRS013+
M+`L4;173OFC.YS&GTCGG4`80[UTEO-_O,UU%X;12NA24R.'A"@AM*C*N>5*_
M#4%2QPS;V@_;4F]$ZAM>XR77:='96SGL5DV;C;K3+/,6!>7P0JY3<XFCIA%Z
MFQ8Q4W".)656523146!5T(J.50[`)#^N^KTZEGLA:.YLK:UC!1E"TF_^X12I
M(("BIRRR`YR#I;IS^#CNO%51<33$A@Q),=!I!'`48O3G0YGD%TZY>V?[E&J>
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M8:3Y?[Q#"5V]TA9[,+(`[4>3Q%=A7/NZ1I&5#H`.3&GL+_+\[>V:CXFHCFBT
M2JX^B\H;`9&OF+YW9M:Y04:]MV':]5*$%*;5##V-H"MQTO>HPSJ2CFK91!))
ML@J8ZHF41#$>9^PPW,UTLLKW310(D@M])(61F?5KED+$(0%)())(H,CCT="[
MO+:QVTD<:PJ925,VJA8*5(TQH!5@:T!H`HX9##8?Y=7W#*_2KU!4*]X[Q@O:
MM8,$4V]PL1FV_.(?/V3J7<X:?R35[VZ2B3.(:JRD8@9-@X1(9J46"2`-T$7"
MPAO?S6Z8EN(I+N.6;1=RLC&)*PQLK!&05S8&FH'/O$U)`QXW0&[QQRK9,D0>
M$*R^(U)""IHQSH!F1R[H'!C3[\O\OGNA+4NMV1SC+755&,W;8YEK^F'ZZ9$7
MQ#C#7MS"IDMF,ZW?WD89XU&ZR[1BA*G9(%>BUC45TUU%1%$-<?FCT_'</")K
MO/;S$UUX,?BR3@]V0H#3N"I6N56((`SQ[-T+NTD(D,4!(N]8@\5]`C)U,NKC
MWLE:E310U2<AE-?^7ZW7BK+`Y?K3O&.+=C__`/0:\YC+F*OY>L<Q(T/62?KK
M-*NPT2R<5M)E-66#M+APX4;&0(HZ;HE34<"!P*73+YH=/O$UA,)I]I_C$B\)
MHE`><$U).JH4K05K0',#&V/H/=$;YJ+PX=R-X7$@<G3&=/;Q(.H\*G(<#E'%
M2^7W]PB'P=L?0WC>EHYBR#CME1V646VS:YJ=EQ\?8BE9.=3]^J+?#K*W'F(Z
MJP[OT\O+3<I(D=@1NFF1L<`35S^:'2TFXVERID^0BE+F,V_>B'@/&`C>*5H6
M(JJHHI4DUXHX.A-_2TN(7T?-2*!K\4:7_K*Y++X8-0NJA9CG04IPF[//L/;3
MH[18RE\&U3`V/-7<%7W7BWXZLU=N4JEDRLU.C!&36;33KBP0,YD&TV>>L:LJ
M_:,F,U%PJRBA#BB"IP\EOVSS+V4[--'N3W,N]7,<ZNK(/#9GJ(J:65%4+I4D
MHS@<Z<5EYT/N2;I$]DD$>V0-&58,=8`%7)JI8G55@`P4G/B116FKWMZY/RW@
MN:W!R>V9:U:M1]JW&0SSGJ+>9?E]C,EU#(@L:9CW&U@P7%UM^\G*S7;^JT<L
ME4DSB=J^<.%C)F:H",QW?JFSLMQ78;,F\WDI;>#"1$((VC)9W68L-+,E0<^*
M@#)CB/V.PW5U9G=IZ6VW#Q/$D4N9&#J@0&,`UH].7YB2:J,;%_RX6KN6ZU@:
MV;F[-DM;C-^>XJEXMH1+PC/Q\_5M;L$P,;0Z%&!`SR#5Q#IVAY`&?<B0XO&3
M=BX[NY0W-5>;&\V,VYIL&SZ!M]LSR/HTE6GF8NYJM:Z0U/0Q8<L3SR^VRZBL
M6W7<-9NY@J)JK58HP%44/;IXC)@JMSQLI]5'BQ,'1@P=&#!T8,'1@P=&#!T8
#,?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g513079logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g513079logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`;@$R`P$1``(1`0,1`?_$`,0``0`!!`,!`0$`````
M```````(!@<)"P0%"@,!`@$!``$%`0$!``````````````4#!`8'"`(!"1``
M``8!`P,"!0,#`00'"0```0(#!`4&!P`1"!(3"2$4,2(5%@J5U5A!,B-184(S
M%X'1DE,DU%9QD;%B-)?7&!H1``(!`P(#!`<$!P4&!0,%``$"`P`1!"$%,1(&
M05$B$V%Q@9'1%`>A,D*2L<%2(U-4%?#A8G(SHK*3TQ87\8+")#1#HU728[,E
M1?_:``P#`0`"$0,1`#\`]_&E*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4J$G+'R-\*^#4Q3(#E7G6&Q#,9"C9B8IS*4K%]GSS<;`NF+*7=
M(J4ZJ6)!L5DZD4""5<R1C"IN4#``B&0[)TIU!U&DDNRXS3I$0&(9%L3<C[[+
M>]NR]0^Y[]M.S,J[E-Y3.+CPNU[?Y5:WMJ)7_P#0+X?/YJU'_P"W&;__`,8Z
MG/\`MAUW_P#CW_XD/_,J*_ZZZ5_FO_MR_P#+K^B_D!^'TYBD#FM3P$Q@*`GQ
MWFQ,H"8=@$QSXS*0A?7U$1``#XZ?]L.N_P#\>_\`Q(?^93_KGI7^:'_#E_Y=
M3:P+SSX7<H%VK#C_`,H<(94FGJ)G#>KU;(5><7(R)$Q54.I2W+UM:V_93*)C
M@HS**8?W;:Q[<NFNH-G!?<\/(AC'XF1N3\X!7[:F<+>]HW!N3"R89)/V0PYO
MRFS?94M-0=2E-*4TI32E-*5A\D_/IXB8>2DH>3YFU1I)1$@^BI)HICG-AE&D
MA&NE63YJH9/&9TQ.W=('((E$2B)?01#6=I],^N9$$B8#E&`(/F0\#P_^I6*O
MUOTO&Q1\JS#_`/;E_P#T5/[C+RLX_<R,9AF+C3DB.RGC8;!+U7[GC8FQPJ`6
M"!]J,M&F86J&@98BK0'J0B86X)G`X"0Q@UC&[[+NFPY?R&[Q&'+Y0W*2I\)O
M8W4L-;'MJ<V_<L'=<?YK`D$D%[7L1K8&UF`/`CL[:D+J+J^II2FE*:4II2FE
M*:4II2FE*LUR`Y!X=XM8HL^<<]W9GCO%=,^E_<UO?QLY+-8KZU+L8&+[C"N1
M<S,+^[EI)!$.TW4Z14`3;%`1"0VO:\_><U-NVR,RYLE^500+V!8ZL0-`"=35
MIG9V)MN,V9FOR8ZVN;$\2`-`"=20-!6-8GY`?A^4.1,G-2HB=0Y$R!_RYS<'
M4=0P$(&XXR``W,(?'TUEO_;#KL?_`.>__$A_YE8[_P!<]*_S8_X<O_+K,0W<
M(NVZ#IN<%6[E%)P@H`&`%$5B%42.`&`I@`Y#`/J`#K`R"I*GB*RP$$7'`U]M
M?*^TTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5X+OR^I<J_(SAM`=)
M`-&85R/,=0"/<,6<O,2RZ3@(]($(-?\`E$/41,;?X!KICZ$1VVO/E_:R$'N0
MG_U5HOZN/?,Q$[HB?>Q^%>97B9Q0S1S9SC6N.^`(6)GLFVN-LDO%,9Z=:5J'
M+'U2%=S\RY?33X#-694F#,P)]0?Y%C$3#YC!K<.^[YM_3NVONNYLRXB%02`6
M-V(46`U.I]VM:QV?9\S?,U<#"`,S7XD`:`MQ)`X`]M9)<P_CP^5S#-)DK[*<
M?HJ]Q,.0Z\G%XFR#6+[;&S-)(ZRSU&J,7#::E4$4TQ$Q623E</Z)CK$<#ZJ]
M%;ADC%3*,3MP,B,BW[N8CE'M(%9-F_3KJ;#@,_D^8HXA2K&WJ5BQ]@-87HR1
MG*I/,9J%D)BKVJMR9'<9,1+Q]!6.O34:XW2=1\BS4:2D1*Q[I+Y3IG3624+Z
M"`AK8+QPY$1CD57A=;$$`JP/80;@@BL,CER,62\;,DBD'2XL1J/=Q%;(G\=;
MRAV[GCQVMF(\\6=6T<D>.*\.RE[,\:BE)9#Q1-MQ:TJY33[O')+V]C)1CV.F
M'`)I&6%-JY5ZUG2AQY*^JW1L'3.ZIG;:@3:<NY"C@D@U=0.Q2"&4=GB`L%%=
M'?3[J>3?MN;&S&+9^/8$GBR$:$GM8$$'MMRDW))KT-S,U#5R*?SMAEHR!@XI
MLH]E)F9?M8N*C6:(=2SM_(OE4&C-LD7U,HH<I"A\1UJN..25Q%$I:1C8``DD
M]P`U-9^[I&I>0A4`U)-@/636*F^>=;Q+XYF7,#/\U\8R$DS=.&;D*5&WC(S!
M)=J8"+%&9H-4LD,H0#CL4Y'!B'$!Z1'8=9IC?3?K?+C$D6WS!2`?&4C.OH=E
M/V5C.1UITQC-RR9:$_X5=Q[U4C[:OOQU\G_C^Y86!K4,`\KL27VYOT2+L*5]
M<6K%TD0.!!%.-J5Q9UZPR3A(#AW$F[911/\`W@#8=1NZ]'=3[)$9]SPIX\<'
M5[<R#ULA91ZR:OL#J/8]R<1863&\K"X4DJQ]2L%)]@J=3MTDR:.GJ_4"#1NN
MZ6$H;F!)NF953I`1`!-T$';U#6-JI9@HXDVJ9)"@L>`%:6>_2*4O?;W+H'%5
M"6NUME$53``&41D;#(O$E#``B`&.FL`CZCZCK]",1#'BQ1GBL:CW`5QIFN),
MIY!P)K9;?C44/[+\2.#9(R(I+9%NF9+^L83D/WP=9)GJRU6`I/5(!CZLB7I-
M\WR[^@"`!R%]7<GYCKC)0'2*.)/_`+88_:QKI/Z=0F'I6!B+,[N?<Q0?8HK+
M1R$Y7<;.*%:;V_DAF['&&8!\J=",=7NS1\.ZF%TR]2C>#B5%#2\XX2*&YB,T
M%CE#X@&L'VO9-WWN8P;3CRY$@X\BD@?YCP7VD5E>=N>W[:@DSYHXE/#F-B?4
M.)]@-8[R?D"^($\E]+#F=5"K>Y.T]TIC[,B<5UD.)!5^KGQT$;[0PE^5;N]H
MQ1`0-L.^LJ/TPZZ"<_\`3WM:_P#J17]WF7OZ.-0'_772I?R_FAS7M_IR_IY+
M5/GC9S+XL<PHFP37&+.N/<TL*FK&HVG[)FB/GM:5F1D?I!)^*63;2D.,J$0Y
M%M[A%/OE0.8G4`;ZQC=M@WG8G6/>,:7'9[\O.+!K6ORG4&UQ>QTO4[@;KMVZ
M*S8$R2\MN:QU%[VN#8B]C:XUM589BY'\?N/44:;SMFS%>'XP&GOB.,CWRLU`
M7#0%P:]]DWG))FY?$%R/;#LD4W/Z?'5#`VG=-T?R]MQYYWO;]VC-8^FP('MJ
MIE[C@8"\^;-%$O\`C8+[KG6L>%G\]'B,J;@6LAS9QS(+`NLW-]K0&1KF@4Z!
MA(<PNZG2YEIV3&#Y%.YT*!ZE$0]=93#]-.N)QS)M\H%OQ-&GV,X-04W6O3$'
MW\M=>Y9&^U4(JY.%?,;XQN0=DB*;B[F3B.1MD^Z!A"5RSO9G',O+/S*`DBPC
M6F1H>J'?/W:@@""*76JN(_XRF'5IN'076&UQ-/F8$XA47++RR`#O/EEK`=I/
M#MJXP^J^GLY@F-E1EV-@&YDN>X<X6YJ<F7LRXHP#0IC*6;,AU+%F.:^K&H3=
MVO$TRK];BUIF2:P\4D]E)!5%J@I(RKY%NB`FW455*4/40UCN!M^;NF2N%MT3
MS9;7LB`LQL"38#N`)/HJ9RLO%P8#DYDBQ8ZVNS&P%S8:^DFU>`[S5^;+E--<
MP,EXOX7<VG+;BC'5_'"E0F./DE6(\DG+/Z3"2-Q+_P`U:Y&!<GRK>T+NDE4D
M90B*0!V1+\H@'3GT\^G>S)L4.;U!MP_K19^83AC8!V"_NV/(/#8BZW[:T1UI
MUMN7]4DQ=FS/_P"N`6QC('X%)\:V;[Q;\5NRVE2-_&MY[X2Q6OS0O'-[F,SK
ME^O$CA6.JTCR*S0^<NK!"0K;)3Z7<0:]XFGCIZX:2DR0'9TC;$!1(#?WAJ)^
MKG3&XY@V_'Z=P"^+&)2P@B%E)\L"_(`!<`V]1[JDOISO^'"N5-O.6!D-Y8!E
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M<D$HF#KUI"RXXD)N3<&2(U80Q<C0%52E'CQ58I$4D#J**J;E(`F`0U7W#H#K
M#:X#DYF!,(%%RR\L@`[2?+9K`=I/"J.%U;T[GR"+&RD+DV`8,ESV`<ZK<GL%
M9.]8?61TTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E>`7\N]1N;F%Q43(
M("Z3XV39E]E`$015R?.>V`R8#N3<Z:H@(_W?]&NGOH4#_0\T_A^;'_\`&M:(
M^K9']0QQ^+R1_O25#G\8J'?R?EEQT^9J(D0KV',VRLH50I3*J,'%80A"%;]1
M#]!@DI9OU&`2B!-PW]1`<@^L;HG1$JMQ:>(#U\U_T`U"_3!6;J9.7@(W)]7*
MP_21[+ULP-<@UTC6K._(&Q34<0^6/E!"4EI&QT-:UZ#DUU%Q1$DFL?8L@4.!
MGK40R")2)-W,C857+]0@`'J[W_KKL_Z6YT^=T1AOD$F1`\=SVJCLJ^Y0![*Y
M?^H6)#B=3Y`AL$<AK#L+(K'WL2?;4Q_Q3;;+0GDLM=9:*O?I-VXRY%;3+9N"
MAVASU^UT":BW<@4IRI)IM52JIIJ&`P@JX`@;=8Z@/K9!')TBDS6\R/,C([]5
M<$#W_94Q]*I73J!X@3Y;8[W'9Q0W/NJB/R!O*YD?F'R4R#QAQY;7L-Q/P+;Y
M&DI5VOR;A&,S#D&JO1966]W/L=@LY'0]@:K,X1DKW6;9)J+LI17<"8EQ]+NB
M,/8MHBWG+C#;UDQA^9@+Q(PNJ)W$J;N>))Y3H*I]?]696Y;@^V8KE=NA:UA<
M<[*=6/?J/#Q``!&I-6T\6'@@R]Y+L56W.*F9*E@/%</8G]+J$M.5MQ<IN]6B
M':)N)SV4$VGZX$76X19XV;J/55SF7744(BD?L*:O>M/J7@=(9L>VC'?*S60.
MP#<@12;"YY6NQL38#06N1<59]+]!Y?4F*^<TR08X:RDCF+&USH"M@+C4GC<6
MT-8KN4_'3(W"SDSDWCU>Y1D.0L*7%"/^YZB]?(L7IO9Q]BJ]MK,@8C.39)R4
M/(M'K<VR;AN=3I$0.01UFFR[KB=1;/#NF.I^5R([\K`7'%65AJ-""#V&L6W3
M`RMAW23!=AY\+VNIT/`@^T6/NK8'^#KR$Y,YB^,#*LQEJQJ6_.7&5O?\=S]M
MF%S+S%RA8^@A;,=VNT.E$B@YFG4<[4CWC@14.[5C#.53"JL<`Y<^HW2V'L'6
M4,>"G)MV84<*."DORNJCNO9@.`YK#0"N@.C-_P`C>.F99<D\V7CAE))U8<MU
M)]MUN;D\MR22:UL0KBZ,9T)")"Z.=R*2>_;2%<PJBFGN(CVTQ/L&_KL&NN@+
M`#T5S;*+2LHX`V]VE;,/QB9XIG##\?#"O(RV"Y?US$O'[).2'+!R"K%>:G7V
M2+W(0U59J"FN*03]JE6\8T7Z3$,"Y%=ND=<?]8;;D=0?5#(VJ"PEGR8X[C6R
MB-`6/^506(]%JZ:Z>S(MGZ&BSGN4BBD:QT))D>R^UB%'KK7@<IN4N:^9>;+C
MG_/UO?VZ^6^0=+D(X<N#PE0@CN5EXNE4R-6541@*C7D%>RU:H@`"!144$ZQU
M%#=5[)LFW=/[='MFV1B/'C'=JQ[68_B9N))]0L``.=]WW?-WG-?+S'9W=O8!
MV`#L`[!V>NY,\^,/@N\EO+C%,%FO%&#HUACFUI(O*C-9'O-<Q\XM<.X*)T+%
M`0\VX"6=UYR4-T'9T4TW)!`Z/<3$##C.\_4GI'8\UMOS<@G+31@B,_*?V6*B
MP;O%[CML:GMKZ#ZAW7%&9!%RP-]TL5',.\!F!MZ;6/9>O3W^-[P/YI<!\X<Q
MJ-RBP;-X[@KS0\0RM:NI):`LM*GYBKSUW;.(J#LE:DY.->/_`*?90661,8BR
M)$R]1"]6M-_5KJ;I_J?;\#)V;)662.24,EBK@,$U*L`0+K:_`WT)K9WTZV'=
M]@RLN'<HF1'5+'0@\I/`J2IOS'2]Q;4"XOQ?,SX9.:WE"\@M:O5!7QKC?`>/
M\&TS'4;DO(UH!XHZF23EUN%G^@TBLQ\E:5"I.K$W:#[KVJ"BR8G(KT=73]^G
M_P!0.GNC>F'QLH2S;G)D/(41>`(1%N[$+P4G2Y[+5ZZPZ0WGJ7>UEQV6/;UB
M526:P-N9K@`$G5K6(`[;ZZ0;R[^++CO`.#[CDW,_DHHF.Y.LP#F8)+6_&3&K
MXU*Y9LU7"D<]DI+(ZEA7]XJB*;<6B"KI0Q@*FU54V(?)<'ZT9>Z;C'A[?M$L
MJ.UK+)S2:GB`(^73MN0.]@-:Q[+^EV+@83Y&9N$<;J+W9++ZKE[F_`64GN7L
MKQ\G*0P"4>E0F_H/28"F`H_*<"G*4Y=]@$-P`P?U`!UOFM/W*-X3J.VO?)B3
M'W*OR@_C-U3$E7".R=GJ:EH:EUE_;KN1@ZG:OACD='J,7]GM-G6[9)^-I59%
M$>\NL9Q[=,1-W%!3)S%G96R]&_5Y\Z:\.V*I=@JWLTL!N%51P+M?0:7/8+UO
M_$AW+JCZ=+C)9\UFY020+B.6^MR!HHMQU`![;5X?,_8*R/QDS-D3`678MC"Y
M,Q9/C6KE%QDLSG8YG+`Q920)LYB/.HRD$#,Y!(P*)B)?FV^(#KH[:MSQ-YV^
M+<\`EL29>9200;7(U!U'"M&[GMV3M6:^#E@"=#8Z@_H)'VU+KA)XI>9_D.J=
MZNG%RE4ZV06.;(QJ5K5L>1*S3';*:DHE.:9I-V<XX17>-U6"H&[I`Z`,`E^(
M#J!ZCZWZ?Z5GCQ]YD=)94++RHS`@&QU4'MJ:V+I'=]_@;)P%!C1@#XE'?^TP
M[C7K4\O&+,F<;_QO,'X+R@Y:L,C8Z9<3L;WUA&O6DFQ3DH.09MWU=:2<>8S*
M19Q*C(B)'"8B1<C4#A_=K1O0N;B;M]6<C<L,$XLIR'0D$&S<&L=03?AV7K;?
M56'-@?3Z+!R3^^B2-3ZU!(&A(T(':0;5X*(">F:K/0EIK<F\A+%69B,L-?FH
MY8S>0AYR%>H243*L'!?F;O8Y^V362.'J10@"'PUTY+%'/$T,P#0NI5@=0018
M@^@C0US_``RR02K-"2LJD$$<01PJ9L3X^N?>5\*VCF%'<<,SW3$*YI:YV++3
MJ)<OW-D;+J.92PWM!"1=?==PB.]WEWLNV;NF_5UG.J/2<0QY^J>F,'<$V%LO
M'CSM$6($#E.@5-/"IX`*2#P`'"IP=/\`4&;AMN_D3/BV+%R";C4EM?$1VE@"
M.TGC4&A`IR[#L8H[#_\``0$!#^H#Z@.LEJ`!9&N-&%;37P#<A;[R2\7''NWY
M,EI*Q7.H'NN)I&S3#E5Y)V*/QO:Y.OUN2?O7"JSEZ^)6$63===4PJKK('4-Z
MF'7%OU.VK&VCK+*Q\-0N._)(%`L%+J"P`X`<UR`.`-JZGZ&SY]QZ:QYLD\TJ
MW2_&X4^'4ZW"V!OVBLS&L`K+JIRVVZMT6`D+1;9=I"046D"CQ^\.)4R]1@(D
MBD0H&5<.5U#`1-),IE%#"`%`1U7QL:?+F7'QE+S-P`_MH.\UXDD2)#)(;(*Q
M;90\@]JD'CAAB:!8P$2FH8B-@LK8).:>D*)@!9&(!0L=&$/N`@5471_3UZ1'
M8-@;?T9CHH?<G+R?LJ;*/_-Q/LM4#/O$A-L<`+WGC[N`^VH_H\S.1:;X789&
M!8YA#=HK7JN=GZ;;@#4L27IW_KL(#_[-3)Z8V0IR^18=_,]_?>K3^I9M[\_V
M#X5*G$'D#45=M87,T*U;H*F!(+G6D%R)MS&$`(:8@#'<G!'<?G6:J#T`'_!V
MW$,>W/HT!3+M;$D?@;_TMI[B/;5_C;N;\N2-.\?K'P]U9-HV2CYA@SE8EZUD
MHV0;I.V+]DNFY:.VRQ0.DNW71,=-5(Y1W`0$0U@<D;Q.8Y`5D4V(.A!J<!##
MF4W4US=>*^TTI32E-*4TI32E-*4TI6N>_*YLIY?R34>!,W61+4N+N/FJ:IE0
M,@[),W7(\OW44@#=)1-18R9Q$?F`A?0-O7J_Z)0A.DI);ZOF.?59(Q^J_MKG
MCZK2%NH$0\%QT_WG/Z_LK]_%$A6$CY*+U*NG)DG=>XK9$<QB!>D0=KR-\Q?&
M.2GW*8P%19K'-N`EV'8!^.VGUND9>D8T`\+9L=_8DA_2!3Z4H#U"[$\,9S;_
M`,R#]!-;`;..=L1<;<96G,6<;[7<;XYIT<O)3=DLC]%DV(5%(ZB3!@B8WNI:
M9D#D[31BU(J[=K&*FDF<Y@`>7MNVW.W;,3`VZ)Y<J0V"J+^T]@`[2;`#4FM^
MYF;B[?CME9CK'`HN2?T#O)[`-3V5J6?(5RN7YO<S^0'*`8YW#164+J+BI0K\
M4C2$11:W%QU3I#"1%$I$ADB5B#:G<[>@.#G`!$``==Q=*;(.G.G\79[AGAC\
M1'`NQ+.1Z.9C;T5R?U)NW]:WF?<0+)(^@]``5?<H`-M+BXKT0?B8X#G9;-'+
M#D^>(?!"X]Q$SQ#59U,3`BK=;S*MK7,L&3<2"G(O8V#J3,ZA1$2H@^2ZBB*I
M1#57UPW2-,#"V;F'/+/YK+_@0%03W`ECZ^4]U;#^E&WNV1D[GRFR1%%/>6(-
M@.T@+KZQWUY+[.O(NK/9G4N9P>7<V.><2QW9"INS2:\L[5D#.DR@!4W)GASB
MH4``"GW`-;Q@"+`BQV\L*+6X6MI:M39)=IV,E^<G6_&L\?!?P(\P>=?&RE<C
ML%<DL`0M'MCRQ1AZG,WO);:ST^<KLX]B9."M475Z?+Q41,JE02?%0!<RAF3Q
MNL8`!4-:SZD^INP]-[O)M.Y8F4V2@4\P2/E8,`05+."1^&]N(([*S_8^@]VW
MG;4S\+(QQ"Q86+-=2"000(VL>!X\"#VU*9U^)CY"'JQW+WD!Q8>N5.D%'+RS
MY<=.%`(4"$`ZZ^,U%3]!```W$=@#;4*OUPZ64<JXN:!Z%B_YE23?2C?7/,T^
M,3_G?_E5G"\>GC3SAXH/'-Y((/,60\:6*TWW'F4<A5R8QF\LCR-@F=7P//QC
M4\@K:8&MJA(A*D.H4B:9R=!2[GW'I#7'5/5VW=;]6;3+@13+#'-&C"0*"2TR
MDVY6;2WI]E9QL/3N9TMTWGQ93QF1H78%"2!:-N-U7M/"W9QK7)-_1NAZ;;(I
M^G^GR%]/^C76-<Z3:S-_F/Z:]YG*)A(,?Q,<4MH6//'MAPCQE>S#=^L=9T:-
M?9DIL@[D69TDDR`23DG*3I,APV(T6$HF$P`8>9]E9&^M\QD-S\QD`6[Q"XL?
M4+CUBM];N'_[7Q\@M>.$GVRJ2?:=?57A&C5(]&2C5I=)1Q$(R+!6601$067B
MTW:)Y%%$0]0559E.4O\`\PAKI:0,8V":/8V]?96AH.7S5YONWK<_XGF:/8L7
M8YG<9.8YWCF6HU5?T-Q$&;GBU*@Y@V*M=%@+01:@U+$F2`A4_E*`;!\-?GWG
M1Y,6;-'F`C+65@]^/-<\U[]M[UV3B/!)BQOC6..44K;ARV%K6]%?3*&2Z=AS
M&^0,L9`E20M(QA2[)?[C*"0RQHVLU2(?3DP\*V3_`,KA5-A'JBFF4!.J<`(4
M!,(!KYA8>1N&7%@XJ\V3-(J(.]F(`'O/LK[E9,.'C29>0;01(78]RJ"3]@K6
MU<Z/R+>??*>\V-#"V29_BI@P)"0;4VEXM70AK^]KYE3I,)"^9)135LKBQO&8
M`=="+<1\>W,<4R)J"45C];]-?2CIG9L9&W&)<W<K`L\@N@;M"1GP\M^!8,Q[
M3V#G3?OJ+O>X9#I@N<?#N0`ALUN\N#<GU$+W#MJ)V`/&QY-O(\BOENK8[RAD
M:FOGSU_(YSS9='$=57AR',ZF):,L>0YD).WBV[RBBIHE)\)E.H@#U[EU-[IU
M=T=TD1@S2PQ9```AB6[#L`*H+)Z.;E]U16!T[U1U$/FD25X3>\CFP/:?$Q!;
MTVYC?B+UBY4*0JBA$U`53(HH0BH$.F"I"'$I5`34`%"`H4-^DP`8-]A]=9J-
M1<\:Q%A8VK:5_CWUMG6_$'P]*T,0PSL!D:T/!3516)[V?S#D%ZL4#(&.4AR%
M,4JA##W"*@8IP*8!*'%_U1F:;KK/+?A:-1ZA$@KJ;H2%8>E<55[?,/OD>M>)
MY2KDID#R1\Z+4J#@HN^467XM)-VD1%PBTJUM?U)BW43((E_\,R@DTRF^)R%`
MP^HCKJKHK'&+TEMT(MIAQ'3O9`Q^TUSUU9D')ZBS)#?3(D77N#L!]E>PW\1-
MO$EX9<G72'MOKBW*(6\GT+`9Y]+;8FQ\I#>X;@<120]RZ?=HXE#K'K#<>CTT
M+]=2_P#U!AJ;^6,/3NOYCW^SE^RMO_24+_1,@_C^8^SD6WLN6]MZN]^5]+MF
M7C2I46=][=W.<K<6HMF95`*:12CZ9E&1=)F((#W4FP($5$`V$#$*/P`=1_T2
MC9NKY'`NJX4FO==XQ_=5[]49%3IQ5)L6R![?W<G]U:_[C[CT,MY\P=BHR"CD
MF2LPXSH2K=)(RRBZ%MND+`N$2(D41.J*B#XP=)3%,._H(#KJ'=LKY':\G-!L
M88)'_*A;]5<_[7`,K<8<8ZB255_,0H^TUN24*Y6("GI5*/A8B*IL-6RUYG7F
MK5NR@HZM,(SZ<A$-V214FK6*:QB0(E3*!4R)%V#8`UP(99I<CSW9FR&?F+$W
M8L3>]^)).OKKL,1Q1P^2J@0A;`<``!:WJM6EQL9&J5CL23)(B#)*P3B;)!+_
M`(2+0DH[*V13]1_QI(`4I?4?0-?H-`6,*%M6Y1?UVKC3)"B=@@LMZV9/XT]=
M?P/B.P4Y>G$Q+-=<UV1@F8?5!@YRE98U)/\`M*`%.K%G4+L)OE4#UWW`./\`
MZNRK)USDA>*1Q*?7Y:G]=JZ7^G*,G2D!;\3R$>H.5^VU_;6>@QBD*8YS%(0A
M1,<YA`I2E*&YC&,.P%*4`W$1^&M9\=!QK.:P8<G,USF?,E)U>K>[>U"%EQ@J
M;#,.XJ-BESK^R//'0((`Y<R*^Y&FX;(MA`?03J".VMAVJ+9\'YC(L,EEYG8_
MA''EOV`=O>?96*YV4V7-R1ZQ@V4=Y[_A4S\(<'*158EG8<NH(6NSJMBNG,$X
M7VJL`8Q14%!1-,4_J[IL00*JJJ<S;J`W000V,.+[MU9E9$AAVTF/'O8-^-O@
M#V`:]YJ3Q=KBC4/D^)^[L'Q_14@19<7IHGV:1+"3_<I&I()L>F&<;]1"II((
MMS@Y!;K,4`Z!Z]Q_UU#<_4$1^:)RQV\QY_UZ5=VP6_=_NCZ/#41.1G!^+0BG
MMSPHR<-W3$AG,G0P65=(/6I`$RR];5<G4<)/42AU>U.<Q%2[@F)3])#9+LG5
M<AD&+NI!4Z"3A8]S6TMZ>SM[ZCLW:U"^9BC4<5^'I]%6WX/Y\>5.T-L0VA\;
M[4LKA9.LF=F`@5ZS*G.K[`AU.DR3&=5ZB=H?0CP2B4`[A][[JO9UR<<[ECC_
M`-S&/%;\2]_K7O\`V?4*H[7EF.3Y=S^[;AZ#_?\`IK,)K6=9'32E-*4TI32E
M-*4TI32E:S?\E^6?6CRTY;:M/J,LVJ.+\)5<I48]VHC&*_9+>R.8U)4B(E4+
MWK&+@1`1`#N#!_377WT@18.B(&:RF2:5N/'QE;_[-O97-WU+8S=32*NO(B#U
M>!3^LFL'%.M&4\=2:\UCRQ9'H,RY9'C7,O2)>UU*5<QRJR+A6/<2-?<1SQ9B
MHX;)J&1,<4S'3*80W*`ALC(AP<Q!'EI%+&#>SA6%^^QN+Z\:P;&ES<1S)BLR
M.1:X-M.[[!796>RYMRL[:C=+#E[)S]N**3+[KE[S>':!C&.5NFU"9<2JJ)A.
MH8"`3;U,.WQ'5."';<%3\ND$*GCRA4'V6JI--N6:0)V>1AWFYK)AP8\'_/GG
M%8H5:(Q)8<,8@7E4&UCS-F.'?TR&CHPHE._=5BLS23&TWJ0(@(E038-3-3.!
M*59PB3K.3$>I/J/TSTY"P>=<C/Y;K%$0Y)[.9A=4'?S&]N`/"LCV+H;?-YE4
M^4T6)?5W'*+=MKZMZ.4$7T)'$;)CA'POPSP'X\4SCGA",7;UNM)GD)ZQ2?9/
M9+]=)!!L2Q7JU.4")I+S<ZLU)N5,I4&S=-)NB4B*290Y'ZBZ@W#J;=9-VW$W
ME?15'W40?=1?0+^LFY.I-=';+L^'L6WIM^$/W:ZDGBS=K'TFW#@``!H!7@I\
MWGA1S]Q>Y"92Y!8$Q=8<C\3\HV>4O[)WC^+D++*8;FK.]/)62GW&O,"/9MA7
M6DZ[64BY0B:S$62R:*RJ2R1BFZ9^G/U#VS>-KAVO<YEBWJ%`A#D*)0HLK*38
M%B+<R_>YKD`@UHKK?HK/P,^3<,"-I-MD8MX1?DO^%NT`&]C;EY;"_-I6'OB[
MSUYB\&Y2>/QFSU><.?7U"J6:L-?ILI5I=ZBF#=)_+46XQDU65)A!(@)E>"R*
M[*F4"=SH#IUGN]=,]/\`4:+_`%C&BGY?NL;A@.X.I#6]%[>BL0VK?=\V3F&V
M2R1JQU`L1?T@@J3ZP2!PM4ALI^9WRKY^B3T^R<R,R.VD@D+'Z)C!*!QJ]ESB
M)UB-%EL35RKS;\ZHC\R?=-UD``,42AJ)Q/I_T5M;_,0X&.&76\EY`/\`B,P%
M2DO6'56>1CY&5-R,1PM&;7_P!+CUW[J]]O)FO/<#>!G*E/F_NBP350\=KRHS
MBL^[?R5K?624P^A`R[V8=/5W<DYD4YR4567[BJBORB43B/KKF/9Y5W+ZEPY$
M?(L;[J&'*`%"B7F`%K"W*+#2M[;E$^+T1+#)<RC`Y3?CS,EB3W:FY[JU;9XF
M8(@8?I,KN5(WK]->_$I!]?\`Z?\`V:[-\R/]H>^N7UB<R"XT+?KK:\8!XP43
MD/X>,$<6+NT5C:;E;@SB6ERGMV_4[KKJP8HKKQG,L&SA0-Y*L6!5)\V*H;_C
MMB=8_'7$NZ;SD[5U[D[UCF^1!N4KCN8+(P(/H9;@^@UU/M^V0Y_2$&V3:12X
M,:GO4E`01Z5;4>D5K7></CPY1^/W*<WC?/6/)QI$-7[HE.RK$Q;U[C;(L"19
M0(^?KME;IKQR*SQJ4IUXYPJF_8*"*2R91+N/773?5>S=482Y>VRJ9"/'&2!(
MC=H9>.G8P'*>(-<X[]TWN6PY309<9$5_"X^ZP["IX'U<1V@&K5XTYG<M<-U0
MM"Q!RFS_`(SI/6L="GT',5[K%;;J.EBN7!V$)"SS5@Q4<KD`YS()IF.;U'?<
M=[S,Z?V'<)_F<[#Q9LC]IXD9O:2I)]M6V/O&]X<7D8^1DQPCL5W4#V`@7[S7
ML]\!_'?(?*OQ)\_&F1KM;G]XYF6?*^*([(]]G+%99U6(9X9AZC7Y5Y)68LD]
M>PT?9;3('*9%1=,Z?<`FQP-KGWZF;KB;)USMC8<:#&P$CE,:!5%S*68`+8`E
M57N[*W-T1@96Z]*9R9;DSY?-&';4V\L<I).ILSFYU/9V5XF<^<>,T<7LD6;$
M.>\=V3&]ZJ<H[AY..GXUTU9/3-E3HDDJ_+F3",L,#(D)W6CUFJLW<)&`Q##K
MHG:]VV[><-,[;94EQG4$%3POV,.*D<"#8@\:TIN.UYVUY;8N7&R3*3H?1VCO
M'I&A&HN*RZ5'\@;R1LN+%'X88F4QK`1--QK&XGA[U1<9OI7,3JB0%?4@&S0A
MUY:9K#.31KB14U)%I"I.R=GOE.FMU*#@D_TNZ2?>I.H,WS7DDF,A1Y`(N=FY
MKZ`-8MKRER-;6(TK+XNO>I%VM-GQEC1%BY`RH>?E`MQ)(T':%!]-]:P:%B)4
M"%`D3*]`%#IVCGPAT@'I\PH#OZ?UULGS(^',/?6!F.5CS$:GU5M</"/!DKWB
M@X,QQ4A0,?",9++IF`Y3`[L$U-S[T3E.4IB'.[DSF$H@'2([?TUQ)]0Y#+UK
MN+G^8(_*JJ/T5U;TBBITWB!?NF,GWLQ_76NX\PW&S*/&CR(<JXK(]<F(R)R%
MFS(65\?VMU%O&E>NE.R;97]WBI"`E%4_8R`QY9T6+LB2ISMWC95,X`)==6=!
M;QA;OTKA/BNI>+'CC=;@E&C4(0PXB]KB_$$&N>.L=IR]OZ@R1,IY9)G=38V(
M=BPMWV!%R.!N.(-0MQ%R,Y$X,)8&G'[-^7\2K7$C)M/M<3Y!MM,-9%6:AOI)
M)1&JR;`TBLV75$J!C@90O68I1V,(#D&X;5M.Y<K;GCX\_EWY3(BORWXVY@;>
MG^ZH?`S]RP&Y,6::%'(YN1F2X!_PD7]'K]->Q;\D>`GL6>+GQJ8(D'D]<)N(
MM5,2L-DL4B^LEQEIO'V`9&&EI>6D5CO7<DYE9.S+*NW*BAC"L8GS#U>N@_I+
M+%F=9[ON2!8XF1^55`50KS!@`-```H`'=6X/J)#)!TM@83,6E0J26-V8K&%-
MR>))<D^JO,YXFX)=QY-^!J,I$OP8FY0XI.M[B+=&1ZT+"@X;]SNH`0A0=)$^
M<1#H_NW`0UN#KF8#H_<BC#F^3E[?\)K6O2$)_P"I,/S!X?F(_?SK6UDS?/-:
MMA;+UG?)K+,JYB^_SSQ)ON"ZK6(JDM(.$T!`0$%CI-Q`NPA\PAKBG;8FFW''
MA7[SS(H]98"NH\Z0184TK?=6)R?8I-:9!*+EU$R*?29<>X4%-S1K\3#UAU;B
M)D!,(COZ[^NOT`\R,:<P]]<=20R!R+=OHK8E<0>7EFX`?C\\*\Q4S#<KEFRR
M"492VE;2!W&QL0]R#ER_**V6VN6;11VUC$U`]LB(@D5S)/&B*BZ*:IER<I;[
ML</4_P!3]PP,C(6"$>(L=20D2>%?3VGN4,0#:U=$;;NLFP=#XN7#"9I"Q4`<
M!SR/XB1V=@[R0+B]ZR4QG,N>S;XZJ!R#D*@KC"ZYT@AKXU9!\\?HQ#Y66F86
M=?PLC)1<0]?04E$03EW'N#-R&%LZ1'J,/SCC$73L6#U?)M:2>=C8K<W-8"X`
M!4$`D!@S`,+\0:R3'W:3.V&//=/*FF6W+>]C<@D$@7!`)!MP(KA<`<3QZQY[
M-,\5N"$$LZK]7%R'0DS<)LB*S\V94YBHD!!FZ*V(8=P+NJ.X"`:NNL=Q<!-K
MAOS.`SV[1?PK[Q?W54VC'!ODOP&@_6?U>^K$\D>1]ISA;5ZU57,HWQ^TD/IU
M>@8OW)7%K<E5.@G+R;9KU+OUWRAQ!JV^9--(2CT"J)C:E]CV/'VG&$^0%.:5
MNS&W@'[()X6[3W]MJM,W-DRI.2._D@V`';Z3W^@504CQ9SS$5\UF>XRF4XU!
M(SE9%`\<YEVJ"104,X6A6CM:43*F4=Q`$Q4+L.Y0V':\3J#:))OEUR%YR;=H
M4_\`F(M]M4C@9:ISE#R_;[N-2+X<\FYBL6.,Q5?99P_J4XN6.K<A*+BHYK$V
MLKTMF"SUVH"@0C]012!-01]LN).CI()@U"=3;#%D0-N&&H&2@NP'!U[38?B'
M'3B..M7FVYS1N,>8DQG0$]A[O5^BJ8YP8G2QQDUA=ZXF,?$7X7$L4&VZ98VW
MQBR*TF=ML'2B#OOHNR``ALJ*FP``!JXZ4W$YV`<2?66'37M0\+^K4>JU>-TQ
M_)G$J:*^OJ(X_&LJF$;Z7)F*:1=!4%1W+0C<DL)B`F/UN/$T=,_XR_*4II-H
MJ8NWH)!`0]!UKW=L/Y#<9<7\*N;?Y3JOV$5/8LWGXZR]I&OK[?MJZFHZKBFE
M*:4II2FE*:4KKY"6BHDB:DK)Q\8FL<4T3R#ULR(J<I>HQ$S.5$RG.!?40#<=
MM>TBDE-HU9B.X$_HKXS*OWB!ZZHUZXQ1).5'LBOCU^\6Z.\[>J5MTY5[9"ID
M[BZYCJGZ$R@4-Q'8``-7*Q[@@Y468+W`,*HGY9CS-Y9/LKB]G#?_`'6,_P#L
M5;_JUZMN7=/_`+5?.7$[H_\`9KFL'N+8M87$8[H$<X,7H,NP7KK-82;@/0*K
M<Z9Q+N&^V^VO+1Y[BSK,1Z0QKZORRFZ\@/HM7=_>50_]55O]<C/_`#6J7RN5
M_#D_*?A7OS8OVE]XI]Y5#_U56_UR,_\`-:?*Y7\.3\I^%/-B_:7WBGWE4/\`
MU56_UR,_\UI\KE?PY/RGX4\V+]I?>*L3D#!W#C+*PN,I8CXU9'<F%,3.;U1,
M8VQR;LF4.ENXG8M\L()G5,)?F]!,(A\1U)XN?U#@BV%-FPCN1Y%_W2*L<C`V
MC*-\J'&D/^)$;](-5)2L?\9<;%1)CNE8*H16YD#H!3*Y0*P"*C5(4&RB?T1F
MQZ%&Z(]!#!ZE+Z!Z:HY&1O67_P#+?*EO^V9&X^N]5(,;;<;_`./'!'_E55_0
M!5RW5HHSYNLT>V*J/&C@@IKM74M#N&ZZ9O[DUD57!TU"&_J!@$!U9KC9:GF6
M.0,.Y6^%7)DA869E(]8JGNSAO_NL9_\`8JW_`%:K6W+NG_VJ\<N)W1_[-5(C
M;*6W2200LU70013(DBBC,Q*:22290(FDDF1R4B:9"```4````-@U1.-E$W,<
MA)_PGX54$D0%@RV]8K@RTSCF?8+Q4[*TF:C'1#)NHV6?04BP<IF*8AB+LWBJ
MS=8AB&$!`Q1`0$0UZCAS8F#Q)*KC@0&!]XKR[8\B\LA1E/8;$58.#XV\&:S/
MN+77,#\4X&SNUDW#FQ0V,\2QLVNX2,!TEU)1G"HO3+)G`!*;KZ@'X#J3DW3J
M::(02Y&<T(_"9)2/<3:K!-LV2*3S8\?%64]H2,'WVO4A&5EH<:U081T_46#%
MJF"+9FRE89JU;)%_M20;H+IHHIE_H4H``:BVQ\QV+.DA8\258G]%2"O"HY5*
MA1V`BJ/OD#@7*D2>`R=#8CR-!G`0/#7IA3K;%F`P&*.["?2D&NX@8?\`<_KJ
MOC-NN$_FX9R(I.].=3[UL:HSQ8.4GEY2Q2)W,%8>XWJG,<XQXL8?;F:8FQ_@
M+&+8Z9DE$,?5;'M.342,19,R:A:\QC@4(9-RH40-N'2H8/@(ZK9>5OF>;YTF
M7,?\;2/_`+Q-4\?%VS$%L6."(?X55?T`56@(X;`-@2QD`!Z``)U78`_]VK>V
MY=T_^U5?EQ.Z/_9JH6EGHK!LBS8V&ILFC<@)H-6DM#MVR"8"(@1%!%P1),@"
M/P*`!JDV/EL>9HY"Q[2K?"O8DA465E`]8JFKFRPKD>'5KN0FN+KW`+[]Z#N2
M-4L\0J(B41%2-FROF9QW('Q)_0/]-5L?^IXDGFXOGQ2]Z<ZGWBQJG,F'DIY>
M0(I(^Y@K#W&XJW./\)<.\3]0XNQ-QMQR)U!5.>C4?&54.=05"*B<RD%&,3F-
MW4RFW$?[B@/Q#5UE9_4.=_\`-FS)O\[2-_O$U;08.T8O_P`:''C_`,J(OZ`*
MO!)2^-YD$2S$I2)4K<3F;EDGL"^!`R@%!0R(.E502%0"@`B7;?8-]6"0YT?^
MFDJW[@P_15XS8[_?*&W?8UP&Y\1M%T730V.6KINH59NY;C64%T%2#N15%9/I
M424*/P,40$->RFXL"K"8J?\`-7D#%!N/+!'JKOU;;3%DU$5K/6%452'2525F
MHI1-5-0HE.FH0SD2G(<HB`@("`@.J0QLH&XCDO\`Y3\*J&2(BQ9;>L5%')^>
M<.X_DU(."Q8TR!)M@)[M2`A:RV@VICD`Y4!F'21B.5RE,'4""2I";[";J`2Z
MR';]DW+,C\Z:?R8SPYBQ8^GE'#VD5'SY.)"W(D8=AW`6]]<O''*;']X42I5F
MH$C06<@G]-;-IA&'DJ>NDN02&CW2K4$T6:*YC=`%6:E0-U?,8NO.=T[F8@.3
M!,LQ74\MP_K`/'V&]?8<Z"7]S(A13I8V*^K^PJ//D#L#6<2Q?6JP<DNSCPL,
MP\""Z9!DV$$HV-C4#C'E5214(EW^DFX;$'X;;:F^C8&A.1/..5FY5'-H3Q)X
M^RK/=W#>7''J!<Z>P"JPL,\ACC@U$5JNK-#VB>JT3$2$9&O$GDJT5NCD75A<
MN6C90SQ)9-F]6(<#$_PF,!!V`/2UAA;.ZM:><'Y=)"P)%@>064`G3B!Z^-57
M<0[4$2WF%0#;CKQJ@>"N/ZG#_<.5[TXBHZ5C7"D+4V<XX;-'4>FBT(O,SC=B
M[.1R*RY'!6R*@$W`I50+N)O2\ZMS,F7DV[$#-&PYG*@D'7PJ2-.RY'JJCM4,
M:WR);!AH+_::OY`<[<=360F5*=5>UP<9*R:,3%6F53:H(+KNU_:Q[EY$"<)!
M@P?N!*4B@]9R]0"<A``VT/-TCG181REDC>15N4%[Z:D`\"0/[C5XFZPO,(BK
M!2;`GX5$KG;B=G1,@0U_K;0(V+O8.57Q6I")-V=OBS)++.6Y$R@5!24:J$<"
M'^\NDJ?^HZR/I'<6S,-L.<\TD-K7XE#V'U'3U$"H[=<<13"9-%?](^-2`Y%+
MJ9:X95+(SIOW)B.;T^SN5P3$ATUUU"5Z=.0#@00075>G/N`"`@`"'R^NH;9%
M&W=428*G]TQ=!_O+^BKS-/S&V+.?O"Q_4:[7@3?(=/#TI7IB9CXY>OW&4(U)
M)2#-F!V,JV929/;`X42,<A7:RW5_=L8?CZ@`4^L,.4[FLT2,RO$+V!.H)&MO
M1:O6TRJ,8HQ`LQX^G6JXOO,JLU>8=0]7H]GO7L5E&[B69N(^(A5%DC]"@,'3
MPR[I\D00$.X"!4S"'RF,7YM6N'TOD9$0ER)8X;B]B"6]H&@]5[]]5)MS1&*Q
MHSV[>`]E5CBOE%3<D.U(J3B)B@S)4EG"+>SJ,`C'B*(EZ@:S39R9K[D"#U"D
MJ5$P@`]'7L.UMN/3^5@KYD;+-%>UTO<>M2+V](OZ;55Q\^*<\K`HWIX>^K_L
M[)79%P5I'S\*_='`YB-F<HQ=.#E3*)CF*B@N=0P$*&XB`>@:A7@GC7F='5>\
M@@5>!T8V4@GUUW6J5>J:4II2K09>CIB1CH4D/14;THD_7.NU6?,&01Z8M3%*
MY*9^[:$4%4_R;%$PA_IJ4VN2*.1S+,805&H!-]>&@-6V2K,HY4Y]:L3]LW;^
M/K']>KG[QJ:^9Q/YUORM\*L_*E_@CWCXT^V;M_'UC^O5S]XT^9Q/YUORM\*>
M5+_!'O'QI]LW;^/K']>KG[QI\SB?SK?E;X4\J7^"/>/C3[9NW\?6/Z]7/WC3
MYG$_G6_*WPIY4O\`!'O'QI]LW;^/K']>KG[QI\SB?SK?E;X4\J7^"/>/C3[9
MNW\?6/Z]7/WC3YG$_G6_*WPIY4O\$>\?&GVS=OX^L?UZN?O&GS.)_.M^5OA3
MRI?X(]X^-/MF[?Q]8_KU<_>-/F<3^=;\K?"GE2_P1[Q\:?;-V_CZQ_7JY^\:
M?,XG\ZWY6^%/*E_@CWCXT^V;M_'UC^O5S]XT^9Q/YUORM\*>5+_!'O'QI]LW
M;^/K']>KG[QI\SB?SK?E;X4\J7^"/>/C3[9NW\?6/Z]7/WC3YG$_G6_*WPIY
M4O\`!'O'QI]LW;^/K']>KG[QI\SB?SK?E;X4\J7^"/>/C3[9NW\?6/Z]7/WC
M3YG$_G6_*WPIY4O\$>\?&GVS=OX^L?UZN?O&GS.)_.M^5OA3RI?X(]X^-/MF
M[?Q]8_KU<_>-/F<3^=;\K?"GE2_P1[Q\:?;-V_CZQ_7JY^\:?,XG\ZWY6^%/
M*E_@CWCXT^V;M_'UC^O5S]XT^9Q/YUORM\*>5+_!'O'QI]LW;^/K']>KG[QI
M\SB?SK?E;X4\J7^"/>/C3[9NW\?6/Z]7/WC3YG$_G6_*WPIY4O\`!'O'QI]L
MW;^/K']>KG[QI\SB?SK?E;X4\J7^"/>/C3[9NW\?6/Z]7/WC3YG$_G6_*WPI
MY4O\$>\?&GVS=OX^L?UZN?O&GS.)_.M^5OA3RI?X(]X^-6'MV?*#0+`]JERH
M4+6[!'"4'45)N3(+E(<.I-=$P`9%VT5#U(LB8Z1_]TP[#J7QMIR\R$9&+.\D
M+<"!?_P/H.M6DF5#"YCE55<=AO7\53D!CZ]3\?5*A1(.Q6"54%%E%1SHRSA4
M0*)CG4$W2BW;ID*(G55,1(@!N8P:^Y&T9F)"V1DS.D*\21_:_J&M(\J&9Q'$
MJLY[!>JFO^383%+]E%WW%L56GTFR/(LFZS]!V+EFDL9NHN4\6L]2#H6()1*8
MP&_V;"&K?#P9-Q0R8>0TB*;$VM8\>VU>YIDQR%FC521_;A7;V:WH4NIQU]LF
M(HF+J<O],&.G!E8YR@[":;"\C#)I,7CEX!7C8.LHF3``#^[8=4X,?YK);#@R
MF;(6]UL1;E-CQ`&A]->W?RHQ*\8$9[;]_MK[TZR&R'77%NIN&XVQ0+5P]:+O
MVDG'E.1U')$6=M@9NGB$@=9))4I@*5(1.!@Z=]PUYR85PIQC9.4R3$`V(/`\
M#<"WVTC;SD\R*(,GK_OJ&N5K=#YPM&/*_CV`CX:?3EE(TKAFHX!XNZDWL>DT
M3,F"/N2DAU6YUSCL':W,/IL8=9+@8\FU8\TV8[/#RWUM8``W]&MP/34=/(N5
M(B0@![VT_MV5+7R(RC!M0\:UQ=R1><7LSB4(41_\09A&0;IB]=G+N/0FJ\DD
M0W'XF]`WV';&NBHW;,GG`M$(P/1<L"![@:D=Y8"%$/WN:_N']]?9^Y1B/'4U
M)(JB0[^DLF;0#IB4RB\M;BFCT"E*0!$.A8NQMMND.H1_KKXBF7K8\@T$I)]B
M:T)Y=FUXE/TFH^<5OKJ5/LIXW$LCD)LM9B`,DT02428+(Q3/N,!.JY0_R"18
MB@@`#Z'#4YOYA^9029(@81\">.IU_55G@<_EMRQ\XOQ]E5A+\I,75^4>P<[0
MF,-,QBYVLA%2::[%^S72,)3I.&KCMK)B`AZ"(;&#U`1#UU0CV'.FC$L,[-$P
MN"+$'VBJC9V.C%'0!QQ!KOZ5GBHY+DW$)0<4%N$FU;"]=LX5$[LS1J4Y2=]T
MH*A&[8ACF`"]9RB<?0H#L.J.5M.1@QB7,R3%&38%C:Y]'::]19<<[<L,89O1
M4F,3J6`UWC@?X1DJ4U]K)">Q.D&Z:34WLU.A$3)NU3=3LW^,-BC\=0&Y^1\F
MWEY8E:X\-^.OZN-7V/S^:.:+D%CK4M]8Q4E32E-*4TI6,ZW<],IV'DKF3C3Q
M2XFS'(:9XX-J0GG:^V3,%2PC1*K:+_7T;?7Z%6G$["6J=N=I5J3M!ZH8C%K&
M(]T$SNRF`=9?C],X46TX^[[WG+B1Y9?R46)IG94;E9V"LH1>8$<2QXA:QR?>
M\IL^7;]KQ3D20<OF,9!$JEA<`$ABQ([@!H;D:7GOC&S6FYX]IUJN^/Y7%-PG
MH"/DK-C>;F8*Q2M)FW")32-=>3U9=OJ_-*1KGJ3!TS5.@N4`.78!V#&<R&''
MRI(<:59X%8A9`"H<=C!6`87[B+BIS&EEFQTEFC,4S*"4)!*GM%UN#;O&AJN`
M.0PF*4Q3&((`<`,`B01#<`,`#N41`?ZZMJKTZR=?;ZR]SIZ^CJ#KZ!$2@?IW
MZND3!MO\-]/3V4]%<.2DXV&9.).7D&,5&M"E.ZD))V@Q9-B'.5(AG#MTHD@B
M4RIRE`3&`!,(!\1UZ1'D8)&"SG@`+GW"O+,J+S.0%':=!7['24=+LF\E$OV4
MI'.R"HU?QSI!ZR<I@8Q!.W=-E%4%B`<HAN4PAN`AHZ/&Q1P5<<018^ZOJLKC
MF4@J>T5:^^9VQ9C/(&',6W6TH0MZS[/6BM8I@E&C]=2T2U,J4E>+*@1VV:JL
M8XD96XI9<3NE42J&`J:8F.8"ZO,;;<W,Q<C-QT+8V*JM(UQX0[!%TO<W8@:7
M[SI5K/G8N-D0XLS\L\[,$&OB*J6/H%@.VU7;*8IR@<ABF*8`$IBB!BF`?@("
M&X"`ZL:NZZF8L5?KR;=6P3L/!I/%P:M%)B391B;IR(;@W;G>KH%77$/4"%$3
M?[-5(XI921$K,0+FP)L/97AY(X]9&"@]Y`KN-4Z]U\E5T6Y#*+K)(ID345.H
MJH1,A$DBB=50QCB!2IID#<PCZ`'J.OH!.@XU\)`XUTR-JJ[F&5L;>R0*]>0!
M05YY&8CU89$$3@FJ*LH1P9BF"2@])MSATCZ#ZZJ&"82>4482G\-C?W<:\B6,
MIY@9?+[[BWOKLV$@PE&;>0C'K218.TP5:OF#E%XS<I"(@"K=RW.HBLF(A_<4
MPAKPRLC%'!##B#H:]*RL.92"I[17Z]>LHUHX?R+MJP8LT3N';UZX2:M&J"8=
M2BSARN=-%!%,H;F,8P``?$=%5G8*@)8\`-2:,RJ.9B`H[37'BIF(GF9)&#E8
MV9CU#'(F_BGS619J'3'8Y2.F:JR!S$'T$`-N&OKQR1-R2*5;N((/VU\1T<<R
M$%>\&]=EKQ7JFE*:4J(/'SES$<@,Z<Q,(1E&FJVYX@Y(H^-IFTR$I'OHN]25
MTH+&^^[A&C1,CF+3AF<BD@LFX,8YCG`P;`.VIW=-C?;-MP-Q>17&=$\@4`@H
M$?DU/;<BXM47A;FN;F96(J%3C.JDWT8L"=--+6]/'ON*EX8Q2["8Q2@(@4!,
M(!N8P[%*&_Q$PCL`?UU!5*5T[>RUQW+N:^UGX5S/,B"H\A&\JQ6EVB8`F83N
M8U-<SQ`@%5*.YR`&Q@_U#50PRK&)65A$>!L;'V\*\"2,N8PRF0=EQ?W5W6J=
M>ZZ2;LU;K2;=6QV"$@$G:ADFJDW*L(I-RJ0`,=)N=\X0*LH4I@$2E$1`!U4C
MAFF)$2,Q'&P)_17AY(X]9&50>\@?IJGKEC+&N2T&I+W1JA=D$"`+(]C@8J;[
M"9]SA[1=ZV7.DD?KZMB&`IM]]5\7/SL$DXDLL1/'E8K[[&O$L$$X_>HKCT@&
ME+Q;C7'!%R4&@T^F^Y+T.3UJNQ4,JX3Z@/VW"[%JBLLF!R@(%,82@/KMOIE;
MAG9MOG)I9;<.9BUO>:18\$'^BBKZ@!4#?(Y7%%H/&EM21ZB1\M-U]XL">_06
M69M7[(JB@$W`O<B50`!,`;F]`W'68=$3@2SXQ.I56'L)!_2*BMZ3P))V`D>_
M_P`*J>EQA.0O"%*KL$4UK'78=2#8HB=0.BRT9=-Q$@!@VV/)1I$`V'<H>Y$!
M^'I;Y4G]%ZK.0YM`[<Q_RR<?<;^ZO<2_.;7Y8^^HM[5X>_\`743N(/(=GA:Q
MRM7NJKAK1K.Y(H[<]E14U9L38"M/J3AL0IG'LG#=/LNP(4QR"F0_2/28-9'U
M+LK;I`N1BV.7&-!^VIUL#WCB/614?MV:,9S'+_I-]A_MQK)RM8^-5+,^R@F_
MQ1%/5D%73FT1`5U2:>E=%'N^W/%E5E'KMZ!A`Q$BF55$1`0'<=8$(-]RK;>1
MD,H-@AYN46[[Z`#TZ"ITOA17GO&#WBU_LUK$=F7(<]RCS3'(UYFY(S?NF5/H
M<4N5,J[=@LY$5)!_T"*::[QRHHZ7$3""*)2D$1!/?6Q]KPH>G]K8S$<R@O(?
M3;@/4+`=YU[:QW)F?/R0$X'11_;WU,+G#(QF/L*8PPU%"4?<.(T`#KW4)#4B
M.1;@J<AQ.H'O))X@(#U?$A@]0WUC72:29FZY&Z2=@/YI#?[`#4ENC+#BQXR^
MCW*/C:KY<':V>`X^U]VJF*:]HF)^R'`R0I'%%=\,8R,(F`#*%48Q:9RF'T$I
M@V]-M1/5DXFWEU'"-57[+G[2:NMJ3EPP>UB3^K]57TN>'<3Y%<$>7S&U(N#U
M-,J*;VQ5B'EGI42#N1$'CQHJY[28B/27JZ0W'8/4=1&+N>XX2\N)/+$O<K,!
M[@;5=2XV/.;S(C'T@&N^J5&I="8&BJ14ZY48XXD,HRKD-'PS=4R?7VSK)Q[=
M`JQR`H;I$VX@`CMJCDY>5F/YF7(\C][,6/VU[CBBA'+$JJ/0`*JK5O52FE*:
M4II2FE*P^<L.*?(#!N:\@^1'Q^RT:\S!9*O7D.3W%.[+K(8NY;57'$>LW@W\
M/,-47$ACC/=9KA5&<-,)).&KQ/I:N40(HJ9;.]DWK;-RV^+I7J<,,!';Y?)3
M_4QFD-R"#H\+-JZW!'$'06Q7<]MS<')EWW8^4Y;*/-B;[LP06T(U$@71>R_=
M=N;('Q5Y(4'E[QVQ%R6Q@632H^8:<PML,RFVWLYF)45478R\%+H%,=(LG7YM
MDY9+F2,H@=5N8R1SIB4XXQO6TY.Q;K/M&9;YB"0J2.![0P]#`@B^NNNM3FVY
M\.Z8,>?CW\J1;B_$&]B---""+C0VTTK''=9"%X<>71'*%BE3UO"WD#XQ3\)<
M)B4D")5F$Y#\.XYW=8R17(8I4HP;)QX?3`F^)G*L"8>HQ@`FLLQTDW_H;Y.)
M>?<-KS%*`#Q&#*/(0.^T_+Z@]0$S1[3U/\S(0N'FXYYC;_ZL(O<G@!Y0(L>)
MO:JT\4M:G<FU',7D+R.PE&60^?%_4R13(>>,JH_QWQ9J:1ZGQIQ^R*L0I6C5
M]1F/W.Z[!4DG3RP&5,3K`1&VZUEBPYX.EL0@XNV1>6Y'!\EO%D/['/EB]R`E
MKVJKTPLF5!+ON0")\URZ@\5A&D2]VJ^*XL""+BXKC>5OC'DC-D;QSRW4<7P_
M**D\8\AV7(.7.$]LD%V];Y'TZ8JQH@7$'%+*EK5DR]C%9(TC5(^<(>)>.G"Z
M*FRAT]_716\8FW-EX,\S8>3F1*D66H\4#!KV)^\L4GW9&3Q``$=M>>I]LFSA
MCY21C)@QW+/CL?#*I`%[6(9TU**="2>/`RKX$7#BWD'BYCR\\.:;#XZP;:S6
M"7BL?P]51HHT>U*S\@C?ZE-4IJ4K.JVBNW-!ZTDV2`=A)\DKVQ.02G-"]30;
MSB[S+C;_`"-+N2<H+EN?G7E'(P<ZLK)8J3K:U['2I38Y-MFVV.7:46/#:Y"@
M<O*USS`J-`0UP;:7X7&M8Y?(1Q6X]9_\I'C+B,O8EI^165YH',QE?&5A0<KC
M-06.<=U"7H*;[M/$A,UK-DM;U5J0A4_\SU0YC&Z0`,LZ6WK=-KZ,WB3!GDB:
M.7$*%>QI)&#VTXLJ@'T`5CF_[9@9_5&V)EQ)(KQY'.#?4(BE+_Y68D>DUF_J
M53K=#JM;I%-A6%<J5/@HJLUBOQ:(-HV$@(-BA&Q$4P0#<$FC!@V323+N(@4H
M>HZUS//-DSODY#%YY&+,QXEB;DGTDUFL,4<$2P0J%A10J@<``+`#U"O,WBK$
MF7><G)7R#9>OW';B)R\;8WY=Y/XM8_K_`"KR[?6#+!V.L0,ZZQB8+'V)8W".
M4*;575R"0^M/["@NA+RSEQL?H(@3JV_FYV!TWM&UX.+EY^"TV!'D.V-$A,TD
MI8DO*9HV8);D"$%5`[;Z:WQL;-WS<,_)GQL/+6+,DA03NP\M4L`%01N!S<2U
MP2;Z#6^7_P`:/'#.?%/CG)8;SE9:Y.*1.7,F3>)H6KWBY9)C,;82LTPC-4/%
M1+M?J]6;//)T$7;MBV57:E`K(B!"B`%Z"8)U?NVV[WNPS]M1U#01B4LB1F29
M19Y.1&95Y[`D`\;^LY;TYM^=MFWG$SF0D2N4"LSA(R;JG,P#'EU%R.%O4(<^
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MD&]ARWM>K+'Z=VN3JC)Q1&/Z9%CQ.8`3Y7FN7`<QWY395-A:U]>-JE/XAZ17
ML96GR88PQZ#ZNXBQEY`KK1L78K(Z?GJ6+H-IB;$UAE8>BQCMTX;5ZN2]BLSI
MX1BT!)JD8XB0A>H0U"]=9$N7#L^9E6?.FVM'DDL.:0F2107('B8*H%S<U*]*
M1QP2[CC0`KBQ9[*B:V4<J,;7)L"6.@TL!5T_*YQ7R?R?POBY3&-<@<MK8.SC
M4<UV[B]=[`ZK6/>5%,K,?-,)G$-HE4#E8HNW!98LA$A)D<0QY)FD1Z@JB<>F
MRZ)WK#V;<)OG':`9.,T2Y"*&?&=B")5'&VEFY;/RDE2#5SU1MF3N6''\LBS>
M3,LC0L2%F47NA(-KF^G-=;\1W7'\;MPXCWSC\^L_$'$$/Q^KKO(5F8Y=P>SI
M3+'-AQ5GF$;1,+D*D7VDQJ2$=!W.#]@T2<>W+[=T@"+A(QTU2G&TZM@WW&W0
M0[].V5*(E,4Q<R+)";E'1SJ4-S:^H-P=15?IV7:9L`R;1$L$?F$21A>0I*``
MRLHT##2]N(L:R`:Q>IZFE*:4K#WXVUQ<<P/,D=JH@I%%YM4=%(Q%"*K!,MN-
M6*&TX0ZA#"`))*(HD*00`4U"J%$1$!VSOJP6V+80U_,_I[^[SY.7[/?6+;"2
M=TW3AR?-+;\@O?VUUWG3A)6X<+*;CNMV>=IUPR;S"X=T"FV.K.W3*S1%AL&>
M*B1&4KZK/_.,Q$,$'#Q``WV.WZMAZ=M5/IO(D'4,F5*BR00X&4[JPNI586T:
M_838'UU3ZS4R;0N.CLDLN5"BLIL0S.`+>GNJ-WDEX%\3^*W'C&F=^.F,([$/
M)O&W)7BVPQKG:J.)$F5+%9KWGG'U*LJ64+@J]-.94:W2OS3XDFE-KO`=K'`Q
MMMMM2W274V][UNLVV[M,9]GEQ,@R0M;RU5(7=?+6UH^5@O+R`6%1G46Q[;M>
MWQYNV1"+<X\B$)(M^=BTBJW.U[O=2Q/,3KK7HFUJJM@5Y_.!_&'!G/6>YA\L
MN8]%JG(_),OR\Y`8(J=(R_%-KM6N..*\&6]?'U3QK3J58$GL)2[!*QT<2:EW
MC1,KJ05?HK&.!NK?:'4N\[ETS%@;)L$LF)B+@P3,\1Y&GDF7G:1G6Q=03RJ"
M;+8BU8)LNV8.^OE[IO"1Y.2<J6)5<<PB2-K*@4W"M:Q8BU]#QO?.I0*%3L64
MFK8XQ[7V%4HU)@X^M5.LQ1%$XV"@8EN1I&Q;!-5151-HR;)E(F43#L4`#6ML
MK)R,W(?+RG+Y,C%F8\68ZDGTFLV@@AQ85Q\=0D"*`JC@`.`'JJK]4*JU9GD#
MC0,M8FME.1`@2J[0LE`*'*!NW.Q*@/8XH"(EZ`=G2%N8V_H18VI39L_^F[C'
ME'_3!LW^4Z'W<?95MF0?,8[1C[UKCUBL5_#O-Y<.7^0I]S<*Q=2MCDD=)"^,
M=)*LVEDJ=HV?.DC_`"M45CB+5X<=@3Z4SF^5,=;!ZFVG^IX8R<4!LF,7%OQ(
M=2!W]Z^T=M0&VY7RTQCETC;CZ#_;0U)ODAPK4O,R]R#B1Q&M)F8.+V<J[U<&
MD9+O5OG5EH>0#K08NW@B!E4E`*@J<14`Y#"(&@=CZI&)$,+<@QB717&I`[F'
M:!V'B.%JOLW;#*QFQ[<QXCL/I%0@9<0^0CJ2+'DQF^:JF4`AGSM]"MHY,IC"
M453OQ?BF9,`+N/1U&VV^7UVUEC=2;*J<YG!'<`Q/NM46-NS"W+R'[+5D;X]\
M;*YQQB97)>19R+<6EO$.#OY0Q@3@:A$=/<>HL%W!"+.'K@H`19?8HG``32+L
M(B?"-ZWV??)%P,%&&.6T'XG/9?N`[![2>Z:P\),)3/,1YEN/8!6//)MNL'*W
M/;-M7D')6LS(-JK362W44T;6VJJJR\L[3$QRME3H]]^Z]?D#Y-QZ`UF>!C0]
M.[.3,1S*"[GO8]@[^Q1[^VH>>1]PRP$X$V7T#O\`UFLY]9@&%4KD#6(LHDC:
M]#QL*Q`W3U^TC&B+-`RG0!2BH9-$!,(`&YA$=:EGF?(G?(D^^[%CZR;UE*((
MT$:_=4`>ZN\U2KW32E-*4TI32E-*4TI6./*OCEC\I63)\D/,GG=0Z=E^0=OK
MGB>@9Z9QF/R)RQR_7XFH%EZ5.VS'\'/-P.DX:P<JP3`JRHDZ!..LLPNK&PHH
M4_I^VRY$``25X27T^Z6LX5RO$%U;@+UCN5T\N5+(WSF='#*;M&LH":\0+J64
M'@0K#2IEX3PQC7CMB:@8/P]66U-QCC"M1]2I=::+NG247#1I!*DFH\?KN7[Y
MVNJ<ZR[A=119==0ZAS&.81'']PS\O=,V7<<YS)ES.69M!<GT#0`<`!H!H*FL
M7%APL=,7''+"@L!Q]Y.I).I)U)UK!YY-%,3>4::X]>/_`!E7,BW:51Y6L[3R
M%R`RH61*3#\>,3X8+<:_E\92\6*MPD6A:,FLG3BKP3-!=8DJC*F>I=QL5$ZN
MQND/GNC8\KJ?,>*-#A%8$YXW,\DO(T5D5B>6,@2.2`5Y>4V-[89U"<3J5H=D
MQE:1UR;RL5=1$B!U?Q$#Q,+A.()L>U;Y_H&"AZO!0M9KT<UB("NQ,=!0<2R3
M[3*+AXAFC'QD<T2`1!-JR9-R))E_H0H!K6$LLDTK32DM*[%B3Q))N2?236<1
MQI%&L48`C4``#@`-`/8*C+R#XMRN=;#!6:#Y0\IN/CZ%KTG6UV&!<@5FOUV?
M:22JK@LA.UNXT:\P[BP1RZ@>VD$4D':28=L#]`B&IC:]Z3;8FADPL+*5G#7F
M1F92.P,KH>4]JDD'C:HW<-K?.D61,K*QR%(M$R@&_:0RL+CL(L:K+C%QIQ=Q
M&PQ5L%8>9S;>F5=:;D?>6>=?6>T6&Q6F;?V6V6NSS\@85Y2PVBQRKE\\5`J2
M9EUS=M-,G20+?>-WS-\W!]RSRIR'L+*`JJJ@*JJHX*J@`<38:DU7V[;\;:\-
M<+%YO*6^K$LQ)-R23Q).I[.X5:[E+PBH?*2Z85RB\R1F3"V7./ZV0/\`EGE/
M!UH@ZU;8N-RA7F]:NT$_+9JM<8&7AIABQ;F%)=D8R2J('3.01-O>[+U%D[-C
MY&$L6/D8&5R>9',I928VYD8<K*P()/`ZWUJTW398-SFARC)-#EX_/R/&0&`<
M`,/$K`@@#L]52RJ\(:LUJNUL\S.6,]?@HF$-8;.]3DK)/&BF#=@:9L,BDW:)
M/YR4%OWW:Q4DBJN#G,!"@.P0<TGG3/+RJG,Q/*HLJW-[*-;`<`+Z"I:)/*B6
M/F9N50+L;L;"UR>TGB3WU`C(/C;QI8,Y9`Y%8CS1R-XJY/R_'1K7,+OCI?*]
M7:SE24@F`QE>MESI-VI5]JCFXPT>842235HU=+$$>\90QC&')L7JW+BVV+:L
M['Q,W#@),0G1F:,$W94='1N4G\))'=:PJ"R>GH)<Q\[%GR<7(D'C\IE`<C@6
M5E87'>`.)/$DF8V&\9CA[&]:QT;(.2\IGKJ+U-2^Y@M!;ED6Q+/Y)Y*+NK'8
MR,(M-\JDL],D@4C=)-!L1-$A0(F4`@=PS/G\M\ORH8`]O!$O)&M@!X5N;<-=
M=3<]M2^'C?)XRX_F22\M_%(W,YN2=387XZ::#2J1L_'#'=MY%XIY0RI[$7)N
M',?9,QG42LY8C>MJ5G+#VHO[46:A_:'4DGQ7-*9"T4[Y"H;'^4PF`0KP[ME0
M;5-LZ<GR<\L<C7'BYHPP6QOH/$;Z:UXDP8),V//:_GQ(RCNLW&^E^SO_`%5\
M*=QHQS1N1F9^4$"M929(SU3L74G(#9U,)N*JO%X@2L2%,=14*+(BL=*(-[0[
M3<*@X.18IB_(`AN/W(W?+R=IQ]FEY/E,:21TT\5Y>7GN;ZCPBVFE>8=NQX,^
M;<8^;YB=45M=+("%[+Z7/;;T5]<&\;L=\?9?.LW0UK(L_P"0^;;)G[()[%,%
MEDRWNTPE<K\@E`$(S:?2J^C&U9H5!J/=%,0,/6/5Z-RW?+W6/&CR>0+B8RP)
MRBW@4LPYM3=KL;G3U5\P=NQ]O>=X.;FR)C*]S?Q,`#;30646%=-R#XY2.=W=
M'D8?D3R.X_R5(7G!*ZP)>("MM;4SGT&*+J/N<%;:?=ZW8$V1HXBC%91F#EB<
MZHHJ%[I]ZFU[LFV+(DF)B922`?ZR,Q4K?5&5D9;WU%['2XTKQN&W-GE&3(R<
M=DO_`*3!>:]M&#*P-K::7&MN-11NO`*U8QX1Y4XO<),KVS&>4,UW]2WWSDGD
M.^666RV[L&1+M`2&;<N.;A#L/?O,I2].8.6T;[9&/9I..P`"@0@F&:Q^IX,W
MJ*'>.HH4FP\>+D2"-%$85$80Q!2;",.06N6-K\:C)=CEQ-GDV[99"F5+(&>5
MV)<EF4R.2MB7900+<OK'&LD5.K+:EU*KT]G)3LRTJM>AJZVE[1+O+!995"%C
MF\<E)6&>D5%7\U-OB-@5=.UC&5<+G,H8=S#K$\B8Y$[Y#!59W+64!5%S>RJ-
M`!V`:`:5D,,0AA6%2Q"*!=C<FPM<DZDGM)XFJCU1JI32E1LP)Q4Q9QQMO(JZ
MX[&S&F^4&9I+.V31L,T67:A>)6&BH%R2N(@S:FAX(C"'1[;43+=!^H0/L.P2
MVY[UF;M!BX^5R>7AXXACY1;P`DCFU-S<\=/55AA[=CX,DTD'-S3REVN;^(DD
MVT&FO;?NO:U=AR*XTXYY/0>.(#)"UG;-<59KQGGVHNJG-!`R+?(&)YA2;J:K
MIW[1X9>)!XJ8'+<`(*Z8]/677G:MWR]GDFEQ.0M/CR0MS"XY)19M+C6W`]G=
M3<-MQ]R2-,CFM%,DJ\IL>=#=>PZ5]>1G&['G*&FU>BY-5L:<!4LJXQS%'I5J
M52B'#JUXDML?=JDA)+JL7X.80)^+04<MRE(98J8%`Y?CKYM6[96S9#Y.'R>:
M\,D1YA>RRJ4:VHUL38]G=7W/V^#<8EAR"P1)4<<IMJAN+Z'2_$5?[495]6-Z
M\>-#',GES*6:L+YXY.\3;CG`2R&867'+(E?KU-R)<$F9(Y#(DW2[M2+[7V=_
M+'IE15E(Y%BX<@4#JB=7J4-EN-U?EI@P[?N&+AYT&/I$9XV9T7CR!T=&*7_"
MQ('`::5CV1TY!)E29>)D96+++]\1.`K']HJRL`VIU%KWN==:E_:L.-K;@R0P
M6]R-ER,:R>/T,?N,IUV].X+-A$D8I"*/;FF1(]JD\97QT"'N%9-)$AQ=',H!
M2B.P0,.>8-Q&Y+%`6$O/Y;(#%QOR\A-B@X!2>&E2SX@DP_DFDEMR!><-:306
MYN8?B/:>^KD5J$3K-=@*VC(2\NC7X6*A$I6PR*LO/R:<2Q08)R$Y+.`!>4EW
MI6X*.7!_G76,8X^IAU:32&:5IB%4NQ-E%E%S>P'8!V#L%7$:"*-8P20J@7)N
M386N3VGO/::[K5.O=8M>9G%R2<2;_+N.8I>1(_ZW-YKD>@"KE)P1,.NQQC1$
MO==$<E*(O4B`8X*?Y0`0,?IV!TOU`@1=MSF"D:1L>%OV2>RWX3[.ZH'<L!BQ
MR(1>_P!X#](_75A<(\S<A8G8M*Y--R7VG,P!)FPD7BC6;B&Y>@H-HN9,FYZV
M:)2"!&[A-0I-]B'(4`*$QNO2^%N+F>(^3DGB0+J3WE=-?2/<:M,7<YL<<C>.
M/T\1ZC4L'?D8H!(M-9CCZXN9DP?Y(YR[A6C!(VWH/U5-R[44)U?Z-@';^FL=
M7HG,\RSS1"+O`8GW6'Z:D#O,7+<(W-[/T_W5!S,W)#)F?GK:%=IC&5T[Q+Z5
M1JZ#IR1X]W`K4[]0"B\GI$#"/;#H(D41W(D`^NLLVO8\#9E,J^*>VLC6%AVV
M[%'V]YJ*R<V?+/*=$OHH_MJ:R+</>-2V*(A2]79DF7(-B:%2;,5`*HI4H-8I
M%1CS#\Q"3+\P`+LQ1'ME*5(!]%.K">IM]&XR?*8A_P#9(=3^VW?_`)1V=_'N
MJ:V[!^77S91^^(]P^/?4X=8G4I32E-*4TI32E-*4TI4>^57)[$O#7`&2.2>;
MY=W#XWQC#)2DRI&,C24U)O'[]I#0->@8T%$0?3MCGI%LQ:)G421[ZY15422`
MZA939=GSM_W.+:=N4-ES-87-@``2S$]@502>)L-`3858[EN.+M.$^?F&T$8%
M[<220%`]))`%R!KJ0-:Q_8I\PF/G^+EL[\M,!Y;X%8*FJ_2K!BO*7(=]3G$9
MF#[[5?'A(&EUR@S%GNJUJ5AVA9,(XT<+D\8<SH"]A,RFLGS>A,I<W^F;)DP;
MEN2NZR1P!KQ<EKEV<*G+<\O-S6YO#Q-JA,?JK&^5&=N44F'A,H9'D_&#J``!
MS7M=K`$\H+&PU-R;5YG/&!2JCC>^6/F%CAG4LN1%AF\?3+6-N\NC/,:G,DKU
ME(="&JD@\AY.$F%"HN&+]-J]3$P&%+H$#:M(>@.L,B>7%BP)3/`P#@E!8L.9
M>+`$$:@K<>FJ\O5G3T,"9$F2@AD'A/*YOJ1K920=#H;'T54[GRV>.)K9,15$
MW+3&CBQYU@*E:,91<<6RRJTS`7J0)%U63EU(R`=MZ4A+/E`(`3IXTZ6PF5`A
M2F$**]$=5M%/.,&;RL9F60GE%B@NP%V'/8?L<U^R]5'ZHV!'BC;)3GFMRBS:
M\QL+Z>$W[&L1VVKI&7F-\9<C7<@VMER]QNO7L7,867N<F5E<BI-(.PW1MCN(
ML<,D>L%<6ZL.KJ\2CADX<C]@DNH7N+$*(&U5;H+J])8H&P91+,2%%TXJA<J?
M%X6Y`6Y6Y6(&@JFO5G3KQO*N4ACCMS&S=K!;CP^(<Q`)6X%Q<U9+*'G\\7>.
M:!7\B0_($N6XBP9188J+'8IJUAG)Z(E%B,7<M8IR*F6->78U&OQ#\CM5X'<,
M](!DV";M8ATRR&'],>LLO)?%?%\ATA,EY&4*1J`H(+79B+6[.+%18U:9/6_3
MF/"LPG\Q6DY+*IN.\D,%T'?VG1;D&U\5O,+XVT;!?ZI_^TE7<6?%QTTKU76-
M0R=)3<(LK-QU=(W+%Q](<O95S]8E4$A39$<J%`QCB`)IJ')'#H/JTQQ3?)OY
M4WW&+Q@'0MQ+V&@)UM[R*NVZLZ>5G4Y(YDXCED["%-O#K8D`VO5G9#SP^-Y;
M)N#L5T+,;W*LUGL9XE8G*-5+"YJ==<1*<JVC6%WDY5A%R$')V>RQ?TIFV39N
M5T7"Q%GA6K00<#?K]->K1AY&;DXXACQK<P=EYFO:Y0`D$*IYB;@$`A>9M*LV
MZXZ>^9AQH)C*\_`JIL-#R\U[$<Q%A8&UP6L"#76XS\\_CQG\)8FR_FK+T7QN
MD<P52QWBMX[OJ<W8[%]JU[)-JQ<>6!_1H"=AG@/+%4'?2BDJ+@B9!,=,"E,;
M7O-^FG5,.XSX.WP'+2!U1I$Y57F:-9+6=E(LKC7AZ=:^8G6^Q38<65E2>0TJ
MDA&#,;!V2]U4C4H=.-@>XU?G(GF#\9V*[!4JM=N8>*6,[>*Y4[;6V<0K8;<1
MW7KRBV<5&1>O:A!3S"$+/M7B2S=-\JV6,BH502`00-J,Q>A.K\V*2;'P)C'&
M[*Q/*MF0V8`,RDV(()`(OIQJ^GZKZ=QW2.7+CYI%#+;F:X(Y@;J"!H0=;$`@
MG2JCYO>33BMX^Y+"4/R&L%H8RN>KBWJU.9U2J2%E-'Q23V,9V.^6-5N**3&H
M5`)AL=[V!=2:@+%!JS<"!^BET[T?O75"9$FU(A3&CYF+,%N;$JB][-8VO9=/
M$PKWO74>V;"85SV8-,UEL+V%P"QX>%;B]KMW*:CAQX\YO!;-^8L@X#M60([!
M>6:KGJ\8+I]2R5)%25R:O2GJL=]Z0<S',UZW`P-A?-ED6"$L]9O554A)VNHR
M8'EMU^G'4FW8$6YPQ')PI,9)F:,?Z?.+\A!/,Q46+%00!K?C:PV_K39<[*EP
MWD$.1'.T8#7LQ4VN#;E`)T`8@D^RIC<=/(9PMY:W>S8WXZ\@Z5E*[U*(7L,O
M7H1.=9NU:VVF3UY>RP*LY#Q32V5I*:(#<TC%*/60*')_EV4()H'=>ENH-CQD
MR]UQ9(<=VY0QY2.8CFY6L25:VO*UCQTT-2VW[]L^Z3-C[?.DLR@D@7X`V)%P
M`P!(N5N-1WUC*G_R#L`4GE'8^/=^PAD^ITRJ<JIOB+/Y\7M&-'M-B,A1!G(#
M.2530LI+XTI!$$`<.Y,6(MV+;K,H;K3,GK+XOI=NF3LZ;IBY$+Y#X0R5AY9`
MQ0@&P;EY"^M@M[D\-#>L>DZYP8=P;#R(G2%,@PF3F6P8,5N5XA=+D\`/3I4P
M8?S2^+:?/)$A^9N+'XQ-IKM.=BBC;@*::M<PO`0"C`ZE9(25@'TPW%`9=J*T
M2B8Z8JN2%52$\#)]/NLH@#)M\PYD+#[O!1<W\6C6UY39CK8&QJ5CZNZ;E)$>
M7&2&L=&X_EU`[6'A&ESJ*K(_EC\=!'SJ/-RRQEWV66;-@]VH4U@48H9+IL0K
M/6F%/)D@S1H1D%#('<N)CN_12(E$WN]M6XZ)ZJ*AAA36,*RC[M^1C93:][DZ
M!+<_^&JYZEV($@Y*:.5/WK7''6UN4?M_=]-4:GYHO%\I19O)(<P,?)TVN6"K
M5B:E'$+?VKAE*W>*G9JHF&%<U!*=7B;%&5I\JTD4FQXY;VYB@OU"4IK@_3_K
M$9"XOR,OGNC,!S)8A"H;7GY;J64%;\VO"J`ZNZ<,;2C*3D5@I\+W!()'AY>;
M4*=;6TXU)3*?./B9A+`M-Y.Y6SC3J1@S(C*J2%#ODP,J#>XM[O&)S56)6X-K
M&N;/,/):'4]T5L@R.X3;E.HH0A$SB6)PNG-\W'<Y-GPL:23<HBP=!;PE#RMS
M$GE`!TN38FP'$5?Y.];7B8*;EDS*F%(`58W\0(YA8`<QTUX:"Y/"L;'(#SY\
M2L;7[B!1L$ME.60<M[(E$QD[B^SLXIC0HI:W15*1?6%K.1)GPSZTV]<%^C+D
M8NT"LCF<F;D41,?+=K^F6^9>+GY.Y'Y'Y%+E9%)+D*7LI!MRV`\0Y@;BU[&V
M.Y_76U8T^)!A?^Z^::P*-;ENP47N.))/A-M!J1<7DCS!\G]3XR\@\8\1\<8#
MS-ROY09.JC[(+3$F%T:PT7K&/F*T@U&UVVT7.:@J]#-7;N*<%2(94=BHB=8R
M0'0[T1L71T^[[7-OF5DX^%L\+A#)+S>)S;PJJ@DVN+^O2]C:3W/J.'`W"/:H
M(I,C<9%YN1.Q==6)X7L?0+:D7%["U;SP<3H?/UKXW<J(>U\,,EUBMX9D?I6;
M5&CPTA:\OUN,LGV*)Z0E8VL/*4U*9:I2#M\LW8&,L!TU3)@8P2<WTUWN3:TW
M?963<,-WE%XM++$Q7G\94D-8\H4$]EKU8Q=;;6N>^W;B&Q<E`ALX)N64-;P@
MVL#J3;TVJ4EJ\N/C=I5\ON-++RWQC'7+&32W.[G&D^Y'[./-0HI*:N<8PGXV
M!>5VQV"M1JP*/(R,=O)%$2G(*'<(<I8>'H;JW(QHLR'!F./,5Y#X03SFRDJ6
M#*K'@S`*>^QJ0DZKZ=BR'Q9,N,3QWYAJ?NB[`$"S$#BJDGT50=:\WOBHN%@K
MM6K?,_&LG/VRSP5.K\:2)OS=:0L-E<-FD(S`[NGMT&R#YX\31]TL9-HFL;H.
MJ4P"`7$WT[ZTQXGGFV^58D0LQNFBKQ.C]EKV&I'`52BZQZ:FD6*+*0R,U@.5
M]3^7L[2=!VFJAF?,?XTXB;RQ5DN6..YZW88KURL5RJU;)/3$HZ0H10"S1E,7
M0APAK_8&*QNW[&&=OG`G`X]($25,2E'T%U=)'!,<*58,AE5&;E`'/]TOK=%]
M+@#VD7]OU;T\CRQ_-(TL*DL!<G07LNEF)[`I-^/`$U":._)+\?SNV\>V\LK?
MJ7BG.]%N]N>9ANL&I&0^*YBE/Y:,5I-TK<4G.3LG-RCYBV22<0@2D>11^0IU
MP%)QVLA?Z2]4+!E%!%)F8TB+Y2-<R!@IYU8\H``)T?E;PG347B5^H&Q&2$.7
M7'F!\9!\)'-H0`2?NC5;CQCN:T_7GEE\<;"R8OJ3GESBD)S,D#2[/C])%Y,.
MF$A!Y%=>QI#V<FVL0M!TD;(\V2;I3CF-6$X@`D`1#?&%Z)ZK:&:=<&;RH&97
MX7!35@HO=[#M0,*G&ZFV%98X6R8_,E`*\>![S:RGO#$$=MJHA'S4>+]TI;&[
M+EM4)%Y1I$T5:XZ+J&4925B'B3J79N>Y$Q]%<R3EHQ7@77N7"*2K=L1,#JG(
M11,Q[G_M]UB.0G!<+(+J2\8!&G:7L";BP.IX`:&J#=7].)S<V2MU.O@DO[N2
MY'>1<`6OQ%?U/>:CQ;UA2D)SO,?&T>7(U3A+S471XR\K1S^I6*4>PL7./I-M
M4UHZOLSRL<N@O]15:':'2-[@J6V^D7T^ZRG$ABP)3Y3E&U2X90"0!S7;0@CE
M!O?2]?9>KNG("@ERD7S`"OA?M)&IY;`W!!#6(MJ!5I[3R`\47(&:KAZUR!JD
M?<\A9^<<:*ZK1&MH:/[/G9O'L9!6E*5]>K+M%5#,95NX"5%NA&KE5*8'I@$=
M2F-B=<[/&RS8SMC18WGL)"I"PZ^+FYK]A\-RPM]VJ+;ATYG%6AF'.\OE@J&U
M>X%K<O"[`<WW;FW->K^I>.*GE7*9;)MJ5;`).I%.'AD5C`!O\@`X$52%ZB^A
M1[?RCZCO\-6)ZWRK:01W];5?_P!%B[7;W"I28HXU8FP\*3RM0'O["0AB#:;`
M=.4G``X[F!LL9))K'`(?+_X9)(1+Z&$VX[X_N.^[CN=UG>T/["Z+[>T^TFK_
M`!\''QM4%W[SJ?[O95_-0]7=-*4TI32E-*4TI32E-*5%/FWQ"QKSOXQY0XMY
M9=SL93LF1L>B>;K+I-I.UZ=@)AA8ZQ88X5TUF;I6%L,4V<&;+D.@Y(0R2@=)
MQ$)KI[?<OIO>(=YP@K3PDZ,+AE8%64]HNI(N-1Q%1N[[7!O.WR;?DDB-[&XX
MAE(93Z;$`V[>%8K;?X5\XY/HN*ZYEWR9Y:R):N-60<69'XI7B1X_898GPO-8
MWCYR(=)2]9;BI#980LL:\CBF--]2C96)3-U+$773/FD'U!VW#R9IL'9X(H<N
M*1,E!/*?-$A!T;C%RGF^YH0YX$`UC,O2.?D0I'D[C([0LC0GRH[1\GHN>>]D
M/B-[H+D@L#9W&OXU^)L:W&!NK?DI:K7)EPQRBH-Y2N.+J_*,;?DWDY6[S6)+
M,D5&-;3'PU(<T]C:6(M(=DU426/$$/[E)17N)7^7]6\[+@;'.(B)\QCNG+(0
M5CQV1A$25)?F*M=B1;G/A(%C:0?3[$A?S#.SR&*16YD!!:1)$YP.:R\H9;"Q
M/@!Y@235>8+\`Z?'BQ5Z2QIS0O<%7I_CY0>-_)&J-L+XX52SQ0Z6U>1;T(RP
M2KZ6L>(G]FB')2KN(IPY=INB>X*N;<$RVNX?4T[I"R9FWQO,F2\\#&5_W+MJ
M+J`%EY3P#`"VENVKJ#HI<:8R8V4T<4D?)*HC7QKH"`224NH`N+M?6_94>JY^
M+MC>NXNN.+2\K9&393Z-#BH6RR''NEEML75ZAE&.R5)U>PSL=<V#^XQ-D"*1
M8BDH=H@U*'>*D<W20LK-]8\N7,CS!A!63F)43MREFC,8904(4BY/:3PN*CX_
MIQBI#)"^1SJ][7B%Q<\VI#W;4`C4"X'JJ0%V_'[@IV\9>R31N5DSB6Z7GFY1
M>:6.)*FX*HHQ^'I7&\-=HBG8[C:[(6!>!LL%#?=J*R:RS=JD91@7N-3@J;IB
M\;ZGRQ8\&)DX2SX\>WOBR!YGO*)"A=RP7F4GD.@)/BT86J]R.AHY9'FAR/*F
M;*$R%8E\!4R%0!S6/+SBQL`>753<UR[1X$#VC&^>JDKS5R/"73D3S(?<L\D9
M*J^-XJLR=J8/X66C%L+V^.A+LQ4L=$.]EU)`Q"O&;8ST`/[0-@V0_4P09F-D
M#;XFQ\7`&,D;2%@I!!\U2R'E>P"\";?BKY)T09<6>!LQQ-/E&9G"!20>;P$!
MAS"[$\0+_AT%J>PC^/>EQ\6XK3F,>9]OA;GQDF\_O2S:N$J=)1-XA.03Z/3L
ML$>MRUJ?IU)9&JMEX@[]FY4=JHK%51%JHD`FJ;C]43NGSL>9MZ-CYBPCE\Y@
M4,-RIY@HYO%9@"``18\P-><3H48*XQQ<IEFQR_B\L&X<!6%BUENMP3KQTY;5
M2F/OQO*I1J',4IWRK=VX[KA=D[A_6Y>Q8#KST]''*.8IS*LUE6L,G.0G2;*R
M),;`YARH%.4X)+*.".DU#]`5\OZLSY.2N0N$([;A'E,%F8<_EQ",1L?+%UNH
M>_>`.4C6J&+]/8<:,QMD\Z_*O"+QCP\\AD+#QFQ`)4=MB3S7K&#F?P/\RL<9
MD+@[BO2KK;./=JO_``TFLGY/MUIX_P`'C:^*X/K<2-FOKV+=3SK/-2-&VAW)
MJIUF/*NP4,/=[[H0:II9C@?4KI_,V_\`J.]21INB1Y0CC59VD3S6/*@(7R6N
MH7]XUCV67Q$XWD=%[SAY@P=L21]O8Q<\A,05^5+%B"WF+XF;PB^AO=K(!ZB^
M?_C_`'W-J<XMW.LY\LG'O(/%#,2F9*%;:]1ZU?A=3:D8C&>U>0MJ=-XH")$1
M`Q%#D7*`B.Z9O00TUTQU.O3T>9CS8R96+FP>4ZL[)I<GBH)[?1ZZV;O6RONS
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MLZLP4J+(0`MKD\3]E7O3G1T'3V4^4LOFL4*K>,*5#,"?$"2W`#6JPQWX6.,4
M+:^;MWRQ'U7,MRYC95S+D"-O<IB^LPF0\$0.::](UR=IV.;HJ[L4DDI'MI59
M9&12*R.+DW<%`#>NK?*^H.\O!MV/@E\?'P(8D*"1C',T1#*SI91J0+J;Z:7J
MM#T?M@DRY<I4EFRI)&#E`'C$G-<*VIN`VA%N`-KU!^"_&GQJ>D7*IY-Y99`R
MF\;\:S\8^/LQ)8HH-71P-4$;S_S"AIQ2/JCZ.<Y,L\'8"@9!W(O&ZPD56*)^
MDR(-\BD^KF8,B.;"PHX%^;^8F`E=O.;DY"+L"(U*\0H(T&G&\0OT]QGC=,O)
M:4F'RXR8U7RQS\XX&[$$G4D'4Z_=M\,5?C`\9:%(V\UHSCD.^P-JXXS^(TX9
M>NLH=>"S#<H)G`7#DE%R#BQ3Z!+9),VYRMHL6OMFR:HIJ+N``>KUF_6/><E4
M\G'BCD3+66_->\2,66`@*OA!M=KW)%P!5/&^FNU0\PDE=U:!DM;@[``R"[-J
M+&PMVV)-J8X_&JQ_2*_3JI+<ETK-"5K.?'?+<PJAQSI5<GKM7>/PW,S3'EIF
M&-T<I2Z%L&X&!S(.FSDR!&Y2@W4`YM,OZN963+),F&4E?&GB'[]V"--R>-04
M%N7DT4$7OQ%,;Z=P8Z)$<@-$LT;D>2HY@@<<I/.;W#?>-_NC0UE8\@OCPA><
MM6P.W@LLSW'O(_&C+$1E[#60:M3ZM>(^N3\6P4C?:O\`'EL(6J3C(&PIF;E7
M+LU60((%,05$SX3TOU3)TY-DF6!<K$RX#%*C.R%@3>XD7Q`\;VX@]]B,IWS8
MEWB*%8Y3!-!('1@H8`BVA4V!L0".XCM%P8C\4?!Q0.*>;.*V:87D!<;O)\=#
M\DK+965DHU=:NLMY/Y,(),K5<G4C&2:+&DQ4''LFJ3*)9,%_5`3&=;J'U.[W
M]1LK>MOS=ODQDC3+$"J5=B(XX#=5L1=R23=B1Q^[H*C=MZ/Q]NR\;,69GD@+
ML;J/$TBE2>/A%N70`GP\=35\>7?B_D\\<JL?<V^/O*G(G#[DQ3,<O,0S-UIU
M%H^2X*[XX<O'\BE"SU.O"1(M9\U>R!A*Y5.X3Z$T=D04135+';%UBFV;++T]
MNF%%G[1)+YH1G>,H]@+ADUMIP%CQUL2*N=UZ;?-W)-WP,I\3<%CY"RJK@K<_
MA:POJ1K<6MI<`B$]U_'V-E-;DA8LM<S[-D;)7)B\<6K9<\E3.#*BRL#-CQO#
MK?P\6E#7*/:Q;C)3ELT,X=QH1H1Z;?M$17(;8N0P?5#Y,8D6#MZ0X>''D*D8
MF8J?/.A-T-_+UL&YN:][@U$-T*)VR)<O+:7(R3&6<Q@']VI%Q9A8MX3X;`<M
MK$$U;IW^,3@Y*UYPDX+D),HU;*2>9W=,A;3AJGW"W8KL.7H"3A"23#)KBPQE
MDLC"IFEUED6JQ&RCP2)`X7,8AE%+M?K#N1@QDDQ5\^'RN9EE95D$3!K&/E*J
M6MJ1>VMAV"U/TWP?.F=9SY,H>RM&"5YAR_?Y@2`/438:WN3\:I^,]2X*0BSS
M/+"2L4(TMW$::DH@N"(.#=RM9XJQDE'%J1;!'9(&7BSY'&0!1[(MSE<M11(&
MS@2E$OV?ZO9$JMY>"$D*9(!\XD!L@@\W*8['R[:*=#?LKYC_`$ZBA(#Y7/&'
MB)'E`$K$I4K</<<W&XU'IJK8+\;+%+*38Q-BY89<LV(\=0W(]GQZQR6BT"NS
M6'IWD@R?MYZSR&2X))K9LF/ZZ\>E<LTI0A$C'03((%1%1-2A)]6\YD,D6%`F
M?*T!GDYW82B`W51&?#&&&AY=;$G4V(K+]/<:_ER94IQ$218D"J#&9!8DN#=]
M;-9AQ`M87!Y-1_'>9QC>B1][YDV')T5B?AMG7A[BEG.8#H\8>C0F9(^Z,(ZY
M-%HRU%3DI.@#=G"K1)TDHY<J%W.\((@)/$WU39C(^+@+"\V?#E2$3.><Q%"5
M-UT#\@!L;`?A-5!T*&7ER<HR*N,\*7B4<@<2"X\6MO,)UN21]X53\7^,]AJ(
MR5B'(*'(!Q*,Z-3>.M4O],M.":39:_D1?`4?78I69A#/[&#['+F_L:VG[X$%
M)!1!9PNH14YCATUG^KV?)ASXK8H#223LCK,ZM'YQ8V-EM)R%M+\H(`%A;6@/
MISB+DQ9"SFR+&K`QAN?D"J;$MX><+K:Y\3:G2U33?X[D&\XU4CCW7N8EZJ9X
M'-><LSWJQQ6+HI"$R^YS(I&%85;(%/87J,=S$%CQE%@G&D<3#A,QUE5#)%ZB
ME)1B^JDB;O)NDN!')S011(ID-XO*YKLC%"`7+>*R`Z#7OKS]!QR;<N!'DE+.
MS,1'HY8(/$O.#IR?M$>)M!<6A%!_CS9RD<[9$P$SS3<,0<6*[P?QCQO0Y`1U
M(QI;GW(Y1]D%UDW)<`M0YVY2\_C,S.R2!1(Y1,02>S*5NL*)C)FR&3ZI;<NV
M1;DV.D^\ON#S^27D4063RT;G"!9+J.!_:U%Q>HE.A<O^H-CQRM#MZ8XCY^56
M\T%ED(L7++XK]M_"-;&I"^-KQ'WZE^33)?,O*?'I]QTPCBFIU^K\<,1W+(](
MRG-V#*#?'%8Q38LV@K17;V!B475<JSMRD+HB,C[R8(<"$,@($C.K>N<;(Z0B
MV#"RAE[C.[-/*D;QA8_,:18O&`3JRC32R$=NMUT]TK/!U"^ZY,!@PXD"Q(SJ
MY+<BH7\.@X,3?4EE(X5ZHM:7K9E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
;32E-*4TI32E-*4TI32E-*4TI32E-*4TI7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
